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FOXM1 EXPRESSION AND CONTRIBUTION TO GENOMIC INSTABILITY 
AND CHEMORESISTANCE IN HIGH-GRADE SEROUS OVARIAN CANCER 
ABSTRACT 
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Supervisor: Adam R. Karpf, Ph.D. 
 
High-grade serous ovarian cancer (HGSC) is the most common and deadly 
subtype of epithelial ovarian cancer. Understanding the molecular basis of HGSC will 
improve diagnosis and treatment approaches. The Cancer Genome Atlas (TCGA) 
discovered that Forkhead Box M1 (FOXM1) transcription factor activation is the second 
most frequent molecular alteration in HGSC (84% of cases), second only to mutations of 
TP53 (100%). We subsequently defined several genetic mechanisms that underlie 
increased FOXM1 expression in HGSC, including genomic amplifications and RB-E2F 
deregulation, and showed that FOXM1 promotes cell cycle progression in cell models 
relevant to HGSC.  
TCGA analyses revealed that genomic instability, consisting of frequent copy 
number alterations, as key defining molecular features of HGSC and basal breast, more 
than any other TCGA cancer type. DNA replication stress results from uncoupling of the 
replicative helicase and polymerase and is a key mechanism of genomic instability. 
FOXM1 expression is linked to genomic instability but the underlying mechanism is 
unclear; induction of DNA replication stress could explain this association. In this context, 
we revealed novel functions of FOXM1 using fallopian tube epithelial (FTE) cells, an 
HGSC precursor cell model. We showed that FOXM1 increased DNA fork rate, origin 
firing, and DNA damage. Furthermore, Cyclin E1 cooperated with FOXM1 to increase its 

































agreement, TCGA HGSC tumors with both FOXM1 and CCNE1 copy number gain show 
increased FOXM1 and CCNE1 expression and genomic instability.  
FOXM1 shares a bidirectional promoter with RHNO1 but this genetic interaction 
has never been studied in any context. Knowledge of this interaction is important for 
understanding the molecular mechanism of HGSC. We investigated FOXM1 and RHNO1 
expression using large-scale genomic datasets from normal and pan-cancer tissues and 
validated these findings with HGSC cell lines and tissues. FOXM1 and RHNO1 showed a 
highly significant correlation in all comparisons suggesting a potential for cooperativity. 
Importantly, we showed that FOXM1 and RHNO1 cooperate to promote cell survival and 
chemoresistance in HGSC cells. Collectively, these studies support in vivo studies 
focusing on the cooperativity of FOXM1 and RHNO1 bidirectional gene partners, to further 
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CHAPTER 1: INTRODUCTION 
Human Ovarian Cancer 
Ovarian cancers  
Ovarian cancer is the most lethal gynecological malignancy and is the fifth leading 
cause of cancer-related deaths in women in the United States, accounting for 14,070 
estimated deaths and 22,240 estimated new cases in 2018 (6). The 5-year survival rate 
for women diagnosed with cancer localized to the ovary exceeds 90%; however, more 
than 60% of cases are diagnosed after cancer cells have metastasized from the primary 
tumor to distant sites, and the 5-year survival rate for these patients is less than 30% (7). 
These dire statistics reflect the lack of an effective screening test for early stage diagnosis 
of ovarian cancer and highlight difficulties in the successful treatment of advanced-stage 
disease (8).  
Ovarian cancer is a generic term that can be used for any cancer involving the 
ovaries. Ovarian cancers can be divided into 3 major categories based on cell of origin: 
epithelial, germ cell, and stromal cell tumors. Epithelial cancers are most common and 
account for at least 90% of ovarian cancer. Epithelial tumors can be further categorized 
based on histological subtype. Histology-based classification of ovarian cancer was 
developed by the World Health Organization (WHO) system (9,10). Based on these 
criteria, epithelial ovarian cancers (EOC) are currently divided into five main types: high-
grade serous (70%), endometrioid (10%), mucinous (3%), clear-cell (10%), and low-grade 





Staging and grading of epithelial ovarian cancer  
According to the International Federation of Obstetricians and Gynecologists 
(FIGO) system, ovarian cancer can be classified into Stage I to Stage IV (11). Stage I 
ovarian cancer is defined as tumors confined to the ovaries and peritoneal fluid/washings 
(11). Stage II ovarian cancer is defined as extension or metastasis to pelvic organs and 
may include curable tumors that have directly extended to adjacent organs but have not 
yet metastasized (11). Stage III ovarian cancer is defined as tumors characteristically 
spread along peritoneal surfaces involving both pelvic and abdominal peritoneum 
including the omentum, surfaces of the small and large bowel, mesentery, paracolic 
gutters, diaphragm, and peritoneal surfaces of the liver and spleen (11). Stage IV ovarian 
cancer is defined as distant metastasis and includes patients with parenchymal 
liver/splenic metastases and extra-abdominal metastases (11). 
According to the FIGO grading system, ovarian cancers can also be classified into 
three grades to indicate the degree of tumor cell differentiation (12). Grade 1 is most like 
normal ovarian tissue; Grade 2 is moderately differentiated tumors; and Grade 3 cancer 
cells are poorly differentiated or undifferentiated (13). This three-grade system can be 
applied to all ovarian carcinomas. Low grade serous ovarian cancer is typically grade 1 
and high-grade serous ovarian cancer is grade 2 and 3 (13-15).  
Prognosis of ovarian cancer is strongly associated with the stage at diagnosis, but 
the histologic grade also plays a prognostic role, particularly in predicting recurrence (16). 
Poor prognostic factors include age older than 65 years, clear cell or mucinous tumors 
(histology), extensive disease (advanced stage), large residual tumor volume, lower global 
quality-of-life score, and poor cell differentiation (high grade) (16). Even though the overall 
5-year survival rate of women with ovarian cancer indicates some recent improvement for 




are rather modest (17). Due to difficulties in early detection, most ovarian cancers are 
diagnosed at an advanced stage, and most of the patients show a poor prognosis because 
of recurrence after chemotherapy.  
 
Diagnosis of epithelial ovarian cancer 
Although the 5-year survival rate of women with localized ovarian tumors exceeds 
90%, only as few as 15% of ovarian cancers are confined to the ovaries at diagnosis (17). 
Furthermore, the diagnosis of ovarian cancer may be difficult because of nonspecific 
symptoms (16). Patients with ovarian cancer may have abdominal pain, swelling, or 
nonspecific gastrointestinal symptoms for more than six months before diagnosis (16). 
When a patient presents with these symptoms, a pelvic examination should be performed. 
However, the physical examination is not sensitive for detecting ovarian masses (16,18). 
Additionally, physical examinations are often nonspecific for ovarian cancer, further testing 
should be performed in women older than 40 of age who have persistent unexplained 
gynecologic or gastrointestinal symptoms (16). Laboratory tests in these patients should 
include a complete blood count, comprehensive metabolic panel, and measurement of 
serum CA125 levels (16). CA125 (MUC16) is a high-molecular mass (1 MDa) glycosylated 
transmembrane mucin that is expressed in 80% of ovarian cancers (8,19). CA125 is shed 
from ovarian cancers and circulates in serum allowing for detection without invasive 
procedures (8,20). It is the first useful biomarker for monitoring the response of ovarian 
cancer to chemotherapy (8,20). CA125 levels are elevated in 90% of patients with 






High-Grade Serous Ovarian Cancer 
Origins of high-grade serous ovarian cancer  
Until recently, the ovarian surface epithelium (OSE) was the assumed origin of the 
majority of HGSC (Figure 1) (13).The OSE is a single layer of epithelial cells that line the 
surface of the ovary (22). The OSE was thought to be the origin of HGSC based on the 
incessant ovulation hypothesis: the extravagant ovulations in the human female, which 
involves repeated rupture and repair of the ovarian surface following exposure to the 
estrogen-rich follicular fluid (23). The incessant ovulation hypothesis was further 
supported by epidemiological studies that demonstrated a relationship between the 
number of ovulations and a woman’s probability of developing ovarian cancer (23). 
A recent paradigm shift based on new clinical and molecular evidence suggests 
that a majority of HGSC cases originate in the fallopian tube epithelium (FTE) (Figure 1). 
Initial evidence for this theory is based on a study done in 2001, when tubal segments 
were removed from women undergoing a risk-reducing bilateral salpingo-oophorectomy 
or the removal of the fallopian tube and ovaries (24). In this study, 12 specimens were 
examined, and six showed areas of cellular dysplasia in the tubal epithelium, and five 
displayed hyperplastic lesions, compared to normal fallopian tubes (24). Remarkably, both 
the hyperplastic and dysplastic lesions histologically resembled high-grade serous ovarian 
cancer, but without invasion (24). In addition, BRCA mutations were found in both ovarian 
cancers and fallopian tube malignancies (25). Based on these data, it was hypothesized 
that most hereditary serous carcinomas originated from the FTE (26) (Figures 1 and 2). 
Gene expression and DNA methylome analyses have since shown that HGSC is more 
similar to FTE than OSE (27,28). More recently, evolutionary genomic analyses were 
performed on tissues isolated from HGSC precursor lesions in the fallopian tube lesions, 




HGSC tumors and metastases from nine patients (Figure 2) (29). Genomic analysis 
showed that STIC lesions had overlap in tumor-specific alterations (TP53, BRCA1, 
BRCA2 or PTEN) that were present in primary and metastatic ovarian cancers, thus 
providing further evidence that HGSC originates in the fallopian tube (Figure 2).  
 
Genomic features of high-grade serous ovarian cancer 
HGSC is broadly characterized by genomic instability, specifically high copy 
number abnormalities but few recurrent somatic mutations. Defects in the homologous 
repair pathway occur in ~50% of tumors due to frequent BRCA1/2 mutations (30,31). TP53 
mutations are present in 100% of tumors and these occur early in HGSC based on the 
detection of p53 signatures in the fallopian tube (Figure 2) (30,31). Additionally, RB-E2F 
deregulation occurs in ~70% of HGSC through loss of CDKN2A and RB1, and activation 
of cyclin D and E, and agrees with the increased proliferation that is observed in STICs 
and HGSC tumors as shown by increased Ki67 staining (Figure 2) (30).  
TCGA analyses revealed that genomic instability is a key defining molecular 
feature of HGSC and basal breast cancer, more than any other TCGA cancer type (32,33). 
One mechanism is deficient homologous recombination DNA repair (HR), exemplified by 
BRCA1/2 mutations and promoter methylation, which occur in ~33% of HGSC cases (30). 
However, all HGSC cases show genomic instability, therefore additional factors contribute 
to this phenotype. One potential example is cyclin E1 (CCNE1) amplifications, which occur 
in ~20% of HGSC and are mutually exclusive with HR deficiency (34). CCNE1 induces 
DNA replication stress and CNA in some cell models, suggesting it could contribute to 
genomic instability in the context of HGSC (35). Furthermore, FOXM1 pathway activation 
occurs in ~84% of HGSC (30,36). Notably, FOXM1 is a member of a 25 gene signature 




FOXM1 is a top biomarker for poor prognosis in solid tumors, potentially consistent with a 
protein promoting genomic instability (38,39). However, the mechanistic basis for the link 
between FOXM1 and genomic instability is unknown (40). Genomic instability contributes 
to tumor evolution and treatment resistance; thus, it is critical to reveal causative factors 
that drive genomic instability in HGSC (41,42). 
 
Treatment of high-grade serous ovarian cancer 
Conventional therapy for ovarian cancer is surgical tumor debulking followed by 
combination chemotherapy (16). Ovarian cancer is one of the few malignancies where 
surgeons will perform cytoreductive operation to eliminate macroscopic tumor before 
chemotherapy (8,43). Surgery can be performed after neoadjuvant chemotherapy if 
optimal cytoreduction is not considered feasible at initial diagnosis (8,44). However, there 
is no reliable evidence that chemotherapy before debulking surgery is superior to 
conventional treatment in women with advanced epithelial ovarian cancer (16). Primary 
chemotherapy for newly diagnosed ovarian cancer after cytoreductive surgery consists of 
six cycles of combination carboplatin/paclitaxel chemotherapy (8). Carboplatin is an 
alkylating agent that binds covalently to DNA, creating adducts that form intrachain and 
interchain cross-links (8). Paclitaxel binds non-covalently to microtubules and increases 
their stability, interfering with mitotic spindle formation (8). Despite the initial response of 
first-line chemotherapy in HGSC patients, more than 70% of patients will experience 
disease recurrence, and become candidates for second-line chemotherapy within 12 to 
18 months (8). Persistent elevation of CA125 after chemotherapy indicates residual 
disease with more than 90% accuracy (8). Retreatment with carboplatin and paclitaxel is 
associated with a 20-50% response when platinum-sensitive disease recurs more than 6 




combinations, such as liposomal doxorubicin and etoposide, can prolong survival in these 
patients (8).  
The discovery of BRCA1/2 mutations and HR deficiency in HGSC led to the first 
clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors (45). PARP inhibitors 
have been found to induce synthetic lethality in BRCA-mutated HGSC (45,46). Synthetic 
lethality occurs between two genes when cells with mutation or loss of either gene alone  
are viable but mutation or loss of both genes leads to cell death (47). PARP1 is a DNA 
repair enzyme that is involved in the base excision repair (BER) pathway (45,46). It is 
believed that PARP inhibitors induce DNA replication stress by trapping PARP on genomic 
DNA and/or inhibiting BER, which creates a dependency on BRCA1/2 for cell survival 
(45,48,49). Studies have shown that loss of both HR and BER forces cells to use non-
homologous end-joining (NHEJ) DNA repair, which is error-prone, thus causing an 
accumulation of DNA damage and cell death (45). In clinical trials, PARP inhibitors have 
shown selective toxicity toward tumor cells with BRCA1/2 germline mutations as well as 
some without germline BRCA1/2 mutations, which is likely due to somatic defects in other 
components of the HR pathway (50-52). In 2014, the PARP inhibitor olaparib received 
FDA approval for the treatment of germline BRCA-mutated ovarian cancers after third-line 
therapy based on a non-randomized study of olaparib monotherapy in BRCA-mutated 
cancer (53,54). Furthermore, PARP inhibitors have shown selectivity for BRCA1/2-
mutated cancers, however, only a fraction of BRCA1/2 mutant cancers respond to PARPi 
therapy and responders typically develop resistance (48,55-57). Thus, a strategy to 
overcome PARPi resistance in BRCA-mutant cancers is needed to improve this otherwise 







Genomic configuration, protein domains and regulation 
FOXM1 was previously known in the literature as Trident (in mouse), WIN or INS-
1 (in rat), FKHL-16, MPP-2 (partial human cDNA) or HFH-11 (in human). FOXM1 was 
initially identified as MPP-2 during a cDNA screen as a protein phosphorylated during the 
mitotic phase of the cell cycle (58). A subsequent publication by Han Clevers group 
reported that the team had cloned FOXM1 and determined it had a sequence motif similar 
to the conserved DNA binding domain of the Forkhead family of transcription factors (59). 
FOXM1 is now recognized as a member of the Forkhead box (FOX) transcription factor 
family, which is unified by a conserved winged helix DNA binding domain (DBD, Figure 3) 
(60). In addition to the DNA binding domain, FOXM1 protein contains a transactivation 
domain at the C terminus, which is important for activating target gene expression (Figure 
3) (61). The binding specificity of FOXM1 relative to other family members is in part 
achieved via an atypical chromatin interaction mechanism in which FOXM1 is bridged to 
DNA by the Myb-MuvB (MMB) transcriptional activator complex (62). Human FOXM1 is 
located at 12p13.33 and has ten exons, nine of which are coding. Alternative splicing of 
exons Va (A1) and VIIa (A2) give rise to three FOXM1 variants: FOXM1a, FOXM1c, and 
FOXM1b (figure 3). FOXM1a contains exons Va and VIIa with the latter disrupting the 
transactivation domain, making this isoform transcriptionally inactive (Figure 3) (63). 
However, the addition of alternative exon A1 does not alter the binding of FOXM1c and 
FOXM1a (64).  
FOXM1 is expressed in a cell cycle-dependent manner and regulated by post-
translational modifications throughout the cell cycle via phosphorylation by many different 
kinases (60). Phosphorylation by ERK on Ser331 and Ser704 in the Pro-Gly-Ser-Pro 




is highlighted by the observation that non-phosphorylated FOXM1 localizes to the 
cytoplasm, but phosphorylated FOXM1 is primarily located in the nucleus (65). 
Additionally, FOXM1b lacks exon A1, which contains an ERK1/2 target sequence 
(Ser331). In contrast FOXM1a/c contain exon A1 and Ser331 must be phosphorylated 
before they can translocate to the nucleus. Therefore, FOXM1b is thought to be 
constitutively active because it is proficient for nuclear translocation independent of this 
phosphorylation event.  
 
FOXM1 function and expression in normal cells 
FOXM1 protein was first identified because it was phosphorylated during mitosis 
and expressed in cycling cells. Further studies determined FOXM1 to be a transcription 
factor important for cell cycle progression through the G1/S and G2/M checkpoints in 
normal cells (58). Early studies showed FOXM1 to be critical for mitotic progression, 
whereby FOXM1-knockout MEFs had slower proliferation, failed to properly enter mitosis, 
accumulated mitotic defects, and eventually underwent progressive cellular senescence 
(66,67). Consistent with these phenotypes, FOXM1 has been demonstrated to play an 
essential role in the maintenance of appropriate chromosomal segregation and its loss 
resulted in genomic instability and accumulation of polyploid cells (68,69). Numerous 
studies have reported transcriptional targets of FOXM1 that allow mitotic progression, 
proper assembly of the mitotic spindles, accurate chromosome segregation and 
cytokinesis (66,70,71). Cell cycle regulation (G1-S and G2-M transitions) is the most 
characterized pathway that is influenced by the transcriptional activity of FOXM1 (40,60).  
The expression and the transcriptional activity of FOXM1 are highly dependent on 
the cell cycle phase (72). FOXM1 mRNA and protein levels are low in quiescent cells, but 




G2 and M-phases (59). The transcriptional activity of FOXM1 correlates with its 
phosphorylation level. Both gradually increase as cells progress through the cell cycle 
reaching maximum levels at the G2/M transition. FOXM1 is initially phosphorylated in G1 
and then further phosphorylated in a sequential order by multiple protein kinases, including 
Cdk-cyclin complexes and mitogenic kinases in the S and G2/M phases of the cell cycle, 
generating the hyperphosphorylated and fully active form of FOXM1 by the G2/M-phase 
(72). Moreover, FOXM1 is overexpressed and activated in many human cancers and 
possesses oncogenic activity in vitro and in vivo (40). Mechanisms accounting for FOXM1 
expression in cancer are diverse and include p53 (73,74), Rb (74) and FOXO3 loss (2,75), 
Myc, HIF-1, Gli1, SP1, STAT3 and E2F activation (76-81), and genomic amplification (82).
  
Oncogenic features of FOXM1 
 FOXM1 has been linked to many hallmarks of cancer through its role as a 
transcription factor, activating target genes that functionally promote oncogenic 
phenotypes (40). By far, the most common phenotype associated with FOXM1 is the 
deregulation of the cell cycle to promote cellular proliferation. FOXM1 is necessary for 
tumor formation, which would be expected since it is an essential gene in normal cells; 
therefore, mice with FOXM1 knockout in all tissue types are not viable (69,83). This lethal 
phenotype agrees with the in vitro studies showing that loss of FOXM1 results in mitotic 
defects and eventually cellular senescence (66,68). Conversely, transgenic models show 
that FOXM1 expression alone is not sufficient for tumor formation (84). When FOXM1 is 
overexpressed in spontaneous and genetically engineered models of cancer, it results in 
shorter time to tumor formation and larger tumor size, supporting its oncogenic role in 




FOXM1 associates with many hallmarks of cancer, but its link to genomic instability 
is not fully understood (40). The first association between FOXM1 expression and 
genomic instability is highlighted by its inclusion in the CIN25 signature, a gene expression 
profile predictive of chromosomal instability in cancer and patient clinical outcome (37). 
Surprisingly, many of the CIN25 genes are targets of FOXM1. FOXM1 was among the 
top-ranking genes whose expression correlated with chromosomal instability in in a pan-
cancer analysis. Furthermore, FOXM1 overexpression in human keratinocytes induced 
genomic instability in the form of CNAs, and upregulated the protein levels of phospho-
p38, phospho-p53, p21 and cleaved PARP1, suggesting induction of DNA damage by an 
unknown mechanism (85). In this context, FOXM1 is a transcriptional regulator of genes 
involved in DNA replication initiation (86,87), and overexpression of genes involved in 
DNA replication have been linked to DNA replication stress (88). Furthermore, FOXM1 
enabled the accumulation of genomic instability by promoting cell cycle progression 
downstream of DNA damage induced by nicotine or UVB exposure (85,89). Similarly, 
FOXM1 was shown to function downstream of DNA damaged induced by MYC activation 
in human keratinocytes, which by itself impaired cell division due to mitotic defects (90). 
However, overexpression of FOXM1 rescued the proliferative capacity of MYC cells 
exhibiting high levels of DNA damage, thus promoting genomic instability (90). Together, 
these data suggest that FOXM1 activation could alter DNA replication dynamics inducing 
DNA replication stress but also enable cells with damaged DNA to evade the G2/M 
checkpoint, resulting in genomic instability. Lastly, FOXM1 is implicated in DNA repair via 
direct transcriptional regulation of genes involved the repair process (91). However, based 
on the literature described above, it seems that aberrant FOXM1 expression promotes 





DNA Replication Stress 
Sources, cellular response and implications for cancer 
DNA replication stress is caused by impediments in DNA replication, leading to 
fork stalling and/or collapse. DNA replication stress results from the uncoupling of the 
replicative helicase and polymerase, and leads to generation of ssDNA and, potentially, 
DNA damage (92-94). Both extrinsic and intrinsic mechanisms can cause DNA replication 
stress, and the latter includes oncogene-induced DNA replication stress. Oncogene-
induced DNA replication stress is a major driver of cancer genomic instability, including 
copy number changes such as genomic duplications (95,96). The normal cellular 
response to DNA replication stress involves activation of cell cycle checkpoints that 
promote fork stabilization, fork restart, and DNA repair. Landmark studies over a decade 
ago showed that circumvention of the DNA replication stress response leads to dsDNA 
breaks and is a critical early event in oncogenesis (97). ATR activates CHK1 in response 
to damaged DNA generated from the resection of DNA double strand breaks (DSBs) and 
DNA replication stress, resulting in cell cycle arrest at S and G2/M checkpoints, inhibition 
of DNA replication and initiation of DNA repair (98,99). Although ATR responds to single 
stranded DNA (ssDNA) at sites of DSBs, it has a more extensive role in responding to 
DNA replication stress (99). The initial step in the activation of ATR in response to DNA 
damage occurs when ssDNA is coated with replication protein A (RPA), which allows for 
the independent recruitment of ATR by ATRIP (ATR interacting protein) and loading of the 
9-1-1 (Rad9, Rad1, Hus1) checkpoint clamp by Rad17 (Figure 4) (99). Once the 9-1-1 
complex is loaded onto DNA, TOPBP1 and RHNO1 interact with Rad9 and ATR, bringing 
TOPBP1 in close proximity to ATR allowing for its activation (Figure 4) (5,100). Once 
activated, ATR phosphorylates and activates CHK1 to mediate this signaling cascade 




G2/M checkpoint by phosphorylating CDC25A, targeting it for proteasomal degradation 
(101). Since CDC25A activates the CDK1-CCNB1 complex to facilitate mitotic entry, cells 
arrest in the G2 phase upon CDC25A degradation (101).  
In addition to serving as a barrier to transformation, numerous studies have now 
shown that tumor cells have elevated levels of constitutive DNA replication stress. These 
observations provide the rationale for therapies that target the DNA replication stress 
response, as the DNA replication stress response contributes to DNA repair and cancer 
cell survival (103,104). In particular, given the frequent impairment of ATM-p53 in cancer 
cells, tumor cells have heightened dependence on ATR-CHK1, the main DNA replication 
stress response pathway, for survival (105). In this regard, several emerging approaches 
that target the DNA replication stress response have entered clinical testing. These 
strategies include inhibitors of the ATR, CHK1, and WEE1 kinases (94,104,106). Inhibitors 
of ATR and CHK1 have anti-cancer activity, including in ovarian cancer, by inducing cell 
death and sensitizing cells to chemotherapeutic agents such gemcitabine, etoposide, 
topotecan, veliparib, and cisplatin (107,108). ATR inhibitors, AZD6738 and VE-822, are 
currently undergoing Phase I clinical trials (NCT02223923 and NCT02157792, 
respectively). VE-822 was the first ATR inhibitor to enter clinical development and is an 
analogue of VE-821, which was the first potent and selective inhibitor of ATR (109). Loss 
of p53, a frequent event in cancer and ubiquitous in HGSC, disrupts the G1 checkpoint, 
forcing cells to be dependent on ATR-CHK1 signaling and the G2/M checkpoint for DNA 
repair (110). It is proposed that tumors with p53 loss select for functional ATR-CHK1 







Genomic configuration and features 
Bidirectional promoters are flanked by two genes arranged in a head to head 
orientation on opposite strands of genomic DNA with less than 1,000 bp between their 
transcription start sites (112). However, nearly 67% of head-to-head promoters have 
intervening sequences that are less than 300 bp in length (113). Trinklein et al conducted 
the first genome-wide computational analysis of bidirectional promoters (114). Of a total 
of 23,752 annotated genes, >10% were found to be in a bidirectional configuration sharing 
common promoter regions that were less than 1,000 bp apart. Ortholog mapping of 
bidirectional promoters in human and mouse showed that most bidirectional promoter 
arrangements are conserved across human and mouse genomes, which suggests this 
orientation supports a critical function (115). Mapping of gene orthologues across nine 
vertebrates species showed selective pressure for the retention of bidirectional gene pairs 
(head-to-head genes) compared to tail-to-tail genes spaced within 1,000 bp of each other, 
supporting a possible regulatory and functional need for this arrangement (116). Genomic 
features of a bidirectional promoter include the presence of a CpG island and lack of a 
TATA box (112,114,117). It was recently shown that bidirectional promoters are enriched 
with histone modifications H3K4me3, H3K9ac, H3K27ac, and H3K4me2 (118). 
Bidirectional promoters are overrepresented with the following transcription factor motifs: 
GABPA, MYC, E2F1, E2F4, NRF-1, CCAAT, and YY1 (119). Bidirectional promoters are 
devoid of repetitive elements, further suggesting that gene partners often play a functional 
role as housekeeping genes (113). Bidirectional genes are often co-expressed, and their 






Genomic configuration and protein domains 
Human RHNO1 is located at 12p13.33 and consists of three exons, two of which 
are coding (Figure 5). Protein blast analysis indicates that RHNO1 orthologs exist only in 
vertebrates with the highest conservation being in the N- and C-termini of the protein (100), 
which agrees with conservation of the FOXM1-RHNO1 bidirectional promoter in 
vertebrates (115,116). RHNO1 protein contains a conserved APSES (Asm1p, Phd1p, 
Sok2p, Efg1p and StuAp) DNA binding domain at the N-terminus, which is necessary for 
interaction with the 9-1-1 complex (100) (Figure 5). Additionally, the C-terminus is required 
for binding the 9-1-1 complex and TopBP1, localizing to sites of DNA damage and 
promoting efficient HR (100). RHNO1 was previously identified to be a substrate of 
ATM/ATR kinases in a high-throughput proteomics screen following treatment with 
ionization radiation (121). This hit was followed up after the function of RHNO1 was 
identified and mutation of the potential ATM/ATR sites did not affect its localization to sites 
of DNA damage or disrupt protein-protein interactions (100). 
 
Contribution to ATR-CHK1 signaling and homologous recombination 
Prior to 2011, RHNO1 was classified as an ORF with unknown function, formerly 
known as C12orf32 (chromosome 12 open reading frame 32) and information on this 
molecule was limited to a single publication (122). In 2011, RHNO1 was identified in a 
high-throughput siRNA screen investigating the DNA damage response (100). Loss of 
RHNO1 abrogated the G2/M checkpoint, allowing cells to enter mitosis with damaged 
DNA. Further biochemical studies established its interaction with the 9-1-1 complex, 




(Rad9, Rad1, Hus1 interacting nuclear orphan). The activation of ATR is dependent on 
the direct interaction of TOPB1 and RHNO1, which ultimately bridges the protein-protein 
interaction between ATR and the 9-1-1 checkpoint clamp (Figure 4) (5,123). Furthermore, 
the loss of RHNO1 also decreased HR proficiency although to a lesser extent than what 
was observed with ATR loss, which agrees with its role as a modifier to ATR activation 
(100). In agreement, depletion of RHNO1 and Rad17, a protein that recruits the 9-1-1 
checkpoint clamp to chromatin after DNA damage, had similar impairment of HR 
proficiency which suggests that RHNO1 primarily promotes HR through the ATR-CHK1 
pathway (100). The observation that the RHNO1 gene is only present in vertebrate 
genomes indicates it is a unique regulatory factor of the ATR-CHK1 pathway (100). 
 
Oncogenic phenotypes of RHNO1 
The study of RHNO1 in cancer is limited to a single publication that found the 
mRNA to be overexpressed in breast cancer and protein was localized to the nucleus 
(122). Subsequent knockdown of RHNO1 in two different breast cancer cell lines 
decreased colony formation and increased the number of sub-G1 cells, suggesting 
RHNO1 depletion promotes cell death (122). These data suggest that RHNO1 is an 
oncogene that is important for cancer cell survival. Although these studies were done prior 
to the discovery of its functional role in ATR-CHK1 signaling, the phenotypes associated 







Since the initial discovery of FOXM1 in 1994, it has been reported to contribute to 
many normal and cancer phenotypes. However, a role for FOXM1 in HGSC was not 
proposed until 2012 when TCGA reported that FOXM1 transcription factor activation as 
the second most frequent molecular alteration in HGSC (84% of cases), second only to 
mutations of TP53 (100%). Therefore, further study of FOXM1 is critical to define its 
potential role in HGSC biology and to address the following knowledge gaps: 1) FOXM1 
transcriptional pathway is activated in HGSC, but genetic mechanisms that contribute to 
FOXM1 expression in HGSC are not known; 2) FOXM1 expression is associated with 
genomic instability and genomic instability is a defining feature of HSGC, yet this 
relationship has not been explored in HGSC nor is the mechanism known in any context; 
and 3) FOXM1 shares a bidirectional promoter with RHNO1, but the cooperativity between 
these gene partners has never been explored. To address these knowledge gaps, we 
propose the following specific aims: 
 
SPECIFIC AIM 1: Determine the genetic contribution to FOXM1 expression in high-grade 
serous ovarian cancer. 
 
SPECIFIC AIM 2: Determine the relationship between FOXM1 expression and genomic 
instability in high-grade serous ovarian cancer. 
 
SPECIFIC AIM 3: Determine the functional contribution of FOXM1 and RHNO1 to survival 

















Figure 1. Epithelial ovarian cancer (EOC) histological subtypes. The upper panels 
show the presumed tissues of origin for EOC histological subtypes. The lower panels show 









Figure 2. HGSC precursor lesions in the fallopian tube. Images represent H&E or IHC 
staining of tissues from different lesions as indicated on the left and top of the figure. 
HGSC = invasive cancer or primary tumor on the ovary, not within the fallopian tube. 
Precursor lesions start with normal FTE to the left and proceed to the right with the 
acquisition of additional malignant features. Lesions are detected in the distal end of the 






Figure 3. FOXM1 mRNA and protein. FOXM1 mRNA is displayed at top showing 10 
exons with intervening introns. The red boxes highlight the alternative exons, A1 and A2, 
which give rise to the different exons shown below. FOXM1 isoforms are shown below 
along with their protein domains. The N-terminus has a repression domain (NRD). The 
forkhead DNA binding domain, DBD, immediately following the NRD. FOXM1a and 
FOXM1c possess alternative exon A1. The C terminus contains the transactivation 














Figure 4. ATR-CHK1 activation in response to DNA damage. DNA damage generates 
single stranded which serves as a scaffold for the recruitment of the 9-1-1 checkpoint 
clamp. Through protein-protein interactions, the 9-1-1 checkpoint clamp recruits ATR 
allowing for its activation. ATR kinase then phosphorylates downstream effector proteins 
to signal the DNA damage response and promote cell cycle arrest and DNA repair. 













Figure 5. RHNO1 mRNA and protein. RHNO1 mRNA is displayed at top showing three 
exons with intervening introns. The N-terminus, in light blue, contains the DBD, which has 
a sequence similar to the APSES (ASM-1, Phd1, StuA, EFG1, and Sok2) domain, a DNA 
binding domain found in fungi and homologous to the KilA-N domain found in eukaryotic 
viruses. The N-terminus interacts with 9-1-1 checkpoint proteins including TOPB1. The 
SWV region, when mutated, impairs RHNO1 for interaction with 9-1-1 checkpoint proteins. 




CHAPTER 2: MATERIALS AND METHODS 
 
Human Tissue Samples 
Bulk normal ovary (NO) tissues and EOC samples (n=143) were obtained from 
patients undergoing surgical resection at Roswell Park Comprehensive Cancer Center 
(RPCCC) under Institutional Review Board-approved protocols, as described previously. 
Pathology specimens were reviewed at RPCCC, and tumors were classified according to 
World Health Organization criteria (124) Flash-frozen bulk tumor tissue samples were 
crushed using liquid nitrogen pre-chilled mortar and pestles. Genomic DNA was isolated 
from approximately 20 mg of powdered tissue using the Puregene Tissue Kit (Qiagen). 
Upon the addition of cell lysis buffer, the tissue powder was immediately homogenized 
using VWR Pellet Mixer (VWR International) with disposable microtube pestles (Argos 
Technologies). Total RNA was extracted by TRIzol reagent (Invitrogen) from 
approximately 20 mg of powdered tissue. The tissue was immediately homogenized in 
TRIzol by an electric homogenizer with disposable microtube pestles. Total protein was 
extracted using radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris HCl pH 7.6, 
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing Protease 
Inhibitor Cocktail (SIGMA), Phosphatase Inhibitor Cocktail 1 (SIGMA) and Phosphatase 
Inhibitor Cocktail 2 (SIGMA). Upon the addition of RIPA buffer, the frozen tissue powder 
was immediately homogenized using an electric homogenizer with disposable microtube 
pestles. The solution was further sonicated with a Bioruptor (Diagenode). 
 
Cell Lines 
COV362 and COV318 cell lines (Sigma) were cultured in DMEM (Corning) 




Technologies), and 1% penicillin-streptomycin (pen-step, Life Technologies). 
KURAMOCHI and OVSAHO (Japanese Collection of Research Bioresources Cell Bank) 
and SNU-119 (Korean Cell Line Bank) cell lines were cultured in RPMI-1640 (Hyclone) 
supplemented with 10% FBS and 1% pen-strep. The OVCAR4 cell line (National Cancer 
Institute Division of Cancer Treatment and Diagnosis Cell Line Repository) was cultured 
in RPMI-1640 supplemented with 10% FBS and 1% pen-strep. The OVCAR8 cell line 
(National Cancer Institute Division of Cancer Treatment and Diagnosis Cell Line 
Repository) was cultured in DMEM (Corning) supplemented with 10% FBS, and 1% 
penicillin-streptomycin (pen-step, Life Technologies). The OVCAR3 cell line (American 
Type Culture Collection) was cultured in DMEM with 10% FBS and 1% pen-strep. Caov3 
and OVCAR5 cell lines were generous gifts from Professor Anirban Mitra (Indiana 
University) and were cultured in DMEM with 10% FBS and 1% pen-strep. UWB1.289, 
UWB1-SyR12 and UWB1-SyR13 cell lines were generous gifts from Professor Lee Zou 
(Massachusetts General Hospital Cancer Center) and were cultured in RPMI 
1640/Mammary Epithelial Growth Media (1:1; Hyclone/PromoCell) supplemented with 3% 
FBS, MEGM growth factors and 1% pen-step. Primary hOSE cells (ScienCell) were 
cultured in Ovarian Epithelial Cell Medium (ScienCell, 7311). HGSC precursor cells or 
immortalized fallopian tube epithelial (FTE; FT190, FT282-E1 and FT282) cells were a 
generous gift from Professor Ronny Drapkin (University of Pennsylvania) and were 
cultured in DMEM-Ham’s F12 50/50 (Corning) supplemented with 2% USG (Pall 
Corporation) or 10% FBS and 1% pen-strep (Figure 6). IOSE-T (IOSE-21, hOSE 
immortalized with hTERT) cells (125) were a generous gift from Professor Francis Balkwill 
(Cancer Research UK) and were cultured in Medium 199/MCDB105 (1:1, Sigma) 
supplemented with 15% FBS, 1% pen-strep, 10 ng/mL human epidermal growth factor 
(Life Technologies), 0.5 μg/mL hydrocortisone (Sigma), 5 μg/mL bovine insulin (Cell 




(IOSE-121, hOSE immortalized with SV40 Large T antigen) were a generous gift from 
Professor Nelly Auersperg (University of British Columbia) and were cultured in Medium 
199/MCDB105 (1:1) supplemented with 10% FBS and 25 µg/ml gentamicin (Life 
Technologies). mOSE cells and floxed p53 and Rb variants (126) were a generous gift 
from Professor Barbara Vanderhyden (Ottawa Hospital Research Institute) and were 
cultured in Alpha Modified MEM (Corning) containing 10% FBS, 0.05% pen-strep, 1 μg/ml 
gentamicin, and 1% insulin–transferrin–sodium–selenite solution (ITSS, Roche). 
HEK293T cells (American Type Culture Collection) was cultured in DMEM with 10% FBS 
and 1% pen-strep. U2OS-DR-GFP (282C) cells were a kind gift from Professor Jeremy 
Stark (City of Hope) and grown in McCoy’s 5A (Corning), 10% FBS and 1% pen-strep 
(127,128). OVCAR8-DR-GFP cells were a kind gift from Professor Larry Karnitz and 
Professor Scott Kaufmann (Mayo Clinic) and grown in the same conditions as the 
OVCAR8 parental cells as described above (108). All cell lines were maintained at 37 °C 
in a humidified incubator with 5% CO2. Cell culture medium was changed every 3-5 days 
depending on cell density. For routine passage, cells were split at a ratio of 1:3-10 when 
they reached 85% to 90% confluence. Cell lines were authenticated by short tandem 
repeat (STR) analysis at the DNA Services Facility, University of Illinois at Chicago, and 
confirmed to be  for Mycoplasma free by RT-qPCR at the Epigenetics Core Facility, 
University of Nebraska Medical Center. Doxycycline inducible cells were treated every 48 
hours with doxycycline (Sigma, solubilized in water) unless otherwise noted.   
 
Pharmacologic Inhibitors 
Cells were treated with the following inhibitors: PARPi (olaparib, ABT-888, 




hydroxyurea (HU) from Sigma or etoposide (Etop, E1383, solubilized in DMSO) from 
Sigma.   
 
DNA, RNA and Protein Extracts from Cell Lines 
Genomic DNA was isolated from cell lines using the Puregene Tissue Kit (Qiagen). 
Total RNA was purified using TRIzol (Invitrogen). Total protein was extracted with RIPA 
buffer. Nuclear and cytosolic proteins were extracted from cell samples using the NE-PER 
Nuclear and Cytoplasmic Extract kit (Pierce Biotechnology). Protease Inhibitor Cocktail 
(Sigma), Phosphatase Inhibitor Cocktail 1 (Sigma) and Phosphatase Inhibitor Cocktail 2 
(Sigma) were added to protein lysis buffers. 
 
Bulk RNA Sequencing (RNA-seq) Analysis  
RNA was isolated from cell lines according to the method described above. The 
RNA samples were transported to the UNMC DNA Sequencing Core Facility. RNA 
samples were analyzed with respect to purity and potential degradation. Purity and 
concentration were assessed by measurement of the A260/280 ratios using a Nanodrop 
instrument (Thermo Scientific, Nanodrop Products, Wilmington, DE) instrument and only 
those samples with values of 1.8 to 2.0 underwent further processing. Potential 
degradation of the samples was assessed by analysis of 200 ng of the RNA with an 
Advanced Analytical Technical Instruments Fragment Analyzer (AATI, Ames, IA) and only 
intact RNA samples were used to generate sequencing libraries. Sequencing libraries 
were generated by the UNMC NGS Core beginning with 1 µg of total RNA from each 
sample using the TruSeq V2 RNA sequencing library kit from Illumina following 




assessed for size of insert by analysis of an aliquot of each library on a Bioanalyzer 
instrument (Agilent Technologies, Santa Clara, CA). Each library had a unique indexing 
identifier barcode allowing the individual libraries to be multiplexed together for efficient 
sequencing. Multiplexed libraries (12 samples per pool) were sequenced across 2 lanes 
of the HiSeq 2500 DNA Analyzer (Illumina) to generate a total of approximately 20 million 
75 bp single reads for each sample. During sequencing the quality was continually 
monitored regarding cluster number and fluorescence intensity and percentages of reads 
passing filter with a Q30 score. Following sequencing, samples were demultiplexed to 
produce FASTQ files. The UNMC Epigenomics Core Facility processed the resulting 
sequence files based on the following steps. Adaptor sequences and low quality (Phred 
score: 20) ends were trimmed from sequences using the Trim Galore software package 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Resulting FASTQ files 
were aligned to the human genome (NCBI37/hg19) using the software TopHat (v2.0.8) 
(http://ccb.jhu.edu/software/tophat/index.shtml). The software Cufflinks (v2.1.1) 
http://cole-trapnell-lab.github.io/cufflinks/ was used to estimate the expression values, and 
Cuffdiff (v2.1.1) was used to determine differential expression. Geneset enrichment 
analysis (GSEA) was performed using the GSEA software version 3, build 0160, available 
from the BROAD Institute (http://www.broadinstitute.org/gsea/index.jsp) (129). Bulk RNA-
seq datasets, with genes ranked by log2 fold-change, were compared against the 
Hallmark Signature genesets 
(http://software.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=H) or a custom 
CIN70 geneset based on the CIN70 gene expression signature (37). Output data included 
normalized enrichment score (NES) and FDR (q-value). Statistical significance was set at 
an FDR < 0.25. NES was used for comparing enrichment because it accounts for 





Single-Cell RNA Sequencing (scRNA-seq) Analysis 
FT282 and OVCAR8 cells were seeded at day 0 at ~50% and ~30% confluency, 
respectively, then harvested at day 2 at ~80% confluence. Cells were trypsinized and 
suspensions were pipetted several times and passed through a 40 μm cell strainer to 
ensure a single cell suspension. Cell viability (Trypan blue exclusion) was confirmed to be 
greater than 90% using the TC20 Automated Cell Counter (Bio-Rad). Cell pellets were 
washed twice in PBS containing 0.04% BSA, then resuspended in PBS and 0.04% BSA 
to ~500,000 cells/ml and transported to the UNMC DNA Sequencing Core Facility for 
single cell capture, library preparation and scRNA-sequencing. As per manufacturer 
instructions, approximately ~2,750 cells were loaded per channel to achieve a target of 
~1,500 captured cells. Single cells were loaded on a Chromium Single Cell Instrument 
(10x Genomics) to generate single cell Gel Bead in Emulsions (GEMs) for the partitioning 
of samples and reagents into droplets. GEMs contain oligos, lysed cell components and 
Master Mix. GEMs were processed as following: briefly, cells were lysed, RNA extracted, 
and reverse transcribed to generate full-length, barcoded cDNA from the poly A-tailed 
mRNA transcripts. Barcoded cDNA molecules from every cell were PCR-amplified in bulk 
followed by enzymatic fragmentation. The Qubit was then used to measure and optimize 
the insert size of the double-stranded cDNA prior to library construction. Single cell cDNA 
and RNA-Seq libraries were prepared using the Chromium Single Cell 3’ Library and Gel 
Bead Kit v2 (10x Genomics) and the products were quantified on the 2100 Bioanalyzer 
DNA High Sensitivity Chip (Agilent). Each fragment contains the 10x Barcode, UMI and 
cDNA insert sequence used in data analysis. During library construction Read 2 is added 
by Adapter ligation. Both single cell libraries were sequenced using the Illumina NextSeq 
550 system using the following parameters: pair-end sequencing with single indexing, 26 
cycles for Read1 and 98 cycles for Read2. FT282 cells produced a total of 85.6 million 




of 87.6%. Sequencing data were transferred to the Bioinformatics and Systems Biology 
Core Facility for analysis. The Cell Ranger Single Cell Software (10X Genomics) was used 
to process raw bcl files to perform sample demultiplexing, barcode processing and single 
cell 3’ gene counting (https://software.10xgenomics.com/single-cell/overview/welcome). 
Each dataset was aligned to a combined human (hg19) reference and only cells that were 
identified as aligned to human in the “filtered” output of the Cell Ranger count module were 
used in the analysis. 
 
Statistical Impute of Transcript Dropouts in Single-Cell RNA Sequencing Datasets 
The statistical method scImpute was used to accurately and robustly impute the 
transcript dropouts (zero values) that exist in scRNA-seq data from sequencing small 
amount of RNA (130). The scImpute R package was downloaded from 
https://github.com/Vivianstats/scImpute and was run in R with default settings. FT282 and 
OVCAR8 scRNA-seq raw gene expression matrix files (.mtx) were converted into dense 
expression matrices using `cellRanger mat2csv` command. The scImpute input data 
consisted of a scRNA-seq matrices with rows representing genes and columns 
representing cells, and output data consisted of an imputed count matrix with the same 
dimension.  
 
Reverse Phase Protein Array (RPPA)  
RPPA was performed at the RPPA Core Facility at MD Anderson Cancer Center 
(https://www.mdanderson.org/research/research-resources/core-facilities/functional-
proteomics-rppa-core.html). The protein lysates were prepared according to the Core's 
instructions and sent to them for the profiling. Briefly, immortalized fallopian cell lines 




doxycycline for 72 hours then harvested for protein. Proteins were extracted by adding 
RIPA buffer to monolayer cultures on ice. Protein concentrations were measured by the 
BCA assay then normalized to 1 μg/ml in 1X sample loading buffer containing beta-
mercaptonethanol. Samples were incubated 95 C for 5 minutes then stored at -80 C until 
they were submitted to the Core for the analysis. All samples were run in biological 
triplicate. The Core stained the slides with 304 unique antibodies (RPPA antibody set 145-
Present). Stained slides were analyzed on Array-Pro then by supercurve R ×64 2.15.1. 
There were 14 sets of replicated antibodies and 3 negative controls for secondary 
antibodies among 243 slides. QC tests were performed for each antibody staining (slide). 
All the data points were normalized for protein loading, transformed to linear values and 
subsequently transformed to log2 values (NormLog2) and then median-centered for 
hierarchical clustering analysis (NormLog2_MedianCentered). Heat maps were generated 
using the online software Morpheus (http://broadinstitute.org) as hierarchical clusters with 
normalized log2, median centered RPPA data using the one minus Pearson Correlation 
metric and average linkage method.  
 
Cell Viability Measurements 
Cells were seeded at a density of 500-1,000 cells per well in quadruplicate into 
sterile 96-well plates and treated with the indicated drug for 96 hours. AlamarBlue 
(BioRad) was used to assess cell viability. Background values from empty wells were 





Homologous Recombination (HR) Reporter Assay 
 U2OS and OVCAR8 cells were previously generated for stable integration of 
DR-GFP, an HR substrate that generates a functional green fluorescent protein (GFP) 
upon successful HR after I-SceI cutting (108,128,131). U2OS and OVCAR8 cells were 
grown in the presence of doxycycline for 48 hours to induce shRNA expression. U2OS 
cells were transfected with pCBASceI (Addgene; #26477) in the presence of 1 µg/ml 
doxycycline. Media containing doxycycline was changed 3 hours post transfection and 
cells were kept in culture for an additional 48 hours. OVCAR8 cells were transduced for 8 
hours with AdNGUS24i, an adenovirus expressing I-SceI (Drs. Frank Graham and Phillip 
Ng). Cells were harvested and fixed with 10% formaldehyde, washed and analyzed by 
FACS to determine the fraction of GFP positivity.  
 
In Vitro Clonogenic Survival Assay  
To assess colony formation, cells were trypsinized, counted and seeded at a 
density of 500-1,000 cells per well in 6-well dishes in single-cell suspension and allowed 
to form colonies for 8-12 days. Following incubation, cells were simultaneously fixed and 
stained in PBS containing 10% methanol and 0.5% crystal violet for 30 minutes at room 
temperature, rinsed with water and air dried overnight. Colonies containing over 50 cells 
were manually counted with an inverted light microscope.  
 
Comet Assay 
The Comet Assay Kit (Trevigen) was used according to the manufacturer's 
instructions. Briefly, cells were suspended in low melt agarose, layered onto treated slides 




V/cm) under alkaline conditions using the Comet Assay Electrophoresis System II 
(Trevigen). Samples were then fixed, dried, and stained with SYBR Gold. Images were 
acquired with a 10X objective lens using the EVOS FL Cell Imaging System 
(ThermoFisher). Comet tail size was quantified using Comet Analysis Software (Trevigen). 
 
Flow Cytometry 
Cells were fixed in 70% ethanol overnight for cell cycle and γ-H2AX expression 
analysis. Fixed cells were washed with PBS and incubated overnight in PBS containing 1% 
BSA, 10% goat serum and pS139-H2AX antibody (Millipore), washed and incubated in goat 
anti-mouse Alexa Fluor 647 antibody for 30 minutes at RT. Cells were incubated in 50 μg/mL 
propidium iodide and 100 μg/mL RNase A for 30 minutes, and 10,000 cells per sample were 
analyzed on a BD FACSarray (BD Biosciences) using 532- and 635-nm excitations and 
collecting fluorescent emissions with filters at 585/42 nm and 661/16 nm (yellow and red 
parameters, respectively).  
 
Production of Lentiviral Particles and In Vitro Lentiviral Transduction 
Replication-deficient lentivirus was produced by transient transfection of psPAX2 
(Addgene; 12260), pDM2G (Addgene: 12259) and transfer plasmid into HEK293T cells. 
Viral supernatant was collected at 48 hours and filtered. Select cell lines were transduced 
with serially diluted viral supernatant followed by antibiotic selection for functional titration. 
Cells were expanded from the viral dilution well that resulted in 30% survival following 




MOSE Cell In Vitro Adenoviral Transduction 
Recombinant adenovirus expressing enhanced GFP (Ad-eGFP, control) or both 
eGFP and Cre recombinase (AdCre-eGFP) were purchased from the University of Iowa 
Gene Transfer Vector Core. mOSE cells were transduced at a MOI of 200. 
  
MOSE Cell Genotyping and Detection of Recombination 
Genomic DNA was isolated using the Puregene Tissue Kit (Qiagen). DNA was 
resuspended in Tris-EDTA (50 mM, pH 6.8). Genotyping was performed as previously 
described (30). PCR was performed with an annealing temperature of 60 °C and 30 cycles 
for all primer pairs. Primer sequences are listed in Table 2.  
 
Plasmid Constructs and RNA Interference 
Tables 2 and 3 contains a list of all plasmids, siRNAs, shRNAs, and sgRNAs. All 
cloning was sequence verified. Plasmids were transfected with Lipofectamine 2000 (Life 
Technologies), according to the manufacturer’s instructions. siRNAs were transfected with 




FOXM1c DNA binding domain was mutated as following, R286A, H267A, and 
S290A, rendering FOXM1 deficient in DNA binding (132). All plasmids were sequence 
verified. Primers were designed using QuikChange Primer Design software (Agilent 




Murine Ovarian Tumor Model 
Trp53loxP/loxP/Rb1loxP/loxP mice (floxed Trp53 and Rb1) were a kind gift from 
Professor Kenneth Gross (RPCCC). All mice were maintained identically, following 
recommendations of the Institutional Laboratory Animal Use and Care Committee (at 
RPCCC). Intrabursal injections of recombinant adenovirus expressing both enhanced 
GFP and Cre recombinase (AdCre-eGFP) or eGFP alone (Ad-eGFP) as the contralateral 
control (University of Iowa Gene Transfer Vector Core) were performed on adult mice in 
estrus as previously described (133). Mice were determined to be in estrus by vaginal 
cytology. The original viral stock solution was diluted with PBS to 3.5x109 pfu/mL 
immediately before injection of 10 µL. Mice were euthanized and subjected to necropsy 
when tumor mass exceeded 1 cm or the animal exhibited other signs of sickness, such as 
abdominal distension and moribund behavior. Tumor samples were dissected and snap 
frozen in liquid nitrogen and stored at -80 °C. Frozen tumor samples were ground into a 
powder with a mortar and pestle over liquid nitrogen and immediately processed for RNA 
(mRNAeasy Mini Kit, Qiagen) and whole cell protein cell extracts were prepared with RIPA 
buffer (1X PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 
protease and phosphatase inhibitors, and centrifuged at 4 °C for 10 minutes at 14,000 g. 
RNA was treated for contaminating DNA using the TURBO DNA-free Kit (Ambion), and 
integrity was determined using a bioanalyzer (Agilent). One µg of DNase treated RNA was 
converted to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). 
 
Immunohistochemistry of Mouse Tumor Tissue Samples 
Formalin-fixed paraffin blocks were cut into 4 µm sections, placed on charged 
slides, and dried at 60 °C for one hour. Slides were cooled to room temperature, 




antigen retrieval, slides were heated in a steamer for 20 minutes in citrate buffer pH=6 
(BioCare Medical, B910) for Smooth Muscle Actin or target retrieval solution pH=9 (Dako, 
S2367) for Cytokeratin and allowed to cool for 20 minutes, endogenous peroxidase was 
quenched with aqueous 3% H2O2 for 10 minutes, and the slides were washed with PBS/T. 
Slides were loaded on a Dako autostainer and serum-free protein block (Dako, X0909) 
was applied for 5 minutes, blown off and the corresponding antibody was applied. Smooth 
Muscle Actin antibody (Abcam, ab5694) was applied at 1:125 (Rabbit IgG) for one hour. 
Powervision poly HRP anti-rabbit IgG (Leica; catalog #PV6119) was then applied for 30 
minutes. L- DAB (Leica; catalog #PV6126), applied for 5 minutes, was used for chromogen 
visualization. Pan-Cytokeratin antibody (Dako, Z0622) was applied at 1:1750 (Rabbit IgG) 
for one hour. Rabbit Envision/ labeled polymer HRP anti -rabbit (Dako; catalog #K4003) 
was then applied for 30 minutes. DAB (Dako; catalog #K3468), applied for 10 minutes, 
was used for chromogen visualization. Lastly, the slides were counterstained with 
hematoxylin, rinsed, and cover slipped. 
 
Reverse Transcription Quantitative PCR (RT-qPCR)  
Total RNA was purified using TRIzol (Invitrogen) and quality was determined by 
RNA denaturing gel. Briefly, one μg of RNA was DNase-treated using the DNA-free kit 
(Ambion) or treated in column during purification with the Zymo Pure RNA Isolation Kit. 
RNA was converted to cDNA using the iScript cDNA Synthesis Kit (BioRad). One µl of 1:5 
cDNA sample dilutions were used for qPCR reactions. Standard curves were prepared 
using gel-purified end-point RT-PCR products. All samples were run in triplicate using the 
CFX Connect Real-Time System (Bio-Rad Laboratories) and all gene expression data 
were normalized to 18s rRNA. PCR was performed with an annealing temperature of 60 




confirm specific product amplification. RT-qPCR standards for each gene were generated 
from a mixture of human or mouse cell cDNA via end-point RT-PCR then gel purification, 
using the appropriate primer pair. Gradient PCR reactions were performed with the C1000 
Touch Thermal cycler (Bio-Rad Laboratories) to determine the annealing temperatures for 
each primer set. Primer sequences are listed in Table 2. Primer sequences corresponding 
to each gene for the mRNA expression analysis were designed using NCBI Primer Blast 
(134) or selected from those previously reported in the literature. 
 
Microarray Analysis of FOXM1 and E2F1 Expression 
Affymetrix HG 1.0ST arrays were used to determine the expression of FOXM1 and 
E2F1 in EOC. Probe generation, array hybridization, and expression analyses were 
performed by the Next Generation Sequencing and Expression Analysis Core Facility at 
the University at Buffalo Center for Excellence in Bioinformatics. Samples included 40 
primary EOC tissues. 
 
Western Blot  
Whole cell protein extracts were prepared with RIPA buffer [1X PBS, 1% NP40, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)] supplemented with 
protease and phosphatase inhibitors (Sigma) and centrifuged at 4 °C for 10 minutes at 
14,000 g. Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic 
Extraction Kit (Thermo Scientific) supplemented with protease and phosphatase inhibitors. 
Protein concentration was determined by the BCA protein assay (Thermo Scientific). 
Equal amounts of protein (30-50 µg) were fractionated on 4-12% gradient SDS-
polyacrylamide gel electrophoresis gels (Invitrogen) and transferred to PVDF membranes 




loading then blocked with 5% nonfat dry milk in Tris-buffered saline Tween-20 (TBST) for 
1 hour at room temperature. The membranes were incubated with primary antibodies in 
5% nonfat dry milk in TBST at 4 °C overnight followed by incubation with secondary 
antibody in 5% nonfat dry milk in TBST for 1 hour at room temperature. Primary antibodies 
are listed in Table 4. Enhanced chemiluminescence (Thermo Fisher Scientific) was used 
for protein detection. Quantification of protein expression was performed using ImageJ 
software (Image Processing and Analysis in Java, National Institute of Health) (135). 
 
Co-Immunoprecipitation  
Cells expressing empty vector, and Flag- or HA-tagged ORFs were lysed with M-
PER (Pierce) containing Halt Protease and Phosphatase Cocktail (Pierce), and Nuclease 
S1. Lysates were mixed end over end at 4 ºC for 30 minutes then centrifuged at 4 °C for 
10 minutes at 14,000 g to eliminate cellular debris. Protein concentration was determined 
by the BCA protein assay (Thermo Scientific). Immunoprecipitation was performed with 
anti-Flag or HA magnetic beads and 500 µg total protein. Samples were incubated 
overnight at 4 ºC with end over end mixing. The next day the magnetics beads were 
washed, and protein eluted with sample loading buffer. The entire sample was loaded on 
the Western blot along with 5% total protein as input. 
 
Illumina Infinium Human Methylation 450K Datasets 
The TCGA pan-cancer DNA methylation (HumanMethylation450K) dataset was 
downloaded from UCSC Xena (http://xena.ucsc.edu), consisting of 9,753 samples. The 
TCGA pan-cancer dataset contains the DNA methylation 450K array beta values, 
compiled by combining available data from all TCGA cohorts. The GDSC1000 collection 




downloaded from NCBI GEO (GSE68379) (136). The NCI-60 cell line DNA methylation 
450K dataset (NCBI GEO: GSE66872) was downloaded from CellMiner (137,138). For all 
datasets, the DNA methylation profile was measured experimentally using the Illumina 
Infinium HumanMethylation450 platform and Infinium HumanMethylation450 BeadChip 
Kit. The method consists of approximately 450,000 probes querying the methylation status 
of CpG sites within and outside CpG islands. The DNA methylation score of each CpG is 
represented as a beta value, which is a normalized value between 0 (fully-unmethylated) 
and 1 (fully-methylated).  
 
Sodium Bisulfite DNA Sequencing  
Sodium bisulfite DNA sequencing was used to determine the methylation status of 
the FOXM1/RHNO1 bidirectional promoter (139). Sanger sequencing analysis was 
performed by the University of Nebraska Medical Center DNA Sequencing Core Facility. 
Genomic DNA was isolated using the Puregene Tissue Kit (Qiagen) as described above, 
and then were chemically converted with sodium bisulfite using the EZ DNA Methylation 
Kit (Zymo Research Corp.). The FOXM1 and RHNO1 bidirectional promoter containing a 
CpG island was amplified from the bisulfite-converted DNA using methylation PCR 
specific primers, designed using MethPrimer (Table 2) (140). Gradient PCR reactions 
were analyzed using a C1000 Touch Thermal cycler (Bio-Rad) to optimize annealing 
temperatures for the primer set. After gel purification using the QIAquick Gel Extraction 
Kit (QIAGEN), PCR products were cloned using either the TOPO TA Cloning Kit 
(Invitrogen). Between 9 and 15 individual clones were sequenced for each sample. DNA 






5’ RNA Ligase-Mediated Rapid Amplification of cDNA Ends (RLM-RACE) Mapping 
The transcription start site of FOXM1 and RHNO1 in different cell lines was 
determined using the FirstChoice RLM-RACE Kit (Ambion), according to the 
manufacturer's instructions. RNA for RLM-RACE analysis was isolated using TRIzol 
reagent (Invitrogen) followed by purification with Direct-zol RNA MiniPrep with in column 
genomic DNA digestion. RLM-RACE assay allows for the specific amplification of 5' 
capped RNA, which is found only on full-length mRNA transcripts. The specific outer and 
inner (nested) primers in combination with adaptor-specific primers were used for 
amplifying the 5’ ends of FOXM1 and RHNO1 mRNA. The 5’ end specific primers are 
listed in Table 2. As negative controls, non-tobacco alkaline phosphatase (TAP)-treated 
aliquots from each RNA source were utilized; in all cases, this did not yield any specific 
product amplification (data not shown). In contrast, FOXM1- and RHNO1-specific PCR 
products of various sizes were yielded from TAP-containing reactions. PCR products were 
separated on 2% agarose gels, excised, and subsequently purified using the QIAquick gel 
extraction kit (Qiagen). Gel-purified PCR products were cloned using the TOPO TA 
Cloning Kit (Invitrogen), and individual clones were sequenced using standard methods. 
 
Promoter Activity Luciferase Reporter Assay  
Firefly and Renilla luciferase activities were measured between 24 hours after 
transfection using the Dual-Luciferase® Reporter Assay System (Promega) and 
luminometer. Bidirectional promoter studies were normalized with secreted embryonic 
alkaline phosphatase (SEAP) activity present in the culture medium was measured at the 
same time using the Phospha-Light System (Applied Biosystems). All transfections were 
performed in triplicate within each individual experiment. Firefly and Renilla luciferase 




second integration time and normalized against SEAP production in the individual 
transfected 24-well dishes.  
 
University of California Santa Cruz (UCSC) Genome Browser 
The genomic region of FOXM1 and RHNO1 was retrieved from UCSC Genome 
Browser (http://genome.ucsc.edu) (141) using the human genome build hg19 with 
genomic coordinates chr12:2,966,265-2,999,264. The following tracks were selected and 
displayed in the Genome Browser: FOXM1 and RHNO1 mRNA, CpG island, Encode 
E2F1, H3K4Me3 and H3K27Ac ChIP-seq tracks, and conserved genome tracks from 100 
vertebrates and mammalian genomes. The Genome Browser screen shot tool was used 
to obtain images.  
 
DNA Fiber Assay 
DNA fiber analysis was performed as previously described with minor 
modifications (142,143). Briefly, FTE cells were seeded at 50% confluency. The next day, 
cells were first pulsed with 8 g/ml chlorodeoxyuridine (CldU) for 30 minutes, washed 3X 
with pre-warmed 1X PBS, and then pulsed with 90 g/ml iododeoxyuridine (IdU) for 30 
minutes. Three microliters of cell suspension containing approximately 3105 cells were 
mixed with 7 l lysis buffer (200 mM Tris-HCl pH 7.4, 50 mM EDTA, 0.5% SDS) on glass 
slides and incubated at room temperature for 8 minutes. The slide was then tilted to allow 
spreading of fibers at approximately a 45o angle to allow the drop to slowly run down the 
slide. Fibers were air dried for 2-3 hours and then fixed in methanol/acetic acid (3:1) at 4 
C overnight, rehydrated by PBS and denatured in 2.5 M HCL for 1 hour. After rinsing 




overnight at 4 ºC overnight with anti-BrdU antibody (Mouse, #347580, Becton Dickinson, 
1:100 dilution) to detect IdU and anti-BrdU antibody (Rat, ab6326, Abcam, 1:500 dilution) 
to detect CldU. Slides were rinsed with PBS with 0.1% Tween-20 (PBST) and incubated 
with AlexaFluor488-conjugated (green) anti-mouse IgG secondary antibody and 
AlexaFluor594-conjugated (red) anti-rat IgG secondary antibody for 1 hour at room 
temperature. Slides were rinsed with PBST and mounted by mounting media (Prolong 
Gold, Invitrogen). Images were taken in Zeiss Axio Imager Z1 microscope and fiber length 
was measured by ImageJ software (NIH). For data analysis, the length of each labeled 
DNA tract (IdU and CldU) determined by ImageJ was then converted to kb using a 
conversion factor of 2.59 kb/μm. Fork rate was calculated by dividing the length of the tract 
by the labeling time (kb/min). Percentage of origins fired was calculated by counting DNA 
fibers with the following with the following staining pattern (G = green and R = red), GRG, 
G, GRG, G, and RG, then using this equation: (GRG + G) / (GRG + G + RG). See Figures 
7 and 8 for the interpretation of the data. 
 
The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), 
Genotype-Tissue Expression (GTEx), and RIKEN Fantom5 Datasets 
TCGA, CCLE and GTEx genomic profiled datasets were retrieved from cBioPortal 
or UCSC Xena Browser. TCGA and CCLE RPPA data were obtained from UCSC Xena 
(https://xenabrowser.net) or The Cancer Proteome Atlas (144,145). TCGA Provisional 
datasets were used for analyses because they contain published data plus data from new 
samples that have since been profiled, thus increasing the sample size. FOXM1 mutation 
and somatic copy-number alterations were analyzed in pan-cancer datasets. The genomic 
profile of FOXM1 and RHNO1 were further analyzed in the HGSC (Ovarian Serous 




alterations from GISTIC (146) using Onco Query Language (OQL) and mRNA expression 
(RNA seq V2 RSEM). In brief, GISTIC predicts gene copy number alterations according 
to sample specific thresholds generated by comparing chromosomal segments with 
median chromosomal arm copy numbers. High gains (Amp) are segments with copy 
number that exceed the maximum median chromosomal arm copy number for that sample 
by at least 0.1; low gains (Gain) are segments with copy numbers from 2.1 to the high gain 
threshold; neutral segments (Diploid) have copy numbers between 1.9 and 2.1; shallow 
losses (Hetloss) have copy numbers between 1.9 and the deep deletion threshold; and 
deep deletions (Homdel) have copy numbers that are below the minimum median 
chromosomal arm copy number for that sample by at least 0.1. Overall patient survival 
was graphed in Kaplan-Meier survival curves. Fraction of genome altered by copy number 
data was downloaded from cBioPortal and was previously calculated as following: length 
of segments with log2 CNA value larger than 0.2 or less than -0.2 divided by the length of 
all segments measured. Mutation burden is the sum of all mutations detected from the 
exome-seq data. These values were used as a basic measurement of genomic instability 
in the form of CNA and mutations. CAGE (Cap Analysis of Gene Expression) analysis of 
mouse tissues in RIKEN FANTOM5 project (RNA-seq) dataset was retrieved from 
www.ebi.ac.uk. 
 
FOXM1 and RHNO1 Correlation in Public Single-Cell RNA Sequencing Datasets 
 Single-cell RNA-sequencing datasets from mouse normal colon epithelium 
(GSE92332) (147) and human melanoma (GSE72056) (148) were downloaded from NCBI 
GEO. Single-cell RNA sequencing data for human high-grade serous ovarian cancer 
tissue was obtained from a published dataset (149). Single-cell RNA sequencing data 





Genome-Wide Correlation of FOXM1 and ORC2 Occupancy 
ORC2 (GSE70165) and FOXM1 ChiP-seq (GSE105524) datasets were retrieved 
from NCBI GEO (151,152). Both ChiP-seq experiments were performed using K562 cells 
and mapped to human genome build hg19. The StereoGene C++ source code was 
downloaded from http://stereogene.bioinf.fbb.msu.ru/. StereoGene was run to determine 
the statistical overlap of genome-wide co-occupancy between FOXM1 and ORC2 in the 
publicly available ChiP-seq datasets (153). FOXM1 ChIP-seq bed files and ORC2 
significant Broadpeak files were input into the StereoGene program and analysis 
performed with the contig settings set at default. Final data output consists of the following 
correlations: 1) foreground distribution, which is calculated from a set of paired windows 
with the same genome positions and the matched windows are compared, and 2) 
background distribution, which is a shuffling procedure that is randomly match windows 
on one profile to the windows on another profile.  
 
Statistical Analyses 
Student’s t-test was used to compare differences between means of two groups. 
Mann-Whitney test was used to compare differences between medians of two groups. 
One-way analysis of variance (ANOVA) with a post-test for linear trend was used to 
compare two or more groups. For all analyses, significance was inferred at P < 0.05 and 
P values were two-sided. GraphPad Prism statistical software (GraphPad Software, Inc) 














Figure 6. Generation of immortalized fallopian tube epithelial cells (FTE; FT282). 
Fallopian tube epithelial cells were dissociated from the lining of the fallopian tube. 
Fallopian tube secretory cells (FTE) were immortalized by transduction with lentivirus 
expressing mutant p53 and retrovirus expressing hTERT. These cells can grow long term 
on plastic but are not transformed and model the p53 signature lesion found within the 


























Figure 7. DNA fiber assay using DNA spreading. A. Asynchronous culture of cells is 
labeled in two pulses with washing between. The first pulse in this example is with IdU 
(red) and the second pulse is with CldU (green). B. A drop of prelabeled cells is transferred 
to a positively coated microscope slide and lysed. C. The slide is then tilted at a 25–60-
degree angle to allow DNA spreading down the slide. D. DNA is then fixed with 
methanol/acetic acid. E. The slide containing fixed DNA is first immunostained with 
primary antibodies that recognize CldU and IdU then immunostained with fluorescently 
conjugated secondary antibodies.  F. DNA fibers are visualized through a fluorescent 


















Figure 8. Schematic showing the different replication events that can be detected 
with DNA fiber analysis. Nucleotide analog labeling scheme according DNA fiber in 
Figure 7. IdU is incorporated as the first nucleotide analog followed by CldU incorporated 
as the second analog. Representative DNA fibers are shown on the left and their 
interpretations on the right. The color of the DNA fibers corresponds to the fluorescence 































CHAPTER 3: GENETIC DETERMINANTS OF FOXM1 OVEREXPRESSION IN HIGH-
GRADE SEROUS OVARIAN CANCER1 
 
Introduction 
TCGA recently reported mRNA and miRNA expression, CNA, promoter 
methylation, and mutational data for HGSC, which led to classification into sub-groups 
based on these molecular criteria (30). CNA is prominent in HGSC and occurs at a higher 
frequency than in any other TCGA-profiled tumor type (30,31,154). It was also notable 
that TP53 was mutated in virtually all HGSC, suggesting p53 as a “gatekeeper” for this 
disease (30). Other tumor suppressors and oncogenes implicated in HGSC include 
BRCA1/2, Rb, PI3K, Ras, and CCNE1 (30,34,155). Finally, FOXM1 pathway activation is 
a highly frequent alteration in HGSC, second only to TP53 mutation (30). 
FOXM1 is a member of the Forkhead box (FOX) transcription factor family, which 
is unified by a conserved winged helix DNA binding motif (60). FOXM1 plays a well-
established role in cell cycle progression, promoting G1/S and G2/M transitions by 
transactivation of genes regulating these checkpoints (40,60). Furthermore, FOXM1 is 
overexpressed and activated in many human cancers and possesses oncogenic activity 
in vitro and in vivo (40). Mechanisms accounting for FOXM1 overexpression in cancer 
cells and tissues are diverse and include: p53, Rb, and FOXO3 loss (2,73-75), Myc, HIF-
1, Gli1, SP1, STAT3 and E2F activation (76-81), and gene amplification (82).  
                                               
1 Part of the data presented in this chapter were previously published: 36. Barger CJ, 
Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, et al. Genetic determinants of 
FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle 




The goal of the current study was to begin to define the genetic determinants of 
FOXM1 overexpression in HGSC, to analyze its expression across cancer types and 
during EOC disease progression, and to investigate its role in EOC cell cycle progression. 
For this task, we utilized publicly available TCGA datasets, primary human EOC tissues, 
immortalized ovarian surface epithelial (OSE) cell models (murine and human), 
immortalized human fallopian tube epithelial (FTE) cell models, a transgenic murine 
ovarian cancer model, and human HGSC cell lines.  
 
Results 
FOXM1 shows highest expression in HGSC compared to other TCGA tumor types  
 FOXM1 is overexpressed and activated in many human cancers. However, the 
expression of FOXM1 protein has not been characterized in HGSC nor has it been 
compared across other cancer types. To determine the level of FOXM1 protein expression 
in TCGA cohorts, we retrieved the level 4 TCGA RPPA dataset from The Cancer Proteome 
Atlas (TCPA) (145). This dataset was a reprocess of raw TCGA RPPA data using a novel 
approach, called ‘replicates-based normalization’ (RBN) to correct for batch effects and 
ultimately allow for the merging of samples across 19 different cancer types for pan-cancer 
analyses (156). We then analyzed this dataset for FOXM1 protein expression across 19 
TCGA cancer cohorts. Notably, we observed that FOXM1 protein expression was the 
highest in HGSC as compared to all other TCGA cohorts (Figure 9). This suggests that 





FOXM1 gene amplification correlates with increased FOXM1 expression and 
reduced survival in HGSC  
HGSC exhibits more frequent copy number alterations than other TCGA cancer 
types. FOXM1 is located at chromosome 12p13.33, a known amplified region in cancer 
(53,99,100). Therefore, we hypothesized that FOXM1 is altered in copy number in HGSC 
thus contributing to its increased expression. To determine if 12p13.33 is a genomic region 
with significant copy number increase in HGSC, we downloaded the TCGA HGSC copy 
number analysis (GISTIC2) data from the Broad TCGA Genomic Data Analysis Center 
(GDAC)-Firehose data portal. Upon review of the TCGA HGSC GISTIC data, we observed 
that 12p13.33 is one of the 33 significant focal amplifications in HGSC as highlighted with 
the black arrow (Figure 10) and FOXM1 was among the 33 genes in this amplicon (Table 
5). We then determined the frequency of FOXM1 amplification among the different cancer 
types using TCGA datasets. Notably, amongst all tumor types with TCGA data, FOXM1 
was most frequently amplified in HGSC, with ~12% of tumors affected (Figure 11A). 
Together, 57% of HGSC cases showed either copy number gain or amplification, 
suggesting FOXM1 as an HGSC oncogene (Figure 11B). To determine if FOXM1 copy 
number status correlates with expression, we compared FOXM1 mRNA and protein 
expression versus FOXM1 copy number in TCGA HGSC data. We observed a progressive 
increase in FOXM1 mRNA and protein expression with copy number status that was highly 
statistically significant (Figure 11C-D). Furthermore, we compared FOXM1 mRNA and 
protein expression and observed a strong correlation (Figure 11E), suggesting that copy 
number contributes to increased FOXM1 mRNA expression thus resulting in a 
corresponding increase in protein expression. Together these data support our pan-
cancer analysis of FOXM1 expression, which showed that HGSC had the highest level of 




CNA and FOXM1 mRNA and protein expression and observed that only the former 
showed a significant correlation with OS (Figure 11F-H). This finding suggests that 
additional genes located at the amplified region of 12p13.33 may contribute to OS in 
HGSC, and/or that FOXM1 activation levels may be more relevant than expression levels 
for impacting OS. Finally, our analysis of TCGA mutational data did not reveal FOXM1 
mutations in HGSC (data not shown). 
  
TCGA HGSC and basal breast cancer exhibit similar FOXM1 copy number status 
and level of expression for FOXM1 
 The TCGA report and subsequent pan-cancer analyses have shown that HGSC 
and basal breast subtype have very similar genomic features including TP53 mutations in 
the majority of cases and more genomic instability, in the form of copy number alterations, 
than other subtypes of breast and ovarian cancer or most other TCGA cancer types 
(32,33). Therefore, we hypothesized that basal breast cancer and HGSC would show 
similar FOXM1 copy number status and expression. In our earlier TCGA pan-cancer 
comparisons (Figure 9 and11A), breast cancer showed lower frequency of FOXM1 
amplification and lower protein expression as compared to HGSC. A caveat to this 
comparison was that it did not differentiate between breast cancer molecular subtypes. To 
address the possible differences between molecular subtypes, we retrieved the TCGA 
PAM50 expression subtype data for TCGA breast cancer and categorized samples based 
on molecular subtype. We compared FOXM1 copy number and expression between 
subtypes in respect to HGSC. Our analysis of FOXM1 amplification showed that basal 
breast and HGSC have an increased frequency of FOXM1 amplification, while the other 
breast molecular subtypes showed infrequent FOXM1 amplification (Figure 12A). 




we next compared FOXM1 copy number status. We observed a striking similarity in copy 
number status between these two cancer types (Figure 12B). To determine if breast 
molecular subtypes and HGSC have similar FOXM1 expression, we compared FOXM1 
mRNA and protein expression among normal breast, breast molecular subtypes and 
HGSC. Again, in agreement with the copy number data, HGSC and basal breast showed 
the highest level of FOXM1 mRNA and protein expression compared to the other breast 
subtypes and normal breast tissue (Figure 12C-D). These data validate our observation 
that FOXM1 copy number status contributes to its frequent expression in HGSC and agree 
with previous reports that HGSC and basal breast subtype have similar genomic features. 
Most importantly, these data further support our hypothesis that HGSC has unique 
genomic features that contribute to the frequent overexpression of FOXM1 that we have 
observed. 
 
FOXM1 expression in relation to EOC type and progression status, and FOXM1 
isoform expression in HGSC 
 The FOXM1 transcriptional factor pathway was initially reported to be activated in 
HGSC by the TCGA (30). The reported FOXM1 pathway activity in HGSC was based on 
the degree of overlap between FOXM1 expression and the expression of its reported 
transcriptional targets. However, the extent of FOXM1 overexpression in HGSC as 
compared to a normal control, such as FTE or OSE, was not determined. To address this, 
we retrieved the provisional TCGA HGSC microarray mRNA expression dataset and 
compared FOXM1 expression in normal ovary tissue, primary and recurrent HGSC 
tumors. We observed a significant increase in FOXM1 expression for primary and 
recurrent tumor as compared to normal ovary tissue, showing that FOXM1 is 




compared by stage and grade. We found that FOXM1 expression was increased in high 
grade (grade 2 and 3; HGSC) but we did not observe a significant difference by stage 
(Figure 13B-C). FOXM1 has three known splice variants: FOXM1a, b, and c, which 
encode proteins with varying activities (10). Furthermore, current knowledge of FOXM1 
isoform expression in different cancer types is inconsistent and the isoform expression is 
not known in HGSC. To address these issues and determine FOXM1 isoform expression 
in HGSC, we then retrieved the TOIL TCGA RNA-seq dataset from UCSC Xena. The TOIL 
dataset was a reprocess of raw TCGA RNA-sequencing data to correct for batch effects 
and to allow for the merging of samples across all TCGA datasets for pan-cancer analyses 
(157). We then analyzed the TOIL HGSC RNA-seq dataset and compared FOXM1 isoform 
expression in primary tumors samples and found that FOXM1c is the predominant isoform 
expressed in HGSC, followed by FOXM1b and FOXM1a (Figure 13D). Furthermore, we 
analyzed TOIL TCGA pan normal and cancer tissue RNA-seq dataset to determine if 
FOXM1 isoforms are differentially expressed across pan-normal and -cancer tissues and, 
more importantly, how the expression compares with HGSC tissues. In agreement with 
the HGSC isoform expression data, pan-normal and -cancer tissues show that FOXM1c 
is the predominant isoform expressed, followed by FOXM1b and FOXM1a (Figure 13E). 
These data suggest that FOXM1 isoform ratios are relatively similar in normal and cancer 
tissues; therefore, the observed increase in FOXM1 expression in cancer is not the result 
of the differential expression of only a single isoform.  
We next validated the TCGA HGSC FOXM1 expression using our own 
independent set of EOC tissues with diverse histology, stage, and grade (158,159). RT-
qPCR analysis demonstrated that FOXM1 is frequently overexpressed in different EOC 
histological subtypes relative to normal ovary (NO), and furthermore shows increased 




expression of FOXM1 isoforms we observed in TCGA HGSC, we used FOXM1 isoform-
specific primers and performed RT-qPCR to quantify their expression, and in agreement 
with the TCGA HGSC data, we found that FOXM1c is the predominant isoform expressed 
in HGSC, followed by FOXM1b and FOXM1a (Figure 14D). Similarly to the mRNA, 
FOXM1 protein expression was elevated in EOC as compared to NO (Figure 14E). 
Together, these data agree with our TCGA analysis, showing that EOC and HGSC 
exhibits frequent overexpression of FOXM1.  
 
FOXM1 expression in HGSC cell models  
Thus far, our analyses have been performed with HGSC tumors which are subject 
to genetic heterogeneity. We next used clinically relevant cell models of human HGSC to 
examine genetic influences on FOXM1 expression (160). All cell lines used have TP53 
mutations as well as additional genetic alterations relevant to HGSC (Figure 15A). We 
found that FOXM1 mRNA expression was elevated in all but one cancer cell line as 
compared to hOSE cells and was heterogeneous in the HGSC cell types (Figure 15B). 
Notably, highest FOXM1 expression was observed in the two cell lines (SNU-119, 
COV362) in which the FOXM1 locus is amplified. Isoform-specific RT-qPCR revealed 
highest expression of FOXM1c, moderate expression of FOXM1b, and low expression of 
FOXM1a in HGSC cell lines. FOXM1c expression was highest in the SNU-119 and 
COV362 lines, in which FOXM1 is amplified (Figure 15C). The relative expression of the 
three FOXM1 isoforms agrees with our data using primary HGSC tumors (Figure 13C). In 
further agreement, FOXM1 protein expression was highest in cell lines with increased 





Disruption of Rb and p53 induces FOXM1 expression in murine and human OSE 
cells  
The OSE is a potential tissue of origin for EOC, and primary OSE cells are useful 
for exploring EOC relevant processes (161,162). We first used established murine OSE 
(mOSE) cell models to examine mechanisms regulating FOXM1 expression. We focused 
on TP53 and RB1, as these disruptions are recurrent in HGSC (30). Trp53 and Rb1 
knockout was achieved through Ad-Cre infection of mOSE cells as described previously 
(Figure 16A) (163). While loss of either tumor suppressor gene (TSG) alone resulted in a 
modest upregulation of Foxm1, combined p53 and Rb loss led to a robust induction (Fig 
16B). Similar effects were observed for FOXM1 protein expression (Figure 16C). We next 
investigated the potential role of p53 and Rb in FOXM1 regulation in human OSE (hOSE) 
cells by measuring FOXM1 expression in hOSE cells immortalized with either SV40 Large 
T antigen (IOSE-SV), which leads to potent inactivation of p53 and Rb, or hTERT (IOSE-
T), which leaves both proteins intact (125). IOSE-SV cells showed significantly higher 
levels of expression of both FOXM1 mRNA and protein as compared to IOSE-T or primary 
(non-immortalized) human OSE cells (Figure 16D-E). These data reveal that Rb and p53 
play a major role in regulating FOXM1 expression in OSE cells.  
 
FOXM1 is overexpressed in murine ovarian cancer driven by combined p53/Rb1 
disruption 
To complement the OSE cell studies described above, we measured FOXM1 
expression in murine ovarian tumors developing after dual disruption of p53 and Rb in the 
OSE. As shown in Figure 17A-B, FOXM1 mRNA and protein expression were significantly 
increased in ovarian tumors as compared to the mouse normal ovary control. These in 




overexpression in ovarian cancer. Notably, immunohistochemistry (IHC) analyses of the 
ovarian tumors arising in this model indicated that the tumors were negative for cytokeratin 
expression and positive for smooth muscle actin (Figure 17C). This finding suggests that 
cancer in this model may represent leiomyosarcoma, and not EOC, as was reported 
previously (163). 
 
E2F1 and FOXM1 expression in OSE cells and EOC 
Transcriptional activation of FOXM1 following Rb loss suggests that E2F 
transcription factors may contribute to FOXM1 overexpression. To test this, we used 
IOSE-SV and COV362 cells, which have high FOXM1 expression as well as alterations in 
p53 and Rb. Following E2F1 knockdown by siRNA (Figure 18A), FOXM1 mRNA 
expression in both cell types was significantly reduced, as compared to the non-targeting 
siRNA control (Figure 18B). To validate this finding in the primary disease setting, we 
tested whether FOXM1 correlates with E2F1 expression in human EOC. As shown in 
Figure 18C-D, in both the TCGA HGSC dataset and in our independent set of EOC 
tissues, expression of FOXM1 and E2F1 were highly correlated. Together, these data 
implicate E2F1 in promoting FOXM1 expression in EOC. 
 
Deregulation of the Rb-E2F pathway contributes to FOXM1 overexpression in 
fallopian tube epithelial cells 
 Thus far we determined that FOXM1 expression was increased with loss of p53 
and Rb in OSE models, while FOXM1 expression was decreased with knockdown of 
E2F1. We next validated these findings in a more relevant HGSC precursor cell model 




overexpress mutant p53-R175H (FT282), large T antigen (FT190) or Cyclin E1 (FT282-
E1). Similarly to our data in IOSE-T, the large T-expressing FTE cells showed increased 
FOXM1 mRNA and protein expression, as compared to FTE cells expressing mutant p53 
alone (Figure 19A-B). Interestingly, the Cyclin E1 expressing cells showed the highest 
expression of FOXM1 and thus revealed a new upstream regulator of FOXM1 (Figure 
19A-B). To improve upon these models, we used the TERT-immortalized FTE-expressing 
mutant p53 as a model to introduce temporal genetic modifications to the Rb-E2F pathway 
to further understand upstream regulators of FOXM1 expression. To determine the impact 
of RB loss, we modified the widely used lenti-CRISPR vector into an inducible system and 
engineered FTE cells for RB1 knockout using a previously characterized guide RNA to 
human RB1 (164,165). We doxycycline treated FTE cells engineered with inducible 
CRISPR-Cas9 targeted to RB1 for 72 hours then sorted cells based on positive GFP 
expression to enrich for knockout. These cells were then expanded in the absence of 
doxycycline for one week and harvested for RNA and protein. We then characterized the 
mRNA and protein expression for RB1 and FOXM1, and we observed a significant 
increase in FOXM1 expression with RB knockout (Figure 19C-D). Similarly, we 
overexpressed E2F1 in FTE cells using a doxycycline inducible lentiviral vector to 
complement our prior results when we knocked down E2F1 with a siRNA. FTE cells 
engineered for E2F1 inducible expression were doxycycline treated for 72 hours then 
analyzed for E2F1 and FOXM1 mRNA and protein expression. In agreement with previous 
data, we observed increased FOXM1 expression when E2F1 was overexpressed (Figure 
19E-F). Cyclin E1 is frequently amplified in HGSC, resulting in its overexpression (155). 
Furthermore, when Cyclin E1 interacts with its kinase, CDK2, this complex phosphorylates 
RB to release E2F1. Since we observed in increase in FOXM1 expression in the FTE cells 
engineered for constitutive Cyclin E1 expression, we next overexpressed Cyclin E1 in 




in a dose-dependent manner (Figure 19G-H). Collectively, these data indicate that 
deregulation of the Rb-E2F pathway contributes to the frequent overexpression of FOXM1 
in HGSC precursor lesions and primary tumors.  
 
Functional contribution of FOXM1 to EOC cell cycle progression and target gene 
expression 
To determine if FOXM1 plays a functional role in EOC cells, we explored its 
canonical function in cell cycle progression using knockdown and overexpression 
approaches. Knockdown of FOXM1 was efficient in IOSE-SV cells and led to accumulation 
of cells in G2-M, with concomitant decreases in both G1 and S (Figure 20A and C). 
Interestingly, in COV362 cells, FOXM1 knockdown also led to decreased cells in S phase 
but caused accumulation of cells in G1 with no significant alteration of G2-M (Figure 20B 
and D). These data suggest that FOXM1 regulates both the G1/S and G2/M checkpoints, 
but in a cell context-dependent manner. To determine whether the observed effect of 
FOXM1 knockdown on cell cycle progression coincided with altered expression of relevant 
FOXM1 target genes, we analyzed SKP2, PLK1, and CCNB1 expression. SKP2 promotes 
G1-S transition, while PLK1 and CCNB1 promote G2-M transition, both downstream of 
FOXM1 (66,68,166). In agreement with our cell cycle data, FOXM1 knockdown in IOSE-
SV and COV362 downregulated these genes, with the lone exception of PLK1 in COV362 
(Figure 20E-F).  
In addition to FOXM1 knockdown, we overexpressed FOXM1b or FOXM1c using 
a stable doxycycline inducible system in primary hOSE cells. Interestingly, while the 
mRNA expression levels were identical, the FOXM1c protein appeared to be more stable 
than FOXM1b in these cells (Figure 21B). FOXM1c overexpression in hOSE led to 




overexpression of FOXM1b did not alter cell cycle (data not shown). To determine whether 
the effect of FOXM1c overexpression on cell cycle coincided with altered expression of 
relevant FOXM1 target genes, we again analyzed SKP2, PLK1, and CCNB1. 
Overexpression of FOXM1c in hOSE cells led to upregulation of PLK1 and CCNB1, while 
SKP2 was unaffected (Figure 21D). These data are consistent with the functional impact 
of FOXM1 in EOC cell cycle regulation and suggest that this activity may be mediated by 
FOXM1’s function as a transcriptional regulator. Although the effects of FOXM1c on cell 
cycle was modest, this could be due to the primary hOSE cell model used, which is 
assumed to have a functional p53 pathway. In agreement, the specific effect of FOXM1 
overexpression on cell cycle progression in primary hOSE are reminiscent of that reported 
in cancer cells, although the effects were more robust in cancer cells (167,168).  
 
Summary 
Together, our data implicate gene amplification, p53 inactivation, and Rb-E2F 
deregulation in FOXM1 overexpression in HGSC. FOXM1 amplification and expression 
are highest in HGSC compared to other TCGA cancer types but comparable to basal 
breast subtype. Among FOXM1 isoforms, FOXM1c showed highest expression in HGSC 
cells and tumors. FOXM1 was overexpressed in late-stage, high-grade disease, and 
FOXM1 gene amplification, but not expression, correlated with reduced HGSC survival. 
Finally, we demonstrate that FOXM1 activates target genes that positively regulate 
progression through the G1/S and G2/M checkpoints, and this functionally contributes to 
cell cycle progression in OSE and HGSC cell models. Finally, we identified CCNE1 as a 



















Figure 9. FOXM1 protein expression (RPPA, RBN normalized) across TCGA cancer 
types. TCGA cancer cohorts are listed on the x-axis and ranked according to median 
FOXM1 expression with the highest expression on the left. Median lines are shown for 
























Figure 10. Recurrent sites of DNA copy number amplification in HGSC determined 
by GISTIC. The GISTIC plot shows 33 recurrent sites of DNA copy number amplification 
in 579 TCGA HGSC samples. The x-axis displays statistical significance as FDR q-value. 
The black vertical line indicates the threshold for significance, which is set with an FDR q-
value less than 0.25. Chromosomes listed on the left are arranged from chromosome 1 
on top to chromosome X on the bottom. Significantly amplified cytobands are listed on the 
right. The 12p13.33 peak is highlighted on the plot. The GISTIC data was retrieved on 
8/21/2015 from the Broad Institute TCGA Genome Data Analysis Center. TCGA HGSC 































Figure 11. FOXM1 copy number alterations (CNA) and overall survival in HGSC. A. 
FOXM1 amplification frequency in TCGA datasets, showing the 19 cancer types from 
Figure 7. Arrow indicates HGSC. B. FOXM1 CNA in HGSC TCGA datasets as determined 
by GISTIC. C. FOXM1 mRNA expression (RNA Seq V2 RSEM, log2) compared to FOXM1 
copy number in HGSC TCGA datasets. D. FOXM1 protein expression (RPPA) compared 
to FOXM1 copy number in HGSC TCGA datasets. E. FOXM1 mRNA expression (RNA 
Seq V2 RSEM, log2) correlated with FOXM1 protein expression (RPPA) in HGSC TCGA 
datasets. F-H. Overall survival as a function of F. FOXM1 amplification, G. FOXM1 mRNA 
expression (dichotomized by group median) and H. FOXM1 protein expression (RPPA) 
(dichotomized by group median) in HGSC TCGA datasets. The p value for Logrank test 









Figure 12. FOXM1 copy number alterations (CNA) and expression in TCGA HGSC 
vs breast tissues. A. FOXM1 amp frequency in HGSC vs breast molecular subtypes. B. 
FOXM1 copy number status in HGSC vs basal breast. C-D. FOXM1 expression in HGSC 
vs breast molecular subtypes C. mRNA expression (RNA-seq) and D. protein expression 































Figure 13. FOXM1 expression in TCGA high-grade serous ovarian cancer. A. FOXM1 
mRNA expression HGSC primary and recurrent tumor as compared to normal ovary 
(RNA-seq) B. FOXM1 mRNA expression in serous ovarian cancer as function of 
pathological grade.  C. FOXM1 mRNA expression in serous ovarian cancer as a function 
of disease stage (RNA-seq). D-E. FOXM1 isoform expression in D. TCGA HGSC tissues 
and E. TCGA pan-normal and -cancer tissues is represented as percentage of total 
FOXM1 transcript levels measured by RNA-seq. Lines represent group medians. The 
Mann-Whitney test P value is shown. P value designation: **** < 0.0001, *** < 0.001, ** < 






Figure 14. FOXM1 expression in EOC tissues. A. FOXM1 expression measured with 
RT-qPCR (log10) in EOC histological subtypes as compared to normal ovary (NO). 
FOXM1 expression was normalized to 18s rRNA. B. FOXM1 expression in NO and in 
EOC as a function of disease stage. C. FOXM1 expression in NO and in EOC as a function 
of pathological grade. Lines represent group medians. Mann-Whitney test p values are 
shown. D. FOXM1 isoform specific RT-qPCR (log10) measured in HGSC tissues. E. 
FOXM1 Western blot analysis in NO and EOC. Ponceau S staining is shown as a loading 
control. Lines represent group medians. The Mann-Whitney test P value is shown. P value 






Figure 15. FOXM1 expression in HGSC cell lines. A. Relevant genetic alterations in 
HGSC cell lines. Data were retrieved from the CCLE dataset and copy number alterations 
were visualized with IGV as described in Methods. B. FOXM1 mRNA expression in HGSC 
cell lines and hOSE cells (control) was measured by RT-qPCR. C. Isoform specific 
FOXM1 mRNA expression in HGSC cell lines was measured by RT-qPCR (log10). D. 
FOXM1 protein expression in HGSC cell lines and hOSE (control) was measured by 



























Figure 16. FOXM1 expression in murine and human OSE cells following Rb and/or 
p53 abrogation. A. PCR genotyping of mOSE cells following infection with recombinant 
adenovirus expressing enhanced GFP (Ad-eGFP, control) or Cre recombinase + eGFP 
(AdCre-eGFP). B-C. FOXM1 expression in Rb and/or p53 floxed (control) and knockout 
(post-Cre infection) mOSE cells. B. Foxm1 RT-qPCR with respective fold-change relative 
to the floxed control. Data represent mean ± SD. Students t-test p value is shown. C. 
FOXM1 Western blot with respective fold change relative to the floxed control, performed 
with nuclear lysates. Ponceau S staining is shown as a loading control. D-E. FOXM1 
expression in primary and immortalized human OSE cells (hOSE and IOSE-T or IOSE-
SV). Cell line descriptions are provided in the Methods. D. FOXM1 RT-qPCR. Data 
represent mean ± SD. E. FOXM1 Western blot. β-actin is shown as a loading control. 








Figure 17. FOXM1 expression in Rb1/Trp53 knockout-driven murine ovarian cancer. 
A-B. FOXM1 expression in Rb1/Trp53 knockout murine ovarian tumor tissues (T) and 
murine normal ovary control tissue (N). The mouse model is described in Methods. A. 
Foxm1 RT-qPCR. Data represents means ± SD. B. FOXM1 Western blot. β-actin is shown 
as a loading control. C. Ovarian tumor histology in Rb/p53 knockout mice. Paraffin 
sections of the tumors were stained with H&E or specific antibodies to pan-cytokeratin 
(Pan-CK) or smooth muscle actin (SMA). Images were captured using 20X objective. 









Figure 18. E2F1 and FOXM1 expression in IOSE-SV, EOC cells, and EOC tissues. A-
B. siRNA knockdown of E2F1 (10nM) in IOSE-SV and COV362 cells for 72 hours. A. E2F1 
Western blot. β-actin is shown as a loading control. B. FOXM1 RT-qPCR, normalized to 
18s rRNA. Data represent mean ± SD. Student’s t-test p value is shown. C-D. E2F1 and 
FOXM1 expression correlation in human EOC tissues. C. Correlation in 263 HGSC tissues 
from TCGA datasets (gene expression determined by RNA seq V2, log2). D. Correlation 
in an independent set of 40 EOC tissues (gene expression determined by Affymetrix HG 




























Figure 19. FOXM1 expression in FTE cells engineered for deregulation of the Rb-
E2F pathway. A-B. FOXM1 mRNA and protein expression were measured by RT-qPCR 
and Western blot, respectively, in FTE cells. β-actin is shown as a loading control. C-D. 
FOXM1 expression by RT-qPCR and Western blot, respectively, in RB1 CRISPR KO 
FT282 cells. E-F. FOXM1 expression by RT-qPCR and Western blot, respectively, in 
E2F1-inducible FTE cells. G-H. FOXM1 expression by RT-qPCR and Western blot, 
respectively, in CCNE1-inducible FTE cells. Bars represent mean ± SD. Student’s t test p 






























Figure 20. Impact of FOXM1 knockdown on cell cycle progression and target gene 
expression in IOSE-SV and COV362 cells. Transient siRNA-mediated knockdown of 
FOXM1 (20nM) was completed for 72 hours. A-B. Validation of FOXM1 protein 
knockdown in A. IOSE-SV cells and B. COV362. FOXM1 protein expression was 
determined by Western blot, and β-actin is shown as a loading control. C-D. Cell cycle 
analysis of C. IOSE-SV and D. COV362 cells following FOXM1 or control siRNA 
treatment. E-F. FOXM1 target gene expression determined by RT-qPCR in E. IOSE-SV 
and F. COV362 cells, following FOXM1 or control siRNA treatment. Expression data are 
shown for SKP2, PLK1, and CCNB1, each normalized to 18s rRNA. Bars represent mean 
± SD. Student’s t test p values are shown. P value designation: **** < 0.0001, *** < 0.001, 






Figure 21. Impact of FOXM1 overexpression on cell cycle progression and target 
gene expression in hOSE cells. A-B. Doxycycline inducible FOXM1b and FOXM1c 
overexpression in primary hOSE cells after 72 hours of doxycycline treatment as indicated. 
A. FOXM1 RT-qPCR (log10). B. FOXM1 Western blot. β-actin is shown as a loading 
control. C. Cell cycle analysis following doxycycline inducible FOXM1c overexpression in 
primary hOSE cells after 72 hours of treatment. Cells treated with 250ng/ml and 1000ng/ml 
doxycycline were combined for analysis and compared against the control without 
treatment. D. FOXM1 target gene expression was measured by RT-qPCR in hOSE cells 
following 72 hours of doxycycline treatment to induce FOXM1c. Expression data are 
shown for SKP2, PLK1, and CCNB1, each normalized to 18s rRNA. Data represents mean 
± SD.  Student’s t-test p values are shown. P value designation: **** < 0.0001, *** < 0.001, 




CHAPTER 4: FOXM1 AND GENOMIC INSTABILITY IN HIGH-GRADE SEROUS 
OVARIAN CANCER 
Introduction 
While FOXM1 is linked to several cancer hallmarks, its role in genomic instability 
has not been explored in HGSC, a disease that exhibits frequent FOXM1 activation and 
has genomic instability as a key defining molecular feature (30). Additionally, we have 
shown that HGSC has the highest level of FOXM1 expression among TCGA cancer types 
and an early pan-cancer analysis observed that FOXM1 expression is associated with 
genomic instability (37). FOXM1 is a transcriptional activator of genes involved in DNA 
replication initiation and cell cycle progression (68,86,130,166), and when dysregulated, 
such genes may promote DNA replication stress and genomic instability (88). These 
observations suggest that aberrant FOXM1 expression and transcriptional activity may 
induce DNA replication stress and promote genomic instability in HGSC. The objective of 
the current study was to determine the functional consequence of aberrant FOXM1 
expression on DNA replication stress and genomic instability in HGSC. For this task, we 
utilized publicly available TCGA datasets, immortalized human FTE cell models, and 
human HGSC cell lines.  
 
Results 
FOXM1 associates with markers of DNA replication stress and genomic instability 
in HGSC tissue and cell lines 
FOXM1 expression has been associated with genomic instability (37,85), but it is 




Oncogene-induced DNA replication stress is linked to genomic instability (88,92,97,169). 
We hypothesized that FOXM1 expression promotes DNA replication stress, providing a 
mechanistic link to genomic instability. To test the possibility that FOXM1 induces DNA 
replication stress, we first analyzed TCGA HGSC cancer datasets to determine the 
association of FOXM1 expression with the expression of P-CHK1-S345, an established 
marker of DNA replication stress (58). Notably, FOXM1 mRNA significantly correlated with 
P-CHK1-S345 protein expression (Figure 22A). The comparison between FOXM1 protein 
and P-CHK1-S345 protein expression did not show a significant correlation but it did show 
a direct correlation (Figure 22B). The discrepancy in correlation for FOXM1 mRNA and 
protein expression may be due to technical differences in the assays (e.g. RNA-seq vs 
RPPA) or differences in samples and sample size. We next analyzed TCGA HGSC 
datasets to determine if FOXM1 expression showed a relationship with genomic instability 
in the form of total mutation count in coding regions of the genome (mutation burden) or 
genome wide CNAs as a fraction of the total genome (fraction of copy number altered 
genome). Analysis of TCGA HGSC data showed a signification correlation between 
FOXM1 mRNA and protein expression and genome wide copy number alterations, a 
marker of genomic instability (Figure 22E-F). In contrast, FOXM1 expression did not show 
a significant correlation with the mutation burden (Figure 22C-D), suggesting FOXM1 may 
promote global copy number alterations but not mutations. Controlling for FOXM1 copy 
number, which we have shown contributes to FOXM1 expression in HGSC (36), we made 
similar comparisons using samples with diploid FOXM1 copy number status and again we 
observed a significant correlation between FOXM1 protein expression and genome wide 
copy number alterations (Figure 22H). The correlation of CNA with FOXM1 mRNA showed 
a direct relationship but did not reach statistical significance, possibly due to smaller 
sample size (Figure 22G). These data suggest that FOXM1 may promote DNA replication 




To expand and independently confirm these observations, we analyzed the Cancer 
Cell Line Encyclopedia (CCLE) pan-cancer and ovarian cancer cell line datasets. Notably, 
FOXM1 protein significantly correlated with P-CHK1-S345 protein expression in both 
CCLE pan-cancer and ovarian cancer cell lines (Figure 23A-B). We then measured total 
FOXM1 protein along with canonical DNA replication stress response markers in a panel 
of HGSC cell lines as compared to an immortalized FTE cell line which represents the p53 
signature precursor lesion in HGSC (Figures 2 and 6). We observed that HGSC cells 
showed increased basal levels of phosphorylated CHK1 and RPA2 as compared to the 
FTE cells (Figure 24A). We also observed that FOXM1 protein expression was increased 
in HGSC cells as compared to FTE (Figure 24A). We next overexpressed FOXM1 in FTE 
cells then measured the expression of P-CHK1-S345 to determine the relationship in their 
expression. We found a dose dependent response between FOXM1 and P-CHK1 
expression (Figure 24B). These data support the idea that FOXM1 induces DNA 
replication stress in HGSC, potentially contributing to genomic instability.  
 
FOXM1 transcriptional activity is required for the induction of DNA replication 
stress and DNA damage in FTE cells 
Our central hypothesis is that FOXM1 induces DNA replication stress thereby 
promoting genomic instability. To test whether FOXM1-induced DNA replication stress is 
dependent on its transcriptional activity, we generated a FOXM1 DBD mutant where three 
key residues in the FOXM1 DNA binding domain (DBD) were changed to alanine. These 
amino acid residues were shown to be essential for FOXM1 to bind DNA based on 
previous reports using X-crystallography and ChIP-seq (132,170). We next overexpressed 
FOXM1 wild-type and DBD mutant in FTE cells using a doxycycline inducible system to 




We first validated the functional activity of FOXM1 wild-type and DBD mutant by 
measuring the endogenous expression of a canonical target gene, CCNB1, and by the 
widely used 6X FOXM1 luciferase reporter assay (171). Following doxycycline induction 
of wild-type FOXM1 in FTE cells and transfection of the the 6X FOXM1 reporter construct, 
we observed a significant increase in luciferase activity, but not for the DBD mutant (Figure 
25A). In agreement, we observed a dose dependent increase in CCNB1 mRNA 
expression, but we did not see a significant increase in CCNB1 mRNA with the induction 
of FOXM1 DBD mutant (Figure 25B). Most importantly, following doxycycline induction, 
we observed that wild-type FOXM1 increased P-CHK1-S317 and -S345 but the FOXM1 
DBD mutant did not (Figure 25C). These data demonstrate that FOXM1 transcriptional 
activity is related to its ability to induce DNA replication stress in a relevant HGSC 
precursor cell model.  
The above data show that FOXM1 is capable of inducing a DNA replication stress 
response in FTE cells. Therefore, we hypothesized that FOXM1 not only induces DNA 
replication stress but also induces DNA damage. To test this, we asked whether FOXM1 
expression in human immortalized FTE cells leads to detectable levels of DNA damage 
measured at single cell resolution with the Comet assay. Following doxycycline induction, 
we observed an increased percentage of Comet tail DNA in FTE cells expressing wild-
type FOXM1, as compared to FTE cells expressing FOXM1 DBD mutant, suggesting that 
transcriptional activity is required for this phenotype as well (Figure 25D). 
 
FOXM1 and CCNE1 produce comparable levels of DNA damage in FTE cells 
FOXM1 is associated with genomic instability but the mechanistic link has not been 
demonstrated. Oncogene-induced DNA replication stress is linked to genomic instability 




direct relationship with markers of DNA replication stress and genomic instability in TCGA 
HGSC. In addition, FOXM1 expression induced the expression of DNA replication stress 
markers and increased DNA damage as measured with the Comet assay. We extended 
these studies by comparing the DNA damage phenotypes between FTE cells expressing 
FOXM1 or CCNE1, an oncogene known to induce DNA replication stress and DNA 
damage in FTE cells (155). We observed that both FOXM1 and Cyclin E1 showed 
increased and comparable levels of γ-H2AX and percentage of Comet tail DNA, but 
CCNE1 showed a greater increase in P-CHK1 (Figure 26A-C). Furthermore, we used Flow 
Cytometry as an independent readout of DNA damage by measuring the levels of γ-H2AX 
in S-phase cells, or the DNA damage occurring during DNA replication. In agreement with 
the Comet data, we observed that FOXM1 expressing cells showed increased expression 
of γ-H2AX in S-phase as compared to vector control (Figure 26D). These results agree 
with the DNA replication stress phenotype we observed for wild-type and DBD mutant 
FOXM1, suggesting that DNA replication stress links FOXM1 to genomic instability. 
 
FOXM1 promotes cell cycle progression in fallopian tube epithelial cells 
 Thus far in our cell models, FOXM1 overexpression in FTE cells activated ATR-
CHK1 signaling with a corresponding increase in DNA damage, indicative of DNA 
replication stress. When cells experience DNA replication stress, the ATR-CHK1 signaling 
pathway is activated, thereby promoting fork stabilization and restart, and inducing cell 
cycle arrest in the S and G2 phases allowing time for damaged DNA to be repaired prior 
to entering mitosis (88). Therefore, the FTE cells with FOXM1-induced DNA replication 
stress and DNA damage might have increased cells in the S and G2/M phases although 
FOXM1 is known to promote G2-M progression. To test this, we overexpressed FOXM1 




analysis after 72 hours of doxycycline induction (Figure 27A). Unexpectedly, the FTE cells 
expressing the FOXM1 DBD mutant showed an increased number of cells in the G2/M 
phase of the cell cycle (Figure 27B). In contrast, FTE cells expressing wild-type FOXM1 
showed an increase in G1 and S phases but a decrease in the G2/M phase, suggesting 
FOXM1 promoted cell cycle progression through the G2/M checkpoint, which agrees with 
its canonical function in cell cycle regulation (Figure 27B). In agreement with previous 
reports using other cell types, we observed that FTE cells expressing Cyclin E1 showed 
a decreased G1 phase with increased S and G2/M phases (Figure 27B). This suggests 
that Cyclin E1 promoted cell cycle progression though the G1/S checkpoint but the 
resulting DNA replication stress leads to cell cycle arrest in S and G2/M phases (172). 
Finally, the failure of FOXM1-expressing FTE cells to arrest in S and G2/M either suggests 
that FOXM1 does not induce a traditional DNA replication stress phenotype or the 
canonical function of FOXM1 has an opposing force on the ATR-CHK1-mediated cell cycle 
arrest, and thus the cells fail to arrest and instead progress into mitosis.  
 
FOXM1 promotes replication fork progression in fallopian tube epithelial cells 
We observed that wild-type FOXM1 expression activates markers of DNA 
replication stress while promoting cell cycle progression. To determine how FOXM1 
associates with these phenotypes, we performed DNA fiber analysis, which is the gold 
standard for measuring DNA replication stress and the most comprehensive method for 
assessing the DNA replication dynamics among a population of mammalian cells 
(169,173). We performed DNA fiber spreading with FTE cells engineered for doxycycline 
inducible expression of empty vector (control), wild-type FOXM1, DBD mutant FOXM1, 
and Cyclin E1, an oncogene shown to cause DNA replication stress in other cell types by 




doxycycline for 72 hours prior to labeling them with nucleotide analogues for DNA fiber 
analysis. Cells were harvested for DNA fiber and we measured fork rate and the number 
of origins fired. As expected, based on previous reports for other cell types, Cyclin E1 
expression in FTE cells decreased fork rate and increased origin firing (Figure 28A-C) 
(120,122,123). Unexpectedly, we observed that wild-type FOXM1 not only promoted 
increased fork rate in FTE cells, but it increased origin firing (Figure 28A-C). Also 
surprising, but in agreement with the cell cycle data, the FOXM1 DBD mutant decreased 
fork movement (Figure 28A-C), the phenotype that results from cells experiencing DNA 
replication stress. DNA replication stress is more generally defined by the replication fork 
dynamics where there is an observed slowing or stalling of the replication forks (169). This 
is also the accepted definition for oncogene-induced DNA replication stress and this type 
of phenotype is often reported in the literature for most oncogenes (88). However, based 
on this recent review, not all oncogenes that promote DNA replication stress promote fork 
stalling (88). In fact, some oncogenes increase fork speed while inducing DNA damage 
although the activation of ATR-CHK1 signaling in these studies was not characterized 
(176-179). Given this knowledge and our recent data, we hypothesized that FOXM1 may 
activate target genes involved in DNA replication or chromatin remodeling that facilitate 
fork movement. 
 
FOXM1 activates target genes involved in the regulation of the G2/M cell cycle 
checkpoint 
Oncogenes, such as Ras, Myc, and Cyclin E, deregulate E2F-dependent G1/S 
transcription to drive progression into S phase and promote DNA replication (180,181). 
Specifically, Cyclin E1 expression enhanced a global transcriptional program, causing 




or CDK inhibition (175,180). However, the mechanism for how Cyclin E1 causes DNA 
replication stress in FTE cells is not known. Furthermore, DNA replication can be affected 
by the expression and interplay between different chromatin factors and histone 
modifications to promote rapid replisome progression (182). In this context, FOXM1 can 
bind DNA and activate target gene expression, but the FOXM1 DBD mutant is deficient in 
this function. Additionally, FOXM1 wild-type increases DNA fork rate and FOXM1 DBD 
mutant decreases DNA fork rate. Therefore, FOXM1 wild-type might activate the 
expression of genes involved in DNA replication initiation and elongation, and chromatin 
remodeling, thus facilitating fork movement.  
To identify a possible mechanism for FOXM1-induced fork movement, as well as 
Cyclin E1-induced fork stalling, we performed RNA-seq analysis with FTE cells expressing 
empty vector (control), FOXM1 and Cyclin E1 (Figure 29A-B). GSEA analysis for Cyclin 
E1-expressing FTE cells showed an enriched gene expression signature for DNA 
replication and initiation (Figure 30A). This suggests that Cyclin E1 expression promotes 
increased DNA replication initiation or origin firing, a condition which can lead to depletion 
of nucleotide pools, and eventually fork stalling and DNA replication stress (169). 
Interestingly, we observed that the FTE cells expressing Cyclin E1 show a significantly 
enriched FOXM1 pathway gene expression signature (Figure 30B) and this is consistent 
with our prior data (Figure 19G-H). Gene Set Enrichment Analysis (GSEA) of FTE cells 
expressing FOXM1 showed an enriched expression signature for FOXM1 target genes, 
specifically those involved in the regulation of the G2/M checkpoint and mitosis, rather 
than a gene expression signature of DNA replication or chromatin remodeling (Figure 30C-
D). We validated the FOXM1 target gene expression by RT-qPCR and found that FTE 
cells expressing FOXM1 or Cyclin E1 both showed increased mRNA expression for 




expressed in our RNA-seq analysis for FTE cells expressing FOXM1, we measured the 
expression of BRCA2 mRNA by RT-qPCR because it has been reported to be a FOXM1 
target gene (91). Furthermore, RNA-seq analysis showed that BRCA2 mRNA expression 
was increased in FTE cells expressing CCNE1. These data support a functional role for 
FOXM1 in the G2/M checkpoint downstream of Cyclin E1 and suggest that FOXM1 
transcriptional activity does not directly explain the increase in fork movement.  
 
Analysis of RPPA functional proteomics data confirms the involvement of FOXM1 
in the G2/M checkpoint  
Our RNA-seq analysis did not identify gene expression changes that may 
contribute to the FOXM1-induced fork movement, therefore, we decided to investigate 
proteomic changes as the possible cause of this phenotype. Reverse phase protein arrays 
(RPPA) provide a large-scale measurement of a defined number of total proteins, and 
phosphorylated and cleaved proteins that can provide insight into post-transcriptional 
changes in multiple signaling pathways, including receptor tyrosine kinases, PI3K‐AKT 
and MAPK cascades, as well as DNA repair, cell cycle and apoptosis/autophagy 
regulators (156,183). We performed RPPA to characterize the proteomic profile in the FTE 
cells expressing FOXM1 and Cyclin E1 to determine if there are differences in these select 
signaling pathways, potentially providing insight for the increased fork rate in FTE cells 
expressing wild-type FOXM1. We overexpressed FOXM1 wild-type, FOXM1 DBD mutant, 
and Cyclin E1 in an inducible manner by growing cells FTE cells in the presence of 
doxycycline for a period of 72 hours. Proteins were harvested and sent to the RPPA Core 
at MD Anderson for analysis. We used the normalized log2, median centered RPPA data 
to generate heat maps for visualization of the data. Vector control, FOXM1 wild-type, 




unsupervised hierarchical clustering. Interestingly, FOXM1 wild-type and DBD mutant 
clustered together and were more similar to FTE-expressing V control than FTE cells 
expressing Cyclin E1 (Figure 32A). The clustering of FOXM1 wild-type and DBD mutant 
is surprising, considering that FOXM1 DBD does not appear to be transcriptionally active 
and should therefore be more similar to V control. This clustering suggests that the FOXM1 
DBD mutant retains functions independent of FOXM1 transcriptional activity. Furthermore, 
Cyclin E1-expressing FTE cells did not cluster with the other cell types suggesting it has 
a signaling profile that is distinct. Next, the heatmaps were sorted based on ranked 
expression by either FOXM1 wild-type, FOXM1 DBD mutant or Cyclin E1, and the top 10 
proteins were compared (Figure 32B-D). We observed that Cyclin E1 showed very 
dramatic changes in the expression of proteins involved in regulation of the G1/S and 
G2/M checkpoints (Figure 32D). FOXM1 wild-type showed very few changes in cell cycle-
associated proteins except for Cyclin B1, which promotes G2/M progression (Figure 32B). 
Lastly, the FOXM1 DBD mutant did not show changes in the expression of proteins that 
promote G2/M progression (Figure 32C).  
 
FOXM1 directly interacts with proteins involved in DNA replication and epigenetic 
modification  
Our analysis of FOXM1 RNA-seq and RPPA did not identify obvious changes in 
gene or protein expression that could explain the increased fork movement and origin 
firing in FTE cells expressing FOXM1. This suggests that this phenotype is independent 
of FOXM1 transcriptional activity or changes in defined downstream protein levels or 
signaling pathways. We next hypothesized that FOXM1 may interact with chromatin or 




movement. In this context, a recent high-throughput proteomics study characterized 
protein-protein interactions for several transcription factors, including FOXM1 (184). 
Intriguingly, FOXM1 was shown to interact with MCM and ORC proteins, proteins involved 
in DNA replication initiation and elongation, along with known interactions related to its 
canonical function in the activation of target gene expression (184). Furthermore, pathway 
analysis showed that FOXM1 protein interactions were enriched in processes such as 
chromatin modification, DNA replication and transcription (184). FOXM1 protein interacts 
with proteins that modify chromatin such as DNMT3b (185), and besides this recent report, 
its interaction with proteins involved in DNA replication has not been explored. FOXM1 
could interact with DNA replication proteins and thus alter fork movement as we observed 
(Figure 28). To this this hypothesis, we performed co-immunoprecipitation (co-IP) studies 
with HA-tagged FOXM1 wild-type isoforms (a, b and c) and FOXM1 DBD mutant 
constructs expressed in 293T FOXM1 knockout cells (Figure 33A-B). Surprisingly, all 
FOXM1 isoforms, including the DBD mutant, similarly interacted with DNA replication 
proteins (Figure 33C). Our studies were performed with total cell protein so it’s possible 
that the interactions exist within different compartments of the nucleus such as soluble 
and chromatin fractions. More so, the FOXM1 DBD mutant could be interacting with these 
proteins but the protein complexes are not able to bind DNA, thus interfering with their 
functions at chromatin. In an independent experiment, we previously investigated the 
interaction between FOXM1 and DNA methyltransferases (DNMTs) based on a previous 
report showing the interactions of these proteins (185). We indeed observed that FOXM1 
interacts with DNMT1, DNMT3A and DNMT3B, further supporting the protein-protein 
interactions between FOXM1 and proteins involved in DNA replication (Figure 33D). 
However, we do not know yet if these protein-protein interactions occur in the nucleus, on 
chromatin, or at sites of DNA replication. In agreement with these data and support for the 




ORC2 ChiP-seq datasets generated from K562 cells and determined the genome-wide 
correlation in their DNA binding. We observed that FOXM1 and ORC2 show a highly 
significant correlation in their DNA binding, indicated by the shifted foreground peak 
compared to background for both replicates (Figure 34A-B). Together, these data suggest 
that FOXM1 interacts with ORC2 on chromatin and possibly at sites of DNA replication.  
 
FOXM1 functions downstream of Cyclin E1 to promote cell cycle progression  
Thus far, our data shows that Cyclin E1 promotes progression through the G1/S 
checkpoint, which contributes to DNA replication stress and DNA damage, ultimately 
leading to arrest in G2. Furthermore, FOXM1 target genes are activated downstream of 
Cyclin E1 in FTE cells. Based on the FOXM1 gene expression signature and cell cycle 
data, we hypothesized that FOXM1 may cooperate with Cyclin E1 to overcome G2 
blockage and allow unscheduled entry into mitosis with damaged DNA, thus contributing 
to genomic instability. To test this, we expressed FOXM1 wild-type or DBD mutant in the 
backdrop of Cyclin E1 expression in FTE cells (Figure 35A). These cells were doxycycline 
induced for a period of 72 hours then harvested for cell cycle analysis (Figure 35A-B). 
Importantly, we observed that FOXM1 wild-type promoted cell cycle progression through 
the G2/M checkpoint, as shown by the increase in G1 phase and decrease in G2/M phase 
compared to the empty vector control (Figure 35B). Conversely, the FOXM1 DBD mutant 
compounded the Cyclin E1-mediated G2/M arrest as shown by the increased G2/M cells 
(Figure 35B). Notably, these data suggest that FOXM1 functions downstream of Cyclin E1 
in a cooperative fashion to promote cell cycle progression in cells experiencing oncogene-
induced DNA replication stress, allowing premature mitotic entry with damaged DNA, 




FOXM1 transcriptional activity is enhanced by Cyclin E1 in FTE cells 
 We previously observed that FOXM1 is expressed downstream of Cyclin E1 in 
FTE cells (Figure 19G-H). Furthermore, FOXM1 and many of its targets were shown to be 
overexpressed in our RNA-seq analyses of FTE cells expressing Cyclin E1, and GSEA 
showed the FOXM1 pathway to be a significantly enriched gene expression signature 
(Figure 30A-B). Therefore, based on previous reports showing that Cyclin E1-CDK2 
phosphorylates FOXM1, increasing its transcriptional activity (186-188), we hypothesized 
that FOXM1 would be more transcriptionally active in the FTE cells when co-expressed 
with Cyclin E1. To test this, we engineered FTE cells for doxycycline inducible expression 
of Cyclin E1 and vector control, or Cyclin E1 and FOXM1 wild-type. We grew cells in the 
presence of doxycycline for 48 hours then proceeded with RNA-seq analysis to determine 
if Cyclin E1 enhances FOXM1 transcriptional activity (Figure 36A-B). We then compared 
the top differentially expressed genes that clustered together in the heat map to determine 
if there was visual difference in overall transcriptional activity between FTE cells 
expressing FOXM1 or Cyclin E1 alone, or FOXM1 and Cyclin E1 together. We observed 
that FTE cells expressing both FOXM1 and Cyclin E1 have a striking gene expression 
pattern showing increased transcriptional activity compared to FOXM1 or Cyclin E1 alone 
(Figure 37A). To validate these findings, we performed RT-qPCR to measure the 
expression of FOXM1 canonical target genes. We observed that FTE cells expressing 
both wild-type FOXM1 and Cyclin E1 showed the highest expression for FOXM1 target 
genes, but the expression of Cyclin E1 with FOXM1 DBD mutant did not show a difference 
when compared to Cyclin E1 alone (Figure 37B-D). These data and the cell cycle data 
suggest that Cyclin E1 increases the transcriptional activity of FOXM1, thus promoting 





Dual FOXM1 and Cyclin E1 expression induces an enriched genomic instability 
gene expression signature in FTE cells 
 FOXM1 expression has been linked to genomic instability by its inclusion in the 
CIN25/CIN70 expression signature (37). However, the mechanistic relationship between 
FOXM1 and genomic instability is not known. Furthermore, the CIN70 expression 
signature contains many of the FOXM1 target genes and has been used as a readout for 
genomic instability. Therefore, we hypothesized the FTE cells expressing FOXM1 may 
show an enriched gene expression signature for CIN70, which is an extended version of 
the CIN25 gene expression signature. To test this, we generated a GSEA CIN70 geneset 
and performed GSEA analysis with the RNA-seq data from FTE cells expressing FOXM1. 
We observed a significantly enriched CIN70 gene expression signature when FOXM1 was 
expressed in FTE cells (Figure 38A). Our data show that Cyclin E1 expression in FTE 
cells induced DNA replication stress, DNA damage and showed an enriched FOXM1 
pathway gene expression signature. We next performed GSEA analysis to determine if 
FTE cells expressing Cyclin E1 have an enriched CIN70 gene expression signature. We 
observed that Cyclin E1 expression showed a significantly enriched CIN70 gene 
expression, and the enrichment was greater than FOXM1 (Figure 38B). We have shown 
that Cyclin E1 enhances the transcriptional activity of FOXM1, thus promoting increased 
cell cycle progression. Therefore, we hypothesized that FTE cells expressing both FOXM1 
and Cyclin E1 would have the greatest enrichment in the CIN70 gene expression 
signature. We performed GSEA analysis and observed that FTE cells expressing both 
FOXM1 and Cyclin E1 had greater enrichment in the CIN70 gene expression as compared 
to Cyclin E1 or FOXM1 alone (Figure 38C). We next generated a heatmap to compare the 
overall expression of the CIN70 genes among FTE cells expressing FOXM1, Cyclin E1 or 




showed the greatest expression of CIN70 genes followed by Cyclin E1 and FOXM1 
(Figure 38D).  
 
HGSC tumors with overexpression of both FOXM1 and Cyclin E1 show increased 
genomic instability 
 Our data show that Cyclin E1 induces FOXM1 expression and enhances its 
transcriptional activity, promoting cell cycle and genomic instability. This phenotype is 
stronger when FOXM1 is overexpressed together with Cyclin E1. To determine this 
relationship in HGSC, we compared the frequency of FOXM1 and CCNE1 copy number 
gains in TCGA HGSC to determine if they tend to co-exist. We found that FOXM1 and 
CCNE1 copy number gain and amplification have a highly significant tendency to co-occur 
in HGSC (Figure 39A). We then tested if the co-occurring copy number gain contributed 
to increased FOXM1 and Cyclin E1 protein expression. We found that HGSC tumors with 
both FOXM1 and Cyclin E1 copy number gain and amplification showed the highest level 
of FOXM1 and Cyclin E1 protein expression (Figure 39B) compared to either one alone. 
Furthermore, FOXM1 and Cyclin E1 protein expression showed a highly significant direct 
correlation thus providing additional support for cooperativity in HGSC (Figure 39C). FTE 
cells expressing both FOXM1 and Cyclin E1 showed increased enrichment in the CIN70 
gene expression signature (Figure 38C-D). We hypothesized that HGSC tumors with both 
FOXM1 and CCNE1 copy number gain would have increased genomic instability as 
compared to either one alone. To test this, we compared the fraction of the copy number 
altered genome among HGSC tumors that had copy number amp/gain for both FOXM1 
and CCNE1, FOXM1 or CCNE1 alone, or neither. In agreement with the GSEA analysis 
for CIN70 enrichment in FTE cells, we found that HGSC tumors with both FOXM1 and 




followed by Cyclin E1 alone then FOXM1 alone and neither (Figure 39D). Collectively, 
these data suggest that FOXM1 and Cyclin E1 may cooperate to promote genomic 
instability in HGSC.    
 
Summary 
In this study we compared the expression of FOXM1 and markers of genomic 
instability and DNA replication stress. We found that FOXM1 expression correlates with 
genomic instability and DNA replication stress markers, thus providing a mechanism link 
between FOXM1 and genomic instability. We next overexpressed FOXM1 in fallopian tube 
cells and found increased expression of P-CHK1, a marker of DNA replication stress. 
Furthermore, FOXM1 expression in FTE cells resulted in increased DNA damage 
measured with -H2AX expression and Comet assays. Cell cycle analysis revealed a 
phenotype that suggested cell cycle progression, not DNA replication stress. However, 
the expression of the FOXM1 DBD mutant showed a cell cycle profile indicative of DNA 
replication stress. Therefore, we next performed DNA fiber analysis in fallopian tube 
engineered for doxycycline inducible expression of FOXM1 wildtype and DBD mutant, and 
Cyclin E1 to characterize the DNA replication dynamics. We unexpectedly observed that 
FOXM1 expression in FTE cells increased fork rate and origin firing, but even more 
surprising, the FOXM1 DBD mutant decreased fork rate. To determine how FOXM1 may 
increase fork rate, we performed RNA-seq analysis to identify gene expression signatures 
contributing to this phenotype. We found that FOXM1 showed enriched gene expression 
for canonical FOXM1 target genes, specifically that promote G2-M progression and 
mitosis, but we did identify enriched genesets for DNA replication or chromatin 




replication, suggesting the increased fork rate and origin firing that we observed might be 
independent of FOXM1’s canonical role as a transcription factor. We tested if FOXM1 
interacted with proteins involved in DNA replication initiation and found that it not only 
interacted with these proteins, but it also interacted with other chromatin modifying 
proteins, DNA methyltransferases.  
RNA-seq analysis revealed that the FOXM1 pathway is activated downstream of 
Cyclin E1 overexpression in FTE cells. Cyclin E1 expression showed a strong DNA 
replication stress phenotype and increased DNA damage. Taken together, this suggests 
that FOXM1 might play dual oncogenic roles downstream of Cyclin E1: 1) to promote DNA 
fork movement; and 2) to promote cell cycle progression and genomic instability. We found 
that co-expression of FOXM1 with Cyclin E1 partially rescued the cell cycle abrogation but 
both FOXM1 and Cyclin E1 expression promote DNA damage. These findings suggest 
that FOXM1 promotes genomic instability downstream of Cyclin E1 by promoting mitotic 
entry. In support, we found that co-expression of FOXM1 and Cyclin E1 produced a gene 
expression signature that had a significant overlap with the CIN70 gene expression 
signature. In agreement, TCGA HGSC tumors with copy number gain for both FOXM1 


































Figure 22. FOXM1 relationship with DNA replication stress and genomic instability 
in TCGA HGSC. A-B. FOXM1 A. mRNA (RNA-seq) and B. protein (RPPA) correlation 
with P-CHK1-S345 protein (RPPA) in TCGA HGSC. C-D. FOXM1 C. mRNA (RNA-seq). 
and D. protein (RPPA) correlation with mutation burden in TCGA HGSC. E-F. FOXM1. E. 
mRNA (RNA-seq) and F. protein (RPPA) correlation with fraction of the copy number 
altered genome in TCGA HGSC. G-H. FOXM1 G. mRNA (RNA-seq) and H. protein 
(RPPA) correlation with fraction of the copy number altered genome in TCGA HGSC 

















Figure 23. FOXM1 relationship with markers of DNA replication stress in CCLE pan-
cancer and ovarian cancer cell lines. A. FOXM1 protein expression (RPPA) correlation 
with P-CHK1-S345 protein expression (RPPA) in CCLE pan-cancer cell lines. B. FOXM1 
protein expression (RPPA) correlation with P-CHK1-S345 protein expression (RPPA) in 















Figure 24. FOXM1 expression correlates with DNA replication stress markers in FTE 
and HGSC cells.  A. Western blot analysis of canonical markers of DNA replication stress 
among a panel of HGSC cells compared to FTE cells. B. Western blot analysis of P-CHK1-






Figure 25. FOXM1 transcriptional activity is required for DNA replication stress and 
DNA damage in FTE cells. A. 6X FOXM1 reporter activity with FTE cells expressing 
FOXM1 wild-type (WT) or FOXM1 DBD mutant (MT). B. CCNB1 mRNA expression 
measured by RT-qPCR for FTE cells expressing FOXM1 wild-type (WT) or FOXM1 DBD 
mutant (MT). C. Western blot analysis of canonical DNA replication stress markers for 
FTE cells expressing FOXM1 wild-type (WT) or FOXM1 DBD mutant (MT). D. Comet 
assay comparing percent DNA in tail for FTE cells expressing FOXM1 wild-type (WT) or 
FOXM1 DBD mutant (MT). t-test P value is shown. P value designation: **** < 0.0001, *** 





Figure 26. FOXM1 promotes DNA replication stress and DNA damage in FTE cells. 
A. Western blot analysis for markers of DNA damage and replication stress in FTE cells 
engineered for doxycycline inducible V control, FOXM1 and Cyclin E1 expression and 
grown for 72 hours in presence of 1 µg/ml of doxycycline. B. Western blot analysis for 
markers of DNA damage and replication stress with FTE cells engineered for constitutive 
expression of V control, FOXM1 and Cyclin E1. 2 mM Hydroxyurea (HU) and 20 µM 
etoposide were used as positive controls to induce DNA replication stress and DNA 
damage. C. Comet Analysis for cells in panel B. D. FACS analysis of γ-H2AX positivity in 
S phase for FTE cells engineered for constitutive expression of V and FOXM1. 20 µM 
etoposide was used as positive control to induce DNA damage. t-test P value is shown. P 







Figure 27. Cell cycle analysis of FTE cells expressing FOXM1 or Cyclin E1.  A. 
Western blot analysis of FTE cells engineered for inducible expression of V, FOXM1 wild-
type (WT), FOXM1 DBD mutant (MT), and Cyclin E1, and grown in the presence of 
doxycycline for 72 hours. B. Cell cycle analysis of FTE cells engineered for inducible 
expression of V, FOXM1 wild-type (WT), FOXM1 DBD mutant (MT), and Cyclin E1, and 





Figure 28. DNA fiber analysis in FTE cells. A. Fork velocity for inducible FTE cells 
expressing V control, FOXM1 wild-type (WT), FOXM1 DBD mutant (MT) or Cyclin E1 
grown in the presence of doxycycline for 72 hours. Data represents a composite of two 
independent experiments. Median lines shown for all samples. B. The median fork velocity 
for the above data. C. Origin firing for inducible FTE cells expressing V control, FOXM1 
wild-type (WT), FOXM1 DBD mutant (MT) or Cyclin E1 grown in the presence of 
doxycycline for 72 hours. Data represents the average of two experiments with at least 
150 fibers analyzed for each group. P value designation: **** < 0.0001, *** < 0.001, ** < 















Figure 29. RNA-sequencing with FTE cells expressing V control, FOXM1 or CCNE1. 
Inducible FTE cells expressing V control, FOXM1, or CCNE1 were grown in the presence 
doxycycline for 48 hours and cells were harvested for RNA or protein. Sample were 
prepared in triplicate for each group. A. Western blot analysis of FOXM1 and CCNE1 










Figure 30. FOXM1 and Cyclin E1 enriched pathway signatures. A-B. GSEA analysis 
of the top two hallmark pathways for FTE cells expressing CCNE1. A. DNA replication 
and B. FOXM1 pathway. C-D. GSEA analysis of the top two hallmark pathways for FTE 
cells expressing FOXM1. C. FOXM1 pathway and D. G, G2/M phases. Enrichment as a 
function of FTE cells expressing FOXM1 or CCNE1 using RNA-seq expression data. 










Figure 31. Validation of top differentially expressed genes from the RNA-seq 
analysis for FTE cells expressing FOXM1 compared to FOXM1 knockdown and 
CCNE1 expression. A-D. A. CCNA2 B. CCNB1 C. CDC25B and D. BRCA2 mRNA 
expression measured by RT-qPCR from FTE cells expressing control or FOXM1 targeting 
shRNA, empty vector, FOXM1 wild-type (WT), FOXM1 DBD mutant (MT) or Cyclin E1. 
BRCA2 mRNA did not show differential expression in the RNA-seq analysis, but instead 





Figure 32. Heat-maps of RPPA data for FTE cells expressing V, FOXM1 wild-type, 
FOXM1 DBD mutant, and Cyclin E1. A. Heat map showing unsupervised hierarchical 
clustering of log2 normalized median centered RPPA from FTE cells grown in the 
presence of 1 µg/ml doxycycline for 72 hours. Samples were performed in triplicate and 
averaged. B-D. Top 10 proteins for FOXM1-wild-type (WT), FOXM1-DBD-mutant (MT) 





Figure 33. FOXM1 interacts with protein involved in DNA replication and chromatin 
modification in 293T cells. A-B. 293T cells with CRISPR-mediated homozygous deletion 
of FOXM1 using guide RNAs that targeted near the start and stop codons. Homozygous 
deletion of FOXM1 was confirmed by A. PCR genotype and B. Western blot analysis. C. 
293T FOXM1 knockout cells were transfected with empty vector, vector expressing HA 
tagged GFP, FOXM1 isoforms a, b, c or FOXM1c DBD mutant (MT). Protein was 
harvested 24 hours post transfection for co-IP and Western blot analysis. D. Parental 293T 
cells were transfected with HA tagged GFP or FOXM1b. Protein was harvested 24 hours 














Figure 34. Genome-wide correlation of FOXM1 and ORC2 DNA binding. A-B. 
StereoGene plots showing correlation between FOXM1 and ORC2 DNA binding across 
the genome using K562 ChIP-seq data retrieved from NCBI GEO. The x axis shows the 
correlation value and y axis shows the density of genomic regions. The blue line 
represents the foreground correlation or correlation between FOXM1 and ORC2 binding 
the same genomic location. The red line represents background shuffling or correlation of 
random genomic windows. The p value represents the difference between the foreground 










Figure 35. Cell cycle analysis of FTE cells expressing Cyclin E1 and/or FOXM1 wild-
type and FOXM1 DBD mutant. A-B. Inducible FTE cells expressing CCNE1 and empty 
vector control, CCNE1 and FOXM1 wild-type (WT) or CCNE1 and FOXM1 DBD mutant 
(MT) were grown in the presence of doxycycline for 72 hours before harvesting cells for 
protein or for cell cycle. A. Western blot analysis. B. Cell Cycle analysis. Data was 














Figure 36. RNA-sequencing with FTE cells expressing CCNE1 and V control or 
CCNE1 and FOXM1 wild-type. Inducible FTE cells expressing CCNE1 and V control or 
CCNE1 and FOXM1 were grown in the presence doxycycline for 48 hours and cells were 
harvested for RNA or protein. Sample were prepared in triplicate for each group. A. 
Western blot analysis of FOXM1 and CCNE1 protein expression. B. RNA sequencing 






Figure 37. Cyclin E1 enhances FOXM1 transcriptional activity. A. Heat map shows 
647 genes with significant upregulation in FTE cells expressing FOXM1, CCNE1, or 
FOXM1 and CCNE1. Heat map values represent log2 fold change from triplicate replicates 
normalized to v control. Heat map color is normalized to the row. B. Validation of top 
differentially expressed genes in the RNA-seq analysis B-D. B. CCNB1 C. CDC25B and 
D. CCNA2 mRNA expression measured by RT-qPCR with FTE cells expressing empty 
vector, FOXM1 wild-type, CCNE1 and FOXM1 wild-type (WT) or Cyclin E1 and FOXM1 

















Figure 38. CIN70 enriched gene signatures in FTE cells expressing FOXM1 and 
CCNE1. A-C. GSEA analysis of CIN70 geneset with RNA sequencing expression data 
from FTE cells expressing A. FOXM1, B. CCNE1 or C. FOXM1 and CCNE1, normalized 
to FTE cells expressing V control. Normalized enrichment score (NES), and false 
discovery rate q values (FDR) are shown. D. Heat map for CIN70 genes comparing the 
overall expression among FTE cells expressing FOXM1, CCNE1, or FOXM1 and CCNE1. 
Heat map values represent log2 fold change from triplicate replicates normalized to vector 



















Figure 39. Frequent FOXM1 and CCNE1 copy number gain and expression 
associate with genomic instability in HGSC. A. FOXM1 and CCNE1 number status in 
TCGA HGSC tissues. Log odds ratio for tumors with both FOXM1 and CCNE1 Amp/Gain 
vs FOXM1 or CCNE1 alone, or neither. B. FOXM1 and CCNE1 protein expression (RPPA) 
compared HGSC tumors with both FOXM1 and CCNE1 Amp/Gain, FOXM1 Amp/Gain 
only, CCNE1 Amp/Gain only or neither. The p value for ANOVA with post-test for linear 
trend is shown. Lines represent group medians. D. FOXM1 protein expression (RPPA) vs 
CCNE1 protein expression (RPPA) in TCGA HGSC tissues. D. Fraction of the copy 
number altered genome compared in HGSC tumors with both FOXM1 and CCNE1 
Amp/Gain, FOXM1 Amp/Gain only, CCNE1 Amp/Gain only and neither. The p value for 




CHAPTER 5: FOXM1 AND RHNO1 BIDIRECTIONAL GENE PARTNERS PROMOTE 




Bidirectional gene partners make up approximately 10% of human genes and they 
often function in similar pathways such as cell cycle and DNA repair (117). FOXM1 shares 
an intergenic space with RHNO1, a protein that interacts with the 9-1-1 checkpoint clamp 
to promote efficient ATR-CHK1 signaling in response to DNA replication perturbations and 
contributes to the homologous recombination DNA repair pathway (100). FOXM1 has a 
well-established role in cell cycle progression and proliferation but it has also been linked 
to DNA repair and drug resistance via its ability to transactivate genes involved in these 
phenotypes. However, our RNA-seq analysis of FTE cells engineered for FOXM1 
overexpression did not show altered expression of genes involved in the DNA damage 
response. Interestingly, we observed that FOXM1 promotes increased DNA replication 
fork rate and interacts with proteins involved in DNA replication and chromatin 
modification, suggesting that FOXM1 might promote fork movement via protein-protein 
interactions. Furthermore, FOXM1 might promote fork progression in the presence of 
endogenous or exogenous DNA damage, thus promoting proliferation in the presence of 
damaged DNA. Together, considering our new findings for FOXM1 and the reported 
function of RHNO1, we hypothesized that FOXM1 may play cooperative roles with RHNO1 
in cell survival and chemotherapy resistance in HGSC. The objective of this study was 1) 
to demonstrate that the intergenic space between FOXM1 and RHNO1 functions as a 
bidirectional promoter; 2) to determine the relationship in expression between these 




RHNO1 bidirectional gene partners to clonogenic survival, homologous recombination 
DNA repair, and chemoresistance in HGSC cells.  
 
Results 
Genomic arrangement of FOXM1 and RHNO1 bidirectional partners at 12p13.33 
We previously showed that FOXM1 is located at 12p13.33 and that this genomic 
region is frequently amplified in HGSC. This region contains 32 other genes (Table 5), so 
we performed analysis of the 12p13.33 region using UCSC Genome Browser and 
observed that FOXM1 and RHNO1 are positioned in a head-to-head orientation with a 
putative bidirectional promoter (Figure 40). This genomic configuration is observed in 
approximately 10% of the human genes and is a feature of bidirectional genes pairs which 
are frequently co-regulated and function in similar pathways (114,117,120). This 
suggested that FOXM1 and RHNO1 have a bidirectional promoter and may be co-
regulated. The FOXM1/RHNO1 promoter region contains a CpG island which is a feature 
of bidirectional promoters (Figure 40) (113,117,189). It was recently shown that 
bidirectional promoters are enriched with histone modifications H3K4me3, H3K9ac, 
H3K27ac, and H3K4me2 (118). Our analysis of ENCODE data revealed that 
transcriptionally active histone marks, including H3K27Ac and H3K4me3, are enriched for 
both FOXM1 and RHNO1, showing bimodal peaks, suggesting the bidirectional promoter 
is active in both directions (Figure 40). In addition, the ENCODE data revealed the 
presence of an E2F1 ChIP-seq peak in this region, which is consistent with E2F1’s known 
involvement in bidirectional promoter regulation and our previous studies of FOXM1 
(Figure 18-19) (81,190,191). These data suggest that FOXM1 and RHNO1 gene partners 





FOXM1 and RHNO1 expression in normal and cancer tissues 
Based on the genomic arrangement of FOXM1 and RHNO1 bidirectional gene 
partners, we hypothesized that their mRNA expressions would correlate in normal tissues 
and cancer types. We first analyzed RNA-seq datasets from RIKEN normal mouse 
tissues, GTEx normal human tissues, and TCGA pan-cancer tissues. We observed a 
highly significant correlation between FOXM1 and RHNO1 mRNA expression in all 
comparisons, showing this relationship is not restricted to normal or cancer tissues and is 
conserved in mammals (Figure 41A-C). We next performed correlation of FOXM1 and 
RHNO1 mRNA expression using the CCLE human pan-cancer cell line microarray dataset 
to validate the correlation we observed in tissue samples. In agreement, the CCLE human 
cancer cell lines showed a strong correlation between FOXM1 and RHNO1 mRNA 
expression, and similar to normal and cancer tissues (Figure 41D). 
We next used the TOIL TCGA dataset to compare the levels of FOXM1 and 
RHNO1 mRNA expression in normal tissue versus primary, metastatic and recurrent pan-
cancer tissues. We observed that FOXM1 and RHNO1 were overexpressed in primary, 
metastatic and recurrent tumor as compared to normal tissue (Figure 42A). Furthermore, 
we found that FOXM1 expression was lower than RHNO1 expression in normal tissues, 
but the inverse was true in tumor tissues (Figure 42A). To follow-up this observation, we 
used the TOIL TCGA GTEx dataset to compare the ratio of FOXM1 and RHNO1 mRNA 
expression in normal and tumor tissues. In agreement, we observed that the expression 
ratio was shifted toward RHNO1 in normal tissues but toward FOXM1 in tumor tissues 
(Figure 42B). Based on these data, we hypothesized that tumors have an increased 
proliferative index compared to normal tissue and FOXM1 is a proliferation associated 




states. To test this, we normalized FOXM1 and RHNO1 mRNA expression to Ki67, a 
canonical marker of proliferation, in TCGA normal and tumor tissues. In agreement with 
our hypothesis, we observed that normalizing the FOXM1 and RHNO1 mRNA expression 
to Ki67 resulted in similar expression ratios in normal and tumor tissues (Figure 42B). 
These data suggest that increased proliferation, as indicated by Ki67 expression, has a 
greater influence on FOXM1 expression than RHNO1 expression.  
 
FOXM1 and RHNO1 expression in single cells from normal and cancer tissues 
Our analysis of FOXM1 and RHNO1 mRNA expression has been limited to the 
bulk RNA-sequencing data, which averages gene expression over a population of cells 
and masks potential heterogeneity in expression. Our data thus far and previous studies 
have shown bidirectional gene partners are frequently co-expressed (117,118,120); 
however, it remains unknown if this correlation exists within single cells. Therefore, 
measuring RNA expression at the single cell level would further the overall understanding 
of bidirectional gene partners and, more importantly, provide data to test potential 
cooperativity between FOXM1 and RHNO1. To test this, we analyzed publicly available 
single cell RNA-seq datasets consisting of cells isolated from normal mouse intestinal 
epithelium (Figure 43A), human melanoma (Figure 43B), and human high-grade serous 
tumors (Figure 43C) (147-149). We observed a significant correlation between FOXM1 
and RHNO1 mRNA expression at a single cell level (Figure 43A-C). Furthermore, the 
correlation we observed among both bulk and single cell population was very similar 
(Spearman r = 0.4 to 0.6) (Figures 41 and 43). These data show that FOXM1 and RHNO1 






DNA methylation analysis of the FOXM1-RHNO1 bidirectional promoter  
We observed that FOXM1 and RHNO1 expression were increased in cancer 
compared to normal, and FOXM1 expression tended to show a more dramatic increase in 
tumor samples. The FOXM1/RHNO1 promoter region contains a CpG island, and 
promoter methylation has been shown to regulate other bidirectional promoters (192). We 
hypothesized that differential methylation might contribute to these expression 
differences. To test this, we performed in silico analysis of publicly available Illumina 
Infinium HumanMethylation450 BeadChip Arrays performed on human cancer cell lines 
(the GDSC1000 collection), as well as human normal and cancer tissues (TCGA). We 
found the CpG island within the FOXM1/RHNO1 bidirectional promoter was 
hypomethylated in all datasets (Figure 44). The 450K methylation array has a technical 
limitation on the number of CpGs interrogated at a gene promoter, specifically within a 
CpG island, so we next performed a comprehensive measurement of DNA methylation at 
the FOXM1/RHNO1 bidirectional promoter using bisulfite clonal sequencing of normal and 
EOC tumor tissues. In agreement with the 450K data, we found the promoter was 
hypomethylated in both tissue (Figure 45). These data suggest that DNA methylation may 
not regulate the FOXM1/RHNO1 bidirectional promoter, and that altered methylation does 
not contribute to the increased FOXM1 and RHNO1 mRNA expression in human cancer 
tissues (Figure 42A). 
 
FOXM1 and RHNO1 copy number status and expression in HGSC  
We previously made comparisons in FOXM1 and RHNO1 expression across 
normal and pan-cancer tissue types and found a strong correlation, with increased 
expression in tumor tissues. We next validated these findings in HGSC and determined if 




analyzed the TOIL TCGA GTEx RNA-seq dataset to compare FOXM1 and RHNO1 
expression in normal fallopian tube tissue and primary HGSC tumors. We observed that 
FOXM1 and RHNO1 were overexpressed and showed a strong correlation in their 
expression (Figure 46A-B). We confirmed this correlation by measuring FOXM1 and 
RHNO1 expression by RT-qPCR among a panel of HGSC tumors in our tumor bank 
(Figure 46C).  
We previously showed that FOXM1 is amplified in HGSC, contributing to its 
increased expression. We next determined the copy number status for both genes, to test 
as a contributing factor to their increased expression. We found that FOXM1 and RHNO1 
copy number status was 100% concordant in HGSC tissues, suggesting that copy number 
might contribute to their frequent overexpression (Figure 46D). To test if FOXM1 and 
RHNO1 copy number status correlates with expression, we compared FOXM1 and 
RHNO1 mRNA and copy number in TCGA HGSC data. We observed a progressive 
increase in FOXM1 and RHNO1 expression with copy number status that was highly 
significant (Figure 46E). This suggests that copy number contributes to the frequent 
FOXM1 and RHNO1 expression in HGSC.  
We next measured FOXM1 and RHNO1 mRNA in a panel of FTE, OSE, and 
HGSC cells by RT-qPCR. In agreement with our comparison of GTEx fallopian tube and 
TCGA HGSC tissues, we found that HGSC cells had significantly higher FOXM1 and 
RHNO1 mRNA expression than FTE and OSE cells (Figure 47A). We tested the 
relationship between FOXM1 and RHNO1 expression in CCLE HGSC cell lines and in 
agreement, FOXM1 and RHNO1 showed a strong correlation (Figure 47B), which we 
confirmed by RT-qPCR using a panel of HGSC cell lines (Figure 47C). Next, we 
determined whether FOXM1 and RHNO1 exhibit similar copy number status in CCLE 




47D), which agrees with the TCGA HGSC data. Additionally, we observed a striking 
similarity in the frequency of FOXM1 and RHNO1 copy number in HGSC tissues and cell 
lines (Figures 45D and 47D), which agrees with previous reports showing that these 
HGSC cell lines are genomically similar to TCGA HGSC primary tumors (160). Further, 
we found that copy number correlates with increased FOXM1 and RHNO1 mRNA 
expression in cell lines (Figure 47E). To confirm these data, we compared FOXM1 and 
RHNO1 mRNA expression by RT-qPCR using normal FTE and OSE, and HGSC cell lines 
with differences in copy number status. We found that as FOXM1 and RHNO1 mRNA 
expression increases as copy number increases (Figure 48A). We then measured FOXM1 
and RHNO1 protein expression in a subset of these cell lines and, in agreement, protein 
expression rises with copy number increases (Figure 48B). These data suggest that 
increased copy number contributes to FOXM1 and RHNO1 overexpression in HGSC.  
 
FOXM1 and RHNO1 expression in single FTE and HGSC cells 
We previously made comparisons in FOXM1 and RHNO1 expression across 
publicly available single cell RNA-seq datasets consisting of cells isolated from normal 
mouse intestinal epithelium, and human melanoma and high-grade serous tumors (147-
149). We observed a significant correlation of FOXM1 and RHNO1 mRNA expression at 
a single cell level. To directly test this relationship in FTE and HGSC cells, we performed 
single cell RNA sequencing using immortalized fallopian tube epithelial cells and 
OVCAR8, an HGSC cell line. We compared FOXM1 and RHNO1 mRNA expression in 
FTE and OVCAR8 cells at the single cell level and observed a significant correlation 
(Figure 49A-B), which agrees with the correlation that we observed from measuring 
FOXM1 and RHNO1 mRNA by RT-qPCR from HGSC tissues and cell lines. Additionally, 




expected, OVCAR8 cells had increased expression of both genes compared to FTE 
(Figure 49C). Together, our expression data provide strong support of co-regulation and 
potential cooperativity between FOXM1 and RHNO1.  
 
FOXM1 and RHNO1 promoter shows bidirectional activity  
We observed that FOXM1 and RHNO1 mRNA showed a strong correlation across 
many cell and tissue types, in both bulk and single cell populations, including FTE and 
HGSC; thus, we next tested their relationship in promoter activity in FTE and HGSC cell 
models. We first performed 5’ RACE to determine the transcriptional start sites for both 
genes, in order to experimentally define the bidirectional promoter, using immortalized 
FTE and two HGSC cell lines. We found that the transcriptional starts sites and intergenic 
distance are similar to those predicted by NCBI (Figure 50). Based on these data, we 
cloned the FOXM1/RHNO1 bidirectional promoter into a reporter construct where FOXM1 
drives the expression of Renilla luciferase and RHNO1 drives the expression of Firefly 
luciferase (Figure 50 and 51A). This reporter construct and control constructs were co-
transfected into immortalized FTE and a panel of HGSC cells. We first compared the 
promoter activity in both directions and observed a direct correlation between FOXM1 and 
RHNO1 promoter activities (Figure 51B). We next compared the promoter activity versus 
endogenous mRNA expression for each gene and found a direct relationship between the 
two, suggesting that the regulation of promoter activity contributes to the frequent co-
expression of FOXM1 and RHNO1 (Figure 51C-D).  
Thus far, we have measured activity of the FOXM1-RHNO1 bidirectional promoter 
using a synthetic reporter construct. The endogenous FOXM1-RHNO1 bidirectional 
promoter could be regulated differently, based on chromatin modifications and genomic 




the endogenous bidirectional promoter, which uses a single guide RNA to recruit a 
catalytically dead Cas9 fused to a transcriptional activator, VP64 (193). We designed 
multiple guide RNAs to target within the bidirectional promoter and regions flanking it 
(Figure 52A). We introduced the CRISPR activation system into FTE cells, which have 
low FOXM1 and RHNO1 expression. Interestingly, we found that guide RNAs targeting 
outside the bidirectional promoter, regions upstream of the transcriptional start site for one 
gene and within the gene body for the other gene, induced the expression of the distal 
gene (Figure 52B). In contrast, the guide RNA targeting within the bidirectional promoter 
efficiently induced the expression of both FOXM1 and RHNO1 (Figure 52B). To 
complement these findings, we tested if a CRISPR-KRAB system could repress the 
bidirectional promoter in an HGSC cell line with high endogenous FOXM1 and RHNO1 
expression. We selected the guide RNAs that targeted within the bidirectional promoter 
and showed the strongest induction in gene expression in FTE cells and cloned them into 
a CRISPR inhibition system, which uses a catalytically dead Cas9 fused to a 
transcriptional repressor, KRAB (194). We then introduced the CRISPR inhibition system 
into a high-grade serous cell line, OVCAR8, via lentiviral transduction. Importantly, we 
found that the guide RNA targeting within the bidirectional promoter efficiently repressed 
the expression of both FOXM1 and RHNO1 (Figure 52C). These data suggest that 
frequent FOXM1 and RHNO1 expression is driven, in large part, by bidirectional promoter 
regulation.  
 
FOXM1 and RHNO1 promote HGSC cell clonogenic survival 
An oncogenic role for FOXM1 has been reported in many different cancer types 
including ovarian cancer; however, the contribution of RHNO1 to cancer, and particularly 




hypothesized that FOXM1 and RHNO1 contribute to growth and survival of HGSC cells, 
as FOXM1 promotes cell cycle progression, and RHNO1 participates in the DNA 
replication stress response (5,100). To test this, we engineered OVCAR8 and CAOV3 for 
inducible FOXM1 and RHNO1 knockdown and performed clonogenic survival assays. In 
agreement, either FOXM1 or RHNO1 knockdown suppressed the clonogenic survival of 
OVCAR8 and CAOV3 HGSC cells (Figure 53A-C). To validate this finding, we conducted 
CRISPR-Cas9 knockouts of FOXM1 and RHNO1 in two different HGSC cell lines 
(OVCAR8 and CAOV3). In each case, we observed a significant diminishment in 
clonogenic survival as compared to the sgRNA control (Figure 54A-C). Furthermore, 
CRISPR-mediated knockout of FOXM1 or RHNO1 also increased the number of apoptotic 
cells, supporting a specific role for each protein in cell survival (Figure 54D).  
FOXM1 and RHNO1 knockdown and knockout both reduced HGSC cell 
clonogenic survival. We next hypothesized that their combined loss may have a greater 
impact on HGSC clonogenic survival than either alone. To test this, we engineered 
OVCAR8 cells for dual FOXM1 and RHNO1 knockdown and performed clonogenic 
survival assays in comparison to the individual knockdowns. We found that dual FOXM1 
and RHNO1 inhibition had significantly reduced clonogenicity as compared to either single 
knockdown (Figure 55A-C). These data suggest that FOXM1 and RHNO1 may cooperate 
to promote cell survival.  
To understand how FOXM1 and RHNO1 loss contributes to decreased survival, 
we investigated the cell cycle dynamics following their loss. We observed that loss of 
FOXM1 showed an increase of G2/M cells, which agrees with earlier FTE cell cycle data 
for FOXM1 overexpression (Figure 56). RHNO1 loss showed an increase in S and G2 
cells suggesting that its loss slowed progression through S phase (Figure 56).  Importantly, 




alone (Figure 56). These data further support FOXM1 and RHNO1 cooperativity in the 
growth and survival of HGSC cells.  
 
FOXM1 transcriptional activity regulates genes involved in cell cycle and the G2/M 
checkpoint  
 Unlike RHNO1, FOXM1 is linked to cell phenotypes through its function as a 
transcription factor. Therefore, to better understand how the loss of FOXM1 reduced cell 
survival, we performed RNA-seq analysis with OVCAR8 and CAOV3 cells following 
FOXM1 knockdown (Figure 57A). We performed GSEA analysis with the RNA-seq 
expression data, and both CAOV3 and OVCAR8 cells showed a significant enrichment in 
a cell cycle gene expression signature, along with enriched mitotic and G2/M checkpoint 
expression signatures, respectively (Figure 58A-D). The enriched G2/M checkpoint 
signature agrees with our data obtained with FTE cells. Surprisingly, FOXM1 knockdown 
did not show enriched gene expression signatures for DNA repair, which has been 
reported for FOXM1 in other cell types, suggesting that FOXM1 has cell context-
dependent differences in its transcriptional program (91,130). We validated the FOXM1 
target gene expression by RT-qPCR and found that CAOV3 and OVCAR8 cells both 
showed a decrease in target gene expression following FOXM1 knockdown (Figure 59A-
C). Furthermore, in agreement with our FTE data, RNA-seq analysis and RT-qCPR 
measurement (Figure 59D) for HGSC cells with FOXM1 knockdown confirmed that the 
DNA repair gene BRCA2 is not a target gene of FOXM1 in these cell models. Together, 
this suggests that FOXM1 primarily regulates genes involved in cell cycle progression and 




RHNO1 localizes to chromatin and interacts with the 9-1-1 complex to promote 
efficient ATR-CHK1 signaling, genomic stability and cell survival in HGSC cells 
RHNO1 was previously shown to contribute to the DNA replication stress response 
by promoting ATR-CHK1 signaling via binding to the 9-1-1 clamp and TOPBP1 (21, 22). 
Furthermore, we determined that RHNO1 loss in HGSC cells reduces clonogenic survival. 
Therefore, we next investigated the role of RHNO1 in ATR-CHK1 signaling in FTE and 
HGSC cells. To test whether RHNO1 augments the DNA replication stress response and 
impacts DNA damage in FTE and HGSC cells, we knocked down RHNO1 using 
doxycycline inducible shRNA in FTE and OVCAR8 cells, and measured P-CHK1-S345 by 
Western blot. We observed ~2-fold reduction of P-CHK1-S345, a canonical readout of the 
DNA replication stress response (Figure 60A-D). This effect size is similar in magnitude 
to that reported in previous studies of RHNO1 (21, 22). RHNO1 loss impairs ATR-CHK1 
signaling in HGSC cells and potentially impairs their ability to respond to endogenous 
levels of DNA replication stress, resulting in increased DNA damage. To directly determine 
whether RHNO1 knockdown impacts DNA damage, we used flow cytometry to measure 
γ-H2AX as a function of cell cycle phase. We observed a significant increase in γ-H2AX-
expressing cells in S and G2 phases. This was to a lesser extent than ATRi, as expected 
(Figure 60E). In agreement, COMET analyses of DNA breakage revealed significant 
increases with RHNO1 knockdown (Figure 60F). 
RHNO1 interacts with 9-1-1 checkpoint proteins but these interactions have not 
been investigated in ovarian cancer cells, nor in the context of treatments that specifically 
cause DNA replication stress. To test if RHNO1 interacts with 9-1-1, we first 
overexpressed HA-tagged wild-type and SWV mutant RHNO1 in 293T cells then co-
immunoprecipitated RHNO1 protein complexes. The RHNO1-SWV, which has mutations 




interaction with 9-1-1 proteins but not TOPBP1 (Figure 61A) (100). As expected, Western 
blotting of the immunoprecipitated protein complexes and cell lysates showed that wild-
type RHNO1 interacts with RAD9 and RAD1 in 293T cells; however, RHNO1-SWV mutant 
was deficient for these interactions (Figure 61B). We then tested if these interactions, 
specifically RHNO1-RAD9, may be enhanced under conditions of DNA replication stress. 
We overexpressed HA-tagged RHNO1 in 293T cells and treated the cells with 
hydroxyurea (HU) prior to harvesting protein for co-immunoprecipitation, and observed 
that RHNO1 and RAD9 interaction was enhanced with HU treatment (Figure 61C). Finally, 
we investigated RHNO1 localization and 9-1-1 protein interactions in HGSC cells. We first 
tested if endogenous RHNO1 localized to chromatin in OVCAR8 cells following HU 
treatment. We observed that RHNO1 is present at chromatin without treatment, but HU 
further enriched chromatin localization (Figure 61D). We then tested if RHNO1 interacts 
with 9-1-1 proteins in OVCAR8 cells, and if this interaction was dependent on the APSES 
DNA binding domain. We used an shRNA to knock down endogenous RHNO1 in 
OVCAR8 cells then reconstituted the expression with HA-tagged wild-type and SWV 
mutant, shRNA-resistant RHNO1 in a doxycycline inducible manner. Following 
immunoprecipitation and Western blotting, we observed that wild-type RHNO1 interacts 
with all 9-1-1 proteins and TOPBP1, but the RHNO1 SWV mutant only interacted with 
TOPBP1 (Figure 61E). Together, these data provide strong support for RHNO1 as a 
significant contributor to the DNA replication stress response and DNA damage protection 
in HGSC cells.  
Based on the data presented above, we hypothesized that RHNO1 wild-type, but 
not SWV mutant, would rescue the decreased clonogenicity following loss of endogenous 
RHNO1 in HGSC cells. To test this, we knocked down RHNO1 with an shRNA then re-




to rescue clonogenic survival in OVCAR8 cells (Figure 62A). We found that only wild-type 
RHNO1 partially rescues the defect in clonogenic survival (Figure 62B). Next, to determine 
if the reduced survival following RHNO1 loss is retained in non-cancer cells, we used 
CRISPR to knock out RHNO1 in immortalized FTE cells and measured their viability 
(Figure 63A-B). RHNO1 knockout and wild-type FTE cells showed no difference in 
viability, but RHNO1 knockout and knockdown HGSC cells showed significant decrease 
in survival as compared to control HGSC cells suggesting that HGSC cells have an 
increased dependency on RHNO1 for growth survival as compared to non-transformed 
FTE cells (Figure 63C).  
 
FOXM1 and RHNO1 promote homologous recombination-mediated DNA repair 
FOXM1 functions as a transcription factor to regulate the expression of genes 
involved in a variety of essential processes, including cell cycle progression and DNA 
repair. FOXM1 has also been shown to promote homologous recombination (HR) (195-
198). However, we observed that loss of FOXM1 in OVCAR8 cells did not alter the 
expression of a gene involved in the DNA damage response, and more specifically, 
BRCA2 which has been reported as a FOXM1 target gene (Figures 58 and 59). RHNO1 
interacts with the 9-1-1 checkpoint clamp to promote ATR-CHK1 signaling upon exposure 
of single stranded DNA resulting from end resection at a DNA double strand break or due 
to helicase-fork uncoupling during DNA replication stress.  
Together, based on their genomic arrangement, co-regulation, reported function, 
and our novel data, we hypothesized that FOXM1 and RHNO1 may cooperatively promote 
homologous recombination. To test this hypothesis, we used the well-established, 
chromosomally integrated HR reporter assay, DR-GFP (direct repeat green fluorescent 




most widely used model to study factors that regulate HR. We engineered U2OS cells for 
inducible FOXM1 and RHNO1 knockdown alone and in combination (Figure 64A). We 
also engineered these cells for RAD51 knockdown as a positive control for HR impairment 
(Figure 64B) (100). Upon transient transfection of the I-SceI expressing plasmid, we found 
that U2OS DR-GFP cells had impaired HR efficiency following RAD51 knockdown, as 
expected (Figure 64E). RHNO1 knockdown decreased HR efficiency, but surprisingly, 
FOXM1 knockdown did not (Figure 64E). However, dual knockdown of FOXM1 and 
RHNO1 showed a greater impairment in HR efficiency as compared to the knockdown of 
RHNO1 alone, suggesting cooperativity (Figure 64E). We next used OVCAR8 DR-GFP 
cells to validate these findings in a HGSC-relevant context. OVCAR8 cells have a 
methylated BRCA1 promoter and show decreased BRCA1 expression but still maintain a 
minimal level of HR proficiency (108). We engineered OVCAR8 cells for inducible FOXM1 
and RHNO1 knockdown alone and in combination (Figure 64C). We also engineered 
these cells for RAD51 knockdown as a positive control for HR impairment (Figure 64D) 
(100). Similar to U2OS cells, in OVCAR8 cells, FOXM1 loss slightly reduced HR and 
RHNO1 loss also reduced HR, but dual loss resulted in a more signification reduction in 
HR proficiency (Figure 64F). These data indicate that both FOXM1 and RHNO1 promote 
HR in HGSC cells and further suggest a functional interaction between these two genes.  
 
FOXM1 and RHNO1 loss sensitizes HGSC cells to the PARPi olaparib 
 Homologous recombination (HR) is defective in about half of the HGSC tumors 
primarily through BRCA1/2 mutations (30). Furthermore, HR can be impaired by defects 
in other genes. HR-deficient tumors are highly sensitive to PARP inhibition due to the 
excess of single strand breaks that ultimately are converted into double strand breaks 




RHNO1 promote the DNA damage response, where we see decreased HR proficiency 
following their loss. FOXM1 expression and its downstream targets have been linked to 
the drug resistance for a wide variety of drugs in various cancer types including resistance 
to platinum, paclitaxel and PARP inhibitors in epithelial ovarian cancer (130,199-201). In 
addition, RHNO1 functions in the ATR-CHK1 signaling pathway in response to ssDNA 
and dsDNA breaks, and intriguingly, it was recently reported that ATRi synergizes with 
PARPi (202). These data suggest that RHNO1 loss may promote PARPi sensitivity 
potentially in combination with FOXM1. A PARP inhibitor, olaparib, received FDA approval 
in 2014 for the treatment of germline BRCA-mutated ovarian cancers after third-line 
therapy (53,54). Furthermore, FOXM1 has been studied for its ability to sensitize ovarian 
cancer cells to olaparib treatment (130,200). Therefore, we focused on the FOXM1 and 
RHNO1 bidirectional gene partners to determine if their loss sensitizes HGSC cells to the 
olaparib. To test this, we engineered OVCAR8 cells for single and dual inducible shRNA 
mediated knockdown of FOXM1 and RHNO1. To determine the impact of FOXM1 and 
RHNO1 loss on olaparib sensitivity, we knocked down FOXM1 and RHNO1 in OVCAR8 
cells and determined the IC50 using AlamarBlue viability assays following 8 days of 
treatment. We observed that FOXM1 and RHNO1 loss alone sensitized OVCAR8 cells to 
olaparib treatment, while OVCAR8 cells with loss of both FOXM1 and RHNO1 had a 
significant increase in sensitivity to olaparib (Figure 65A-B). To address a potential 
mechanism whereby FOXM1 and RHNO1 loss promotes sensitivity to olaparib, we 
characterized the cell cycle profile under the same conditions, and loss of both FOXM1 
and RHNO1 resulted in an increased number of cells in G2/M as compared to either 
knockdown alone (Figure 66). Together, our data suggest that FOXM1 and RHNO1 not 
only play a role in maintaining a basal level of genomic stability, but they also promote 
genomic stability when challenged with PARPi, suggesting they play cooperative roles in 




 To validate these findings, we next used OVCAR8 cells with KRAB-mediated 
inhibition of the FOXM1 and RHNO1 bidirectional promoter. We then determined the IC50 
of olaparib with the AlamarBlue viability assay following 8 days of treatment. In agreement 
with the shRNA knockdown data, we observed that the combined loss of FOXM1 and 
RHNO1 sensitized OVCAR8 cells to olaparib treatment (Figure 67A-C). Next, we 
measured the percentage of apoptotic cells following FOXM1 and RHNO1 loss after 
PARPi treatment. We found OVCAR8 cells with FOXM1 and RHNO1 depletion had 
increased apoptotic cells as compared to control (Figure 68A). Moreover, PARPi treatment 
significantly increased cell death in the FOXM1- and RHNO1-depleted cells as compared 
to control cells (Figure 68B). We performed cell cycle analysis on FOXM1- and RHNO1-
depleted cells following PARPi treatment. In agreement with the apoptosis data, we found 
that OVCAR8 cells with FOXM1 and RHNO1 depletion had increased G2/M arrest as 
compared to control when treated with PARPi (Figure 68B).  
 
FOXM1 and RHNO1 loss re-sensitizes PARPi-resistant HGSC cells to olaparib 
 In vitro and in vivo experimental studies have confirmed that BRCA1/2 deficient 
tumor cells are more sensitive to PARP inhibitors than are BRCA1/2 wild-type tumor cells 
(45,46,203). However, only a fraction of BRCA1/2 mutation carriers respond to PARPi 
therapy and even those who respond subsequently develop resistance (48,55-57). Thus, 
a strategy to overcome PARPi resistance in BRCA-deficient cancers is needed to improve 
this otherwise promising targeted therapy. In this context, we obtained two isogenic 
derivatives of UWB1.289, a BRCA1 null HGSC cell line, that were treated in vitro with 
olaparib, and subsequently developed acquired resistance in vitro (202). Furthermore, 
these two PARPi-resistant BRCA1-deficient cell lines, SyR12 and SyR13, are dependent 




G2/M checkpoints and activation of ATR signaling, respectively (202). We first validated 
these cell lines by determining the IC50 of olaparib with the AlamarBlue viability assay after 
8 days of treatment (Figure 69A). As expected, both PARPi resistant clones, SyR12 and 
SyR13, had resistance to olaparib relative to parental cells. It was reported that the UWB1 
clone SyR13 showed an enriched gene expression signature for ATR activation. We 
measured ATR mRNA by RT-qPCR and observed that the SyR13 clone had increased 
expression of ATR as compared to the parental line and resistant clone SyR12 (Figure 
69B). These data suggest that FOXM1 and RHNO1 may show increased expression in 
the PARPi-resistant clones. To test this, we performed RT-qPCR and observed that the 
SyR13 clone had increased expression of FOXM1 and RHNO1 mRNA expression as 
compared to the parental line and resistant clone SyR12 (Figure 69C).  
Based on the reported data and our expression data together, we hypothesized 
that targeting FOXM1/RHNO1 may re-sensitize these PARPi-resistant clones to olaparib. 
To test this, we engineered UWB1.289 parental and PARPi-resistance cells for KRAB-
mediated inhibition of the FOXM1/RHNO1 bidirectional promoter. We found that the KRAB 
repressor targeting the FOXM1/RHNO1 bidirectional promoter efficiently silenced FOXM1 
and RHNO1 mRNA expression in the PARPi-resistant cells (Figure 70A). We then tested 
the olaparib sensitivity by assessing the IC50 after 8 days of treatment. We observed that 
the loss of FOXM1 and RHNO1 re-sensitized both SyR12 and SyR13 PARPi-resistant 
cells to olaparib by 3-fold and 4-fold, respectively, but did not completely restore the 
sensitivity to the level observed in the UWB1 parental cells (Figure 70B-C). In support of 
the magnitude of IC50 shift that we observed for olaparib with FOXM1 and RHNO1 loss in 
both PARPi-resistant cells, an ATR inhibitor was reported to shift the IC50 by ~3-fold and 
did not completely restore the sensitivity observed in parental cells (202). These data 




Furthermore, a FOXM1 inhibitor has very recently been reported to sensitize ovarian 
cancer cell lines to PARPi treatment (130). Potentially FOXM1 inhibitors could be 
combined with ATR inhibitors to re-sensitize PARPi-resistant cells to these agents. 
 
Summary 
Our analysis of 12p13.33 identified that FOXM1 shares a bidirectional promoter 
with RHNO1, a gene shown to promote efficient ATR-CHK1 signaling. We hypothesized 
that FOXM1 and RHNO1 would have frequent co-expression and play cooperative roles 
in cell survival, HR and chemoresistance. Our analysis of in silico genomic data sets 
showed a strong correlation between FOXM1 and RHNO1 mRNA expression in normal, 
HGSC and pan-cancer tissues. The relationship was validated in our independent HGSC 
tumor banks and HGSC cell lines and using scRNA analyses. In agreement with the 
genomic analyses, we found that the FOXM1 and RHNO1 intergenic space functions as 
a bidirectional promoter in immortalized FTE and HGSC cells. We found that depletion of 
FOXM1 and RHNO1 reduced HR efficiency and survival in HGSC cells. Furthermore, we 
found that FOXM1 promotes cell cycle progression and RHNO1 promotes ATR-CHK1 
signaling, and this is dependent on interactions with the 9-1-1 checkpoint clamp. The 
depletion of FOXM1 and RHNO1 promoted PARPi sensitivity in HGSC cells. Furthermore, 
loss of FOXM1 and RHNO1 re-sensitized HGSC PARPi-resistant cells to olaparib. These 
data support additional studies of FOXM1 and RHNO1 gene partners, specifically, to 
further the understanding of HGSC biology through in vivo modeling of FOXM1 and 
RHNO1, and to determine if RHNO1 and FOXM1 cooperate in normal and other cancer 
cells. Broadly, these data support the study of other bidirectional gene partners to 










Figure 40. Genomic features of the FOXM1/RHNO1 bidirectional gene partners. 
UCSC Genome Browser (http://genome.ucsc.edu, human genome build hg19 with 
genomic coordinates chr12:2,966,265-2,999,264) displaying FOXM1 and RHNO1 genes. 
The following tracks are displayed in the browser: FOXM1 and RHNO1 mRNA, CpG 
island, Encode E2F1, H3K4Me3 and H3K27Ac ChIP-seq track, and conserved genome 
tracks 100 vertebrates and mammalian. The putative FOXM1/RHNO1 bidirectional is 










Figure 41. FOXM1 and RHNO1 expression correlation in normal and cancer tissues. 
A-D. FOXM1 and RHNO1 mRNA expression in A. Riken normal mouse tissues (RNA-
seq), B. GTEx normal human tissues (RNA-seq), C. TCGA pan-cancer tissues (RNA-seq) 






Figure 42. FOXM1 and RHNO1 mRNA expression (RNA-seq) in normal and pan-
cancer tissues. A. FOXM1 and RHNO1 expression (RNA-seq) in GTEx and TCGA 
normal tissues and TCGA tumor tissues. B. FOXM1 and RHNO1 expression ratio in 












Figure 43. FOXM1 and RHNO1 mRNA expression correlation in single cell RNA-seq 
from normal and cancer tissues.  A. Single cells isolated from normal mouse epithelium 
tissue (single cell RNA-sequencing) (GSE92332). B. Single cells isolated from human 
melanoma tissue (single cell RNA-sequencing) (GSE72056). C. Single cells isolated from 







Figure 44. DNA methylation at the FOXM1/RHNO1 bidirectional promoter in TCGA 
normal and tumor pan-cancer tissues, and CCLE pan-cancer cell lines. Beta values 
represent the level of DNA methylation, averaged across 7 CpG sites within the 
FOXM1/RHNO1 CpG island. A value of 1 is the highest level of methylation and 0 is the 










Figure 45. FOXM1/RHNO1 bidirectional promoter methylation analysis by bisulfite 
sequencing. Sodium bisulfite clonal sequencing of the FOXM1/RHNO1 bidirectional 
promoter region was performed on the indicated samples. The NCBI predicted TSS is 
indicated by the red broken arrows. The intergenic space spans between the two arrows. 
Filled and open circles indicate methylated and unmethylated CpG sites, respectively, and 


























Figure 46. FOXM1 and RHNO1 copy number and expression in HGSC tissues. A. 
FOXM1 and RHNO1 expression (RNA-seq) in TCGA HGSC tissue as compared to GTEX 
normal fallopian tube tissues. B. FOXM1 mRNA expression vs RHNO1 mRNA expression 
(RNA-seq) from TCGA HGSC tissues. C. FOXM1 mRNA expression vs RHNO1 mRNA 
expression from Karpf lab HGSC tissues. D. FOXM1 vs RHNO1 copy number from TCGA 
HGSC tissues E. FOXM1 and RHNO1 mRNA expression (RNA-seq) correlated with copy 
number in TCGA HGSC tissues. The p value for ANOVA with post-test for linear trend is 
shown. Lines represent group medians. t-test P value is shown. P value designation: **** 

























Figure 47. FOXM1 and RHNO1 expression in HGSC cell lines. A. FOXM1 and RHNO1 
mRNA expression from FTE and OSE cell lines compared to HGSC cell lines as measured 
by RT-qPCR. B. FOXM1 mRNA expression vs RHNO1 mRNA expression (microarray) 
from CCLE HGSC cell lines. C. FOXM1 mRNA expression vs RHNO1 mRNA expression 
from Karpf lab HGSC cell lines as measured by RT-qPCR. D. FOXM1 vs RHNO1 copy 
number among CCLE HGSC cell lines. E. FOXM1 and RHNO1 mRNA expression 
(microarray) correlated with copy number in CCLE HGSC cell lines. The p value for 
ANOVA with post-test for linear trend is shown. Lines represent group medians. t test P 











Figure 48. FOXM1 expression comparison in FTE and HGSC cell lines. A. FOXM1 
and RHNO1 mRNA expression were measured RT-qPCR. B. FOXM1 and RHNO1 protein 
expression were measured by Western blot. Lamin B and Histone H3 are shown as 
loading controls. The arrow below panels A and B indicates the increasing FOXM1 and 











Figure 49. FOXM1 and RHNO1 mRNA expression in FTE and HGSC single cells. A. 
FOXM1 and RHNO1 mRNA expression correlation among FTE single cells (single cell 
RNA sequencing). B. FOXM1 and RHNO1 mRNA expression correlation among HGSC 
single cells (single cell RNA sequencing). C. FOXM1 and RHNO1 mRNA expression 
comparison in FTE and HGSC single cells. t-test P value is shown. P value designation: 








Figure 50. FOXM1 and RHNO1 mapping of transcription start sites (TSS). RLM-RACE 
mapping the 5' end of FOXM1 and RHNO1 mRNA. The red left and right arrows indicate 
the orientation of each gene. The left y-axis indicates the sequenced clones from the 
respective HGSC and FTE cell line. NCBI predicted TSS is show on the bottom. The green 
line at the top indicates the bidirectional promoter cloned for reporter assays in subsequent 








Figure 51. FOXM1/RHNO1 bidirectional reporter assay. A. FOXM1/RHNO1 
bidirectional reporter construct with the promoter colored in green. FOXM1 drives Renilla 
luciferase and RHNO1 drives Firefly. luciferase. Secreted embryonic alkaline 
phosphatase (SEAP) was co-transfected and used as the internal normalization control. 
B. Correlation of FOXM1 and RHNO1 promoter activity in a panel of FTE and HGSC cells. 
C. Correlation of FOXM1 promoter activity and mRNA measured by RT-qPCR. D. 















Figure 52. CRISPR mediated activation and repression of the endogenous 
FOXM1/RHNO1 bidirectional promoter.  A. FOXM1/RHNO1 bidirectional reporter and 
guide RNAs indicated below. B. CRISPR mediated activation of the FOXM1/RHNO1 
bidirectional promoter in FTE cells expressing synergistic activation mediator (VP64) and 
a guide RNA targeting the bidirectional promoter and the corresponding changes in mRNA 
expression as measured by RT-qPCR. C. CRISPR mediated inhibition of the 
FOXM1/RHNO1 bidirectional promoter in HGSC cells expressing Krüppel associated box 
(KRAB) transcriptional repressor and a guide RNA targeting the bidirectional promoter 
and the corresponding changes in mRNA expression as measured by RT-qPCR. NT1 and 



























Figure 53. Clonogenic survival for HGSC cells following FOXM1 or RHNO1 
knockdown. OVCAR8 and CAOV3 cells engineered for inducible FOXM1 or RHNO1 
knockdown were seeded for protein extraction and Western blot or clonogenic survival. A. 
Cells were grown in the presence of doxycycline for 72 hours to harvest protein followed 
by Western blot analysis to confirm knockdown efficiency. B. Cells were seeded into a 6-
well dish, in triplicate, at a density of 500 or 1,000 cells, respectively. Doxycycline was 
added at the time of seeding and media containing doxycycline was replenished every 48 
hours. Clonogenic survival was measured at 12 and 14 days, respectively, after the cells 
were fixed with methanol and stained with crystal violet. C. Colonies containing more than 
50 cells were counted and clonogenic survival was quantified as an average of the 
replicates. NS = non-targeting shRNA. t test P value is shown. P value designation: **** < 























Figure 54. Clonogenic survival for HGSC cells following FOXM1 or RHNO1 
knockout. OVCAR8 and CAOV3 cells engineered for FOXM1 or RHNO1 knockout were 
seeded for protein or clonogenic survival. A. Cells were for 72 hours to harvest protein 
followed by Western blot analysis to confirm knockout efficiency. B. Cells were seeded 
into a 6-well dish, in triplicate, at a density of 500 or 1,000 cells, respectively. Media was 
replenished every 48 hours. Clonogenic survival was measured at 12 and 14 days, 
respectively, after the cells were fixed with methanol and stained with crystal violet. C. 
Colonies containing more than 50 cells were counted and clonogenic survival was 
quantified as an average of the replicates. D. Total apoptotic cells for OVCAR8 FOXM1 
or RHNO1 knockout cells was determined by Annexin V staining and FACS. Etoposide 
was used a positive control CTL = non-targeting guide RNA. test P value is shown. P value 




















Figure 55. Clonogenic survival for HGSC cells following FOXM1 and/or RHNO1 
knockdown. OVCAR8 cells engineered for FOXM1 and/or RHNO1 knockout were 
seeded for protein or clonogenic survival. A. Cells were seeded in the presence of 
doxycycline and grown for 72 hours to harvest protein followed by Western blot analysis 
to confirm knockdown efficiency. B. Cells were seeded into a 6-well dish, in triplicate, in 
the presence of doxycycline at a density of 500 cells. Media containing doxycycline was 
replenished every 48 hours. Clonogenic survival was measured at 12 days after the cells 
were fixed with methanol and stained with crystal violet. C. Colonies containing more than 
50 cells were counted and clonogenic survival was quantified as an average of the 
replicates. NS = non-targeting shRNA. test P value is shown. P value designation: **** < 
















Figure 56. Cell cycle analysis of HGSC cells following knockdown of FOXM1 and/or 
RHNO1. OVCAR8 cells engineered for FOXM1 and/or RHNO1 knockout were seeded in 






Figure 57. RNA sequencing for HGSC cells with FOXM1 knockdown. CAOV3 and 
OVCAR8 cells with inducible non-targeting or FOXM1 shRNA were grown in the presence 
doxycycline for 48 hours and cells were harvested for RNA or protein. Sample were 
prepared in triplicate for each group. A. Western blot analysis of FOXM1 protein 








Figure 58. OVCAR8 and CAOV3 enriched pathway signatures. A-B. GSEA analysis 
of the top two hallmark pathways for OVCAR8 FOXM1 knockdown cells A. Cell Cycle and 
B. G, G2/M checkpoint. C-D. GSEA analysis of the top two hallmark pathways for CAOV3 
FOXM1 knockdown cells C. Cell Cycle, mitotic and D. cell cycle. Enrichment analysis as 
a function of OVCAR8 and CAOV3 with knockdown of FOXM1 using RNA-seq expression 













Figure 59. Validation of top differentially expressed genes from the RNA-seq 
analysis for HGSC cells with knockdown of FOXM1. A-D. A. CCNA2 B. CCNB1 C. 
CDC25B and D. BRCA2 mRNA expression measured by RT-qPCR from CAOV3 and 
OVCAR8 cells expressing control or FOXM1 targeting shRNA. BRCA2 did not show 
differential expression in the RNA-seq analysis, but instead was included used as a 




















Figure 60. RHNO1 promotes ATR-CHK1 signaling in FTE and HGSC cells. FT282 and 
OVCAR8 cells were engineered for doxycycline inducible RHNO1 knockdown. A-B. 
Inducible FT282 RHNO1 knockdown cells were seeded and grown in the presence of 
doxycycline for 72 hours to harvest RNA followed by A. RT-qPCR to confirm RHNO1 
knockdown and protein followed B. Western blot analysis to measure the efficiency of 
ATR-CHK1 signaling. Cells for protein harvest received 2-hour treatment with 2 mM HU 
to induce DNA replication stress and ATR-CHK1 signaling. C-D. Inducible OVCAR8 
RHNO1 knockdown cells were seeded and grown in the presence of doxycycline for 72 
hours to harvest protein followed by Western blot analysis to C. confirm RHNO1 
knockdown or D. measure the efficiency of ATR-CHK1 signaling at basal levels without 
HU treatment. E-F. Under the same conditions in C-D, Cells were harvested for the E. y-
H2AX FACS analysis. ATRi was added at the indicated dose for 24 hours as a positive 
control. or F. Comet Assay.  t test P value is shown. P value designation: **** < 0.0001, 




















Figure 61. RHNO1 interactions with 9-1-1 checkpoints proteins in 293T and OVCAR8 
cells. A.  Comparison of RHNO1 wild-type and SWV mutant proteins. The proteins are 
the same molecular weight, but they are different for residues 55-61. The residues at 55-
61 were all converted to alanine for the SWV mutant, thus disrupting its ability to interact 
with 9-1-1 checkpoint proteins. B. 293T were transfected with empty vector, vector 
expressing HA tagged RHNO1 wild-type or SWV mutant. Protein was harvested 24 hours 
post transfection for co-immunoprecipitation and Western blot analysis. C. 293T cells were 
transfected with vector expressing HA tagged RHNO1 wild-type. Cells with treated with 
vehicle or 5 mM HU for 1 hour at 24 hours post transfection then protein was harvested 
for co-immunoprecipitation and Western blot analysis. D. OVCAR8 cells were seeded for 
growth for 24 hours then treated with vehicle or 5 mM HU for 1 hour then cells were harvest 
for subcellular fraction into soluble nuclear and chromatin bound protein followed by 
Western blot analysis to determine RHNO1 localization. Histone H3 was used as the 
chromatin control and Sp1 as the soluble nuclear control. E. OVCAR8 inducible RHNO1 
knockdown cells were engineered for inducible expression of HA tagged RHNO1 wild-
type or SWV mutant and grown in the presence of doxycycline for 72 hours then protein 

























Figure 62. RHNO1 interaction with 9-1-1 checkpoint clamp is important for survival 
in HGSC cells. OVCAR8 inducible RHNO1 knockdown cells engineered for inducible 
expression of HA tagged RHNO1 wild-type or SWV mutant were seeded for protein or 
clonogenic survival. A. Cells were seeded in the presence of doxycycline and grown for 
72 hours to harvest protein followed by Western blot to confirm knockdown efficiency. B. 
Cells were seeded into a 6-well dish, in triplicate, in the presence of doxycycline at a 
density of 500 cells. Media containing doxycycline was replenished every 48 hours. 
Clonogenic survival was measured at 12 days after the cells were fixed with methanol and 
stained with crystal violet. C. Colonies containing more than 50 cells were counted and 
clonogenic survival was quantified as an average of the replicates. NS = non-targeting 












Figure 63. RHNO1 knockout in FTE cells does not impact cell viability. Homozygous 
deletion of RHNO1 in FT282 cells was achieved with CRISPR-Cas9 and guide RNAs that 
targeted near the start and stop codon. A. RHNO1 homozygous knockout was confirmed 
by A. PCR with genomic DNA and B. RHNO1 mRNA expression measure by RT-PCR. C. 
FT282 parental and RHNO1 clonal knockout cells were seeded in quadruplicate and 
grown for a period of one-week. Cell viability was measured with the AlamarBlue assay 
























Figure 64. FOXM1 and RHNO1 bidirectional gene partners promote HR in U2OS and 
OVCAR8 cells. A-D. Cells were treated with doxycycline to induce shRNA expression 
and knockdown was confirmed by measuring A and C. FOXM1 and RHNO1 mRNA 
expression and B and D. RAD51 mRNA expression by RT-qPCR. E-F. Following 
knockdown, the HR repair rate of I-SceI-induced DSBs was measured in E. U2OS and F. 
OVCAR8 DR-GFP cells. Each value is relative to the percentage of GFP-positive cells in 
I-SceI-transfected (U2OS) and transduced (OVCAR8) control cells. Results are shown as 
mean ± SE from three independent experiments; Student’s t-test was used for 
comparisons. RAD51 knockdown was used as a positive control. All results are shown as 

























Figure 65. FOXM1 and RHNO1 knockdown sensitizes OVCAR8 cells to olaparib.  
OVCAR8 cells engineered for FOXM1 and/or RHNO1 knockout were grown in the 
presence of doxycycline for 72 hours prior to seeding cells for olaparib IC50 or clonogenic 
survival. A. Cells were harvested then seeded in 96-well plates in quadruplicate in the 
presence of doxycycline at a density of 500 cells per well. Twenty-four hours later cells 
received media containing doxycycline and vehicle or olaparib, and this was repeated 
every 48 hours. Cell viability was measured at 8 days using AlamarBlue and the IC50 for 
olaparib was determined. B. Cells were harvested and seeded into a 6-well dish, in 
triplicate, in the presence of doxycycline at a density of 5,000 cells per well. Twenty-four 
hours later cells received media containing doxycycline and vehicle or olaparib, and this 
was repeated every 48 hours. Media containing doxycycline was replenished every 48 
hours. After 8 days of growth, cells were fixed with methanol and stained with crystal violet. 











Figure 66. OVCAR8 FOXM1 and/or RHNO1 knockdown cells show increased cell 
cycle arrest following olaparib treatment. OVCAR8 FOXM1 and RHNO1 knockdown 
cells were treated with olaparib for 24 hours and the corresponding changes in Cell cycle 












Figure 67. FOXM1/RHNO1 CRISPR inhibition sensitives OVCAR8 cells to olaparib 
treatment. A. OVCAR8 cells expressing KRAB transcriptional repressor and a guide RNA 
targeting the bidirectional promoter, and the corresponding changes in mRNA expression 
as measured by RT-qPCR. NT1 – non-targeting guide RNA. B. Cells were seeded in 96-
well plates in quadruplicate at a density of 500 cells per well. Twenty-four hours later cells 
received media containing vehicle or olaparib, and this was repeated every 48 hours. Cell 
viability was measured at 8 days using AlamarBlue and the IC50 for olaparib was 
determined. C. Cells were seeded into a 6-well dish, in triplicate, at a density of 5000 cells 
per well. Twenty-four hours later cells received media containing vehicle or olaparib, and 
this was repeated every 48 hours. After 8 days of growth, cells were fixed with methanol 










Figure 68. OVCAR8 FOXM1 and RHNO1 depleted cells show increased cell death 
and G2/M arrest after olaparib treatment. A-B. OVCAR8 cells expressing KRAB 
transcriptional repressor and a guide RNA targeting the bidirectional promoter were 
treated with olaparib for 24 hours and the corresponding changes in A. apoptosis were 
measured by Annexin V staining and FACS, and B. cell cycle were measure measured 
with PI staining. t test P value is shown. P value designation: **** < 0.0001, *** < 0.001, ** 


























Figure 69. Differential FOXM1 and RHNO1 expression and olaparib sensitivity for 
UWB1.289 parental cells and isogenic PARPi resistant clones. A. Cells were seeded 
in 96-well plates in quadruplicate at a density of 750 cells per well. Twenty-four hours later 
cells received media containing vehicle or olaparib, and this was repeated every 48 hours. 
Cell viability was measured at 8 days using AlamarBlue and the IC50 for olaparib was 
determined. B-C. Cells were seeded and grown for a period of 72 hours before RNA was 
harvested for RT-qPCR measurement of B. ATR mRNA expression and C. FOXM1 and 
RHNO1 mRNA expression. t test P value is shown. P value designation: **** < 0.0001, *** 


























Figure 70. Inhibition of FOXM1/RHNO1 in UWB1 resistant clones restores olaparib 
sensitivity. UWB1 parental and PARPi resistant cells were engineered to express KRAB 
transcriptional repressor and a control guide RNA or guide RNA targeting the bidirectional 
promoter. A. Cells were seeded and grown for 72 hours to harvest RNA followed by RT-
qPCR to confirm knockdown efficiency. B-C. UWB1 parental KRAB and B. SyR12 KRAB 
or C. SyR13 KRAB cells were seeded in 96-well plates in quadruplicate at a density of 
750 cells per well. Twenty-four hours later cells received media containing vehicle or 
olaparib, and this was repeated every 48 hours. Cell viability was measured at 8 days 





CHAPTER 6: DISCUSSION AND FUTURE DIRECTIONS 
 
Genetic Determinants of FOXM1 Expression in HGSC  
Several mechanisms have been reported to contribute to FOXM1 overexpression 
in cancer, including gene amplification, loss of negative regulation by p53, Rb, and 
FOXO3, and transcriptional activation by E2F and Myc (2,73-76,81,82). To date, the 
mechanisms underlying FOXM1 upregulation in HGSC have not been described, although 
FOXM1 pathway activation is extremely frequent in this malignancy. Here we demonstrate 
that, in HGSC, FOXM1 is upregulated at the transcriptional level by combined loss of Rb 
and p53, and show that FOXM1 copy number gains correlate with increased FOXM1 
expression in primary tumors and cell lines. Combinatorial loss of p53 and Rb in murine 
and human OSE cells synergistically induced FOXM1 expression, and murine ovarian 
cancer arising in a p53/Rb compound deletion model led to FOXM1 overexpression. In 
addition, we demonstrate that E2F1 contributes to FOXM1 overexpression in cell models, 
and closely correlates with FOXM1 expression in primary tumors. Genetic manipulation of 
the RB-E2F pathway in FTE cell models further supports a role for their regulation of 
FOXM1 expression in HGSC. Moreover, basal/TNBC breast cancer show similar patterns 
of FOXM1 copy number gains as HGSC. Thus, our data establish p53 loss, RB-E2F 
deregulation and copy number gain as positive regulators, of FOXM1 expression in EOC. 
Consistent with our p53 data, it was recently shown that Nutlin 3 (an MDM2 inhibitor)-
mediated p53 activation repressed FOXM1 in EOC cells (204). 
Consistent with our findings, loss of Rb function leads to activation of E2F 
transcription factors (205), and two putative E2F sites have been identified in the FOXM1 
promoter (81). Second, the Rb-E2F pathway is regulated by p21, a potent negative 




Therefore, functional loss of p53 may relieve p21-mediated repression of E2F1, which in 
turn may promote FOXM1 expression. In agreement, prior work shows that p53-mediated 
repression of FOXM1 is partially p21-dependent (74,81). p53-mediated negative 
regulation of FOXM1 may also be independent of any effects on the Rb-E2F pathway, 
although this remains to be determined. In addition to p53, Rb, and E2F1, other relevant 
mechanisms of FOXM1 regulation involve Myc and FOXO3 (2,76). These may act 
independently or in concert with p53 and Rb loss, and require further study using EOC 
models. 
 
Implications of FOXM1 Expression in HGSC 
Importantly, a recent study showed increased FOXM1 IHC staining in STIC 
lesions, early HGSC precursor lesions, and that FOXM1 expression is maintained in 
invasive tumors (2). As TP53 mutations appear to be a ubiquitous early event in human 
HGSC, and Cyclin E1 overexpression occurs in STIC lesions (2,155), we speculate that 
during HGSC tumor progression, deregulation of the RB-E2F pathway and/or FOXM1 
amplification, coupled with the p53 impairment already present, leads to high level FOXM1 
expression. Consistent with this model, our data indicate that FOXM1 expression is 
markedly elevated in late stage, high-grade disease. FOXM1 is not only expressed in STIC 
lesions and HGSC tumors, but also in FTE stem cells (2,206). These observations suggest 
that FOXM1 may have oncogenic potential that contributes both to early and late stages 
of HGSC progression. To test this hypothesis and determine if FOXM1 is important for 
HGSC development and/or progression, an HGSC mouse model should be engineered 





FOXM1 has three known splice variants: FOXM1a, b, and c, which encode 
proteins with varying activities (10). An earlier study showed that FOXM1c is the 
predominant isoform expressed in pancreatic cancer, while another study showed that 
FOXM1b is the major isoform expressed in other cancer types (79,207). FOXM1c has 
alternative exon A1; residues in this region can be phosphorylated by the RAF/MEK/MAPK 
signaling cascade, providing a distinction with FOXM1b (65). Considering the differential 
expression and functional potential of different FOXM1 isoforms, it is important to 
determine which variants are responsible for oncogenic activity in EOC. We performed a 
comprehensive analysis of FOXM1 isoform expression in normal, HGSC and pan-cancer 
tissue and cell lines to determine isoform expression profile and if normal and cancer show 
differential isoform expression. We found that the predominant FOXM1 isoform expressed 
in all contexts was FOXM1c. Furthermore, our cell cycle data suggests that FOXM1c, but 
not FOXM1b, drives cell cycle progression in hOSE cells. In agreement, FOXM1c 
promoted cell cycle progression in FTE cells. In contrast to the cell cycle phenotype, we 
found that all FOXM1 isoforms interacted with DNA replication proteins suggesting these 
isoforms may have important functions that are independent of their transcriptional activity. 
This is especially true for FOXM1a which is transcriptionally inactive. Alternatively, FOXM1 
isoforms may complement each other to perform certain functions and possibly regulate 
each other through direct interaction, considering FOXM1 is capable of dimerizing 
(208,209). However, the knowledge of FOXM1 dimerization has been in the context of 
studies overexpressing a single isoform, FOXM1c and FOXM1b. In this setting, the 
homodimerization has been shown to repress transcriptional function until post-
translational modifications relieve the protein-protein interaction, thus activating the 
protein (209,210). Furthermore, the functional role and regulation of dimerization may be 
cell context dependent based on the genetic background of the cell type, suggesting there 




FOXM1 isoforms dimerize and if these interactions promote or inhibit function or give rise 
to a new function. Notably, a recent study discovered the expression of additional isoforms 
of FOXM1 in ovarian cancer and speculated that these isoforms may be constitutively 
active (211).  
 
FOXM1 and CCNE1 and Genomic Instability in HGSC  
Prior to this study, the role of FOXM1 in DNA replication stress and genomic 
instability had not been explored in HGSC, a disease characterized by FOXM1 
overexpression and genomic instability. It was also unknown if FOXM1 promoted DNA 
replication stress in any context. Many phenotypes associate with genomic instability 
including increased proliferation, cell cycle progression and DNA replication stress, and 
we show that FOXM1 is associated with these phenotypes in HGSC. STIC lesions have 
both increased DNA damage and FOXM1 expression, suggesting they may be related. In 
the current study, we demonstrated a role for FOXM1 in cell cycle progression using 
primary and immortalized human HGSC precursor models and HGSC cell lines. 
Additionally, it is plausible that FOXM1 overexpression, combined with p53 gain of function 
mutations, may synergistically promote genomic instability in ovarian cancer. For example, 
FOXM1 upregulation induced genomic instability in normal human keratinocytes, and 
FOXM1 is a member of a conserved gene expression profile for genomic instability in 
human cancer (37,85,89). Furthermore, p53 gain of function mutations can positively 
regulate FOXM1 and correlate with higher levels of genomic instability as compared to 
p53 null mutations (204,212).  
Interestingly, we observed a novel phenotype for FOXM1 where FOXM1 
overexpression in FTE cells increased DNA fork rate suggesting a novel form of DNA 




to be independent of FOXM1 transcriptional activity, but instead related to FOXM1 protein 
interacting with DNA replication proteins. However, this is speculative at this point and it 
requires additional studies to confirm this mechanism. Based on the data in our study and 
reports in the literature, it is possible that FOXM1 contributes to HGSC genesis and 
progression, through its promotion of genomic instability in STIC lesions, and promoting 
progression to HGSC. Notably, in our study, FOXM1 activation occurred downstream of 
Cyclin E1. We found that CCNE1 increased the transcriptional activity of FOXM1, 
promoted cell cycle progression and contributed to genomic instability. Cyclin E1 and 
FOXM1 are both expressed in STIC lesions, thus supporting a potential role for 
cooperativity in promoting genomic instability early in HGSC development (2,155).  
 
FOXM1 and RHNO1 in HGSC Development and Progression 
 Our data thus far showed that FOXM1 and RHNO1 are frequently expressed in 
normal and cancer cells and tissues. Importantly, HGSC shows overexpression of both 
FOXM1 and RHNO1. The FOXM1/RHNO1 bidirectional promoter and copy number gains 
contribute to their frequent co-expression, but DNA methylation does not appear to 
regulate their expression. It remains unknown which transcription factors regulate the 
bidirectional promoter. Bidirectional promoters are overrepresented with following 
transcription factor motifs: GABPA, MYC, E2F1, E2F4, NRF-1, CCAAT, and YY1 (119). 
E2F1 appears to be a potential candidate for future studies related to the regulation of the 
bidirectional promoter based on our data showing a relationship between FOXM1 and 
E2F1 expression. In agreement, the bidirectional promoter has two E2F motifs. 
Additionally, FOXM1 is reported to regulate its own promoter through a positive feedback 




expression (213).  However, we did not see a difference for RHNO1 expression in the 
RNA-seq analysis from FTE cells expressing FOXM1 or HGSC with FOXM1 knockdown.  
We focused on FOXM1 and RHNO1 in the context of HGSC cell lines, specifically 
survival, genome stability and chemoresistance. Taken together, our data suggest a dual 
role for FOXM1: 1) promoting genomic instability in FTE cells, which suggest that FOXM1 
promotes genomic instability early in HGSC development, contributing to the evolution of 
the disease, and 2) promoting genomic stability in HGSC cells, thus promoting survival 
and chemoresistance in tumors. Therefore, it is important to further differentiate and 
understand these phenotypes, but most importantly, to determine how RHNO1 
contributes, in vitro and in vivo. FOXM1 has been studied for its ability to promote tumor 
formation in mouse models, and it was necessary but not sufficient for tumor formation, 
while RHNO1 has never been studied in vivo. Our data suggests cooperatives roles for 
FOXM1 and RHNO1 using in vitro models, therefore, in vivo studies should be further 
revealing. More broadly, bidirectional gene partners have never been studied in vivo, 
therefore, these experiments would provide much needed knowledge to expand the 
concept of cooperativity between bidirectional gene partners in oncogenesis  
 
FOXM1 and RHNO1 in Chemoresistance and HR DNA Repair, and Potential for 
Therapeutic Targeting 
We showed that FOXM1 and RHNO1 loss decreased homologous recombination 
DNA repair and sensitized HGSC cells to the PARP inhibitor olaparib. We observed that 
FOXM1 loss alone sensitized HGSC cells to PARP inhibitor, but surprisingly, our RNA-
seq analysis did not reveal DNA repair genes as transcriptional targets of FOXM1. 
However, we observed that FOXM1 regulated genes involved in the G2/M checkpoint and 




cells. Furthermore, we observed that FOXM1 promoted DNA fork progression in FTE cells, 
a function that appears to be independent of its transcriptional activity. Therefore, we 
hypothesize that FOXM1 may be promoting chemoresistance in HGSC cells through 
protein interactions with DNA repair and chromatin modifying proteins, and not through its 
transcriptional activity. Further studies are needed to test this hypothesis.  
Importantly, we observed that PARP inhibitor sensitization was greatest when both 
FOXM1 and RHNO1 were inhibited. These data support additional studies to determine if 
FOXM1 and RHNO1 loss will sensitive HGSC cells to other chemotherapeutic agents. 
Potential candidates for these studies include carboplatin and paclitaxel based on 
previous studies showing that FOXM1 promotes resistance to these drugs (199-
201,214,215). CHK1 inhibitor has been shown to be synthetically lethal with ATR inhibitor, 
suggesting that RHNO1 loss may synergize with a CHK1 inhibitor (216). RHNO1 functions 
proximal to ATR, therefore, we would expect there to be synergy with a CHK1 inhibitor 
and potentially not an ATR inhibitor. We also observed a novel function for FOXM1 in 
promoting increased DNA fork rate so potentially inhibition of FOXM1 and RHNO1 in 
combination with CHK1 inhibition will show the greatest synergy.  
Based on growing recognition of the oncogenic role of FOXM1 in cancer, there is 
great interest in developing drugs to target this protein. This is particularly true in HGSC, 
for which the current therapeutic regimens are inadequate. Until recently, FOXM1 
targeting drugs, such as the thiazole antibiotics Siomycin A and Thiostrepton, were non-
specific and had global effects on proteasome-dependent pathways (217,218). However, 
Gormally et al. recently reported the identification and characterization of a specific 
inhibitor of FOXM1, which they named FDI-6 (219). Importantly, FDI-6 specifically inhibited 
the DNA binding activity of FOXM1, but not other FOX family members, and inhibited 




concerns about its specificity for FOXM1 only and not other forkhead family members 
specificity (220), and the potency will need improvement for in vivo treatment of FOXM1-
dependent cancers. Regardless, the existence of a specific inhibitor of FOXM1 provides 
a new opportunity for translational studies of FOXM1-dependent cancers, including 
HGSC. Furthermore, there are currently no inhibitors of RHNO1. Therefore, ATR inhibitors 
could be used in lieu of RHNO1 inhibition to combine with FOXM1 inhibitors as a 
potentially feasible and novel treatment strategy for HGSC.  
 
CONCLUSION 
 Our data identified genetic mechanisms that contribute to FOXM1 overexpression 
in HGSC. More importantly, we determined the functional consequences of FOXM1 
overexpression in HGSC, showing that FOXM1 promotes cell cycle progression and alters 
DNA replication dynamics, thus providing a mechanistic link to its association with 
genomic instability. We identified FOXM1 activation downstream of Cyclin E1-induced 
DNA replication stress, which cooperatively promoted cell cycle progression, increased 
transcriptional activity and enriched the CIN70 gene expression signature. In agreement, 
HGSC tumors with copy number gain for both FOXM1 and CCNE1 showed increased 
genomic instability. Furthermore, for the first time, we investigated the contribution of 
FOXM1 and its bidirectional gene partner, RHNO1, in HGSC cell survival and 
chemoresistance, showing that FOXM1 and RHNO1 augment the phenotypes to a greater 
extent than either gene alone. Finally, taken together, our data support additional in vitro 
and in vivo studies focusing on the cooperativity of FOXM1 and RHNO1 bidirectional gene 






1. Vaughan S, Coward JI, Bast RC, Jr., Berchuck A, Berek JS, Brenton JD, et al. 
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev 
Cancer 2011;11:719-25 
2. Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, 
et al. FOXO3a loss is a frequent early event in high-grade pelvic serous 
carcinogenesis. Oncogene 2014;33:4424-32 
3. Quinet A, Carvajal-Maldonado D, Lemacon D, Vindigni A. DNA Fiber Analysis: 
Mind the Gap! Methods Enzymol 2017;591:55-82 
4. Karst AM, Drapkin R. Primary culture and immortalization of human fallopian tube 
secretory epithelial cells. Nat Protoc 2012;7:1755-64 
5. Lindsey-Boltz LA, Kemp MG, Capp C, Sancar A. RHINO forms a stoichiometric 
complex with the 9-1-1 checkpoint clamp and mediates ATR-Chk1 signaling. Cell 
Cycle 2015;14:99-108 
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 
2018;68:7-30 
7. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for 
clinicians 2014;64:9-29 
8. Romero I, Bast RC, Jr. Minireview: human ovarian cancer: biology, current 
management, and paths to personalizing therapy. Endocrinology 2012;153:1593-
602 
9. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumors. Geneva: 
World Health Organization1973. 
10. Scully R, Xobin L. Histological typing of ovarian tumours. New York: Springer 
Berlin1999. 
11. Prat J. Staging classification for cancer of the ovary, fallopian tube, and 
peritoneum. International journal of gynaecology and obstetrics: the official organ 
of the International Federation of Gynaecology and Obstetrics 2014;124:1-5 
12. Benedet JL, Bender H, Jones H, 3rd, Ngan HY, Pecorelli S. FIGO staging 
classifications and clinical practice guidelines in the management of gynecologic 
cancers. FIGO Committee on Gynecologic Oncology. International journal of 
gynaecology and obstetrics: the official organ of the International Federation of 
Gynaecology and Obstetrics 2000;70:209-62 
13. Cho KR, Shih Ie M. Ovarian cancer. Annual review of pathology 2009;4:287-313 
14. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. 
Grading ovarian serous carcinoma using a two-tier system. The American journal 
of surgical pathology 2004;28:496-504 
15. Diaz-Padilla I, Malpica AL, Minig L, Chiva LM, Gershenson DM, Gonzalez-Martin 
A. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecologic 
oncology 2012;126:279-85 
16. Roett MA, Evans P. Ovarian cancer: an overview. American family physician 
2009;80:609-16 
17. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal 
for clinicians 2013;63:11-30 
18. Drake J. Diagnosis and management of the adnexal mass. American family 
physician 1998;57:2471-6, 9-80 
19. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: 
identification as a new mucin, MUC16. The Journal of biological chemistry 
2001;276:27371-5 




radioimmunoassay using a monoclonal antibody to monitor the course of epithelial 
ovarian cancer. The New England journal of medicine 1983;309:883-7 
21. Gynecologists ACoOa. The role of the generalist obstetrician-gynecologist in the 
early detection of ovarian cancer. Gynecologic oncology 2002;87:237-9 
22. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface 
epithelium: biology, endocrinology, and pathology. Endocrine reviews 
2001;22:255-88 
23. Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia? Lancet 
1971;2:163 
24. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, 
et al. Dysplastic changes in prophylactically removed Fallopian tubes of women 
predisposed to developing ovarian cancer. J Pathol 2001;195:451-6 
25. Erickson BK, Conner MG, Landen CN, Jr. The role of the fallopian tube in the origin 
of ovarian cancer. American journal of obstetrics and gynecology 2013;209:409-
14 
26. Piek JM, Verheijen RH, Kenemans P, Massuger LF, Bulten H, van Diest PJ. 
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecologic 
oncology 2003;90:491 
27. O'Shannessy DJ, Jackson SM, Twine NC, Hoffman BE, Dezso Z, Agoulnik SI, et 
al. Gene expression analyses support fallopian tube epithelium as the cell of origin 
of epithelial ovarian cancer. International journal of molecular sciences 
2013;14:13687-703 
28. Klinkebiel D, Zhang W, Akers SN, Odunsi K, Karpf AR. DNA Methylome Analyses 
Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian 
Cancer. Mol Cancer Res 2016;14:787-94 
29. Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, et al. High grade 
serous ovarian carcinomas originate in the fallopian tube. Nat Commun 
2017;8:1093 
30. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian 
carcinoma. Nature 2011;474:609-15 
31. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging 
landscape of oncogenic signatures across human cancers. Nat Genet 
2013;45:1127-33 
32. Network CGA. Comprehensive molecular portraits of human breast tumours. 
Nature 2012;490:61-70 
33. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. 
Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013;45:1134-
40 
34. Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J, et al. 
Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl 
Acad Sci U S A 2013;110:19489-94 
35. Teixeira LK, Wang X, Li Y, Ekholm-Reed S, Wu X, Wang P, et al. Cyclin E 
deregulation promotes loss of specific genomic regions. Curr Biol 2015;25:1327-
33 
36. Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, et 
al. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer 
and functional contribution to cell cycle progression. Oncotarget 2015;6:27613-27 
37. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of 
chromosomal instability inferred from gene expression profiles predicts clinical 
outcome in multiple human cancers. Nature genetics 2006;38:1043-8 




prognostic landscape of genes and infiltrating immune cells across human 
cancers. Nat Med 2015;21:938-45 
39. Dai J, Yang L, Wang J, Xiao Y, Ruan Q. Prognostic Value of FOXM1 in Patients 
with Malignant Solid Tumor: A Meta-Analysis and System Review. Dis Markers 
2015;2015:352478 
40. Halasi M, Gartel AL. FOX(M1) news--it is cancer. Molecular cancer therapeutics 
2013;12:245-54 
41. Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC, Jr., Beral V, et al. 
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian 
cancer. Nat Rev Cancer 2015;15:668-79 
42. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat 
Rev Cancer 2010;10:803-8 
43. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical 
trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus 
Conference. International journal of gynecological cancer : official journal of the 
International Gynecological Cancer Society 2011;21:750-5 
44. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. 
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. 
The New England journal of medicine 2010;363:943-53 
45. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. 
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. 
Nature 2005;434:917-21 
46. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific 
killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. 
Nature 2005;434:913-7 
47. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. 
Nat Rev Cancer 2005;5:689-98 
48. Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons 
learned from the development of PARP inhibitors. Annu Rev Med 2015;66:455-70 
49. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 
2017;355:1152-8 
50. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, 
et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 
or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 
2010;376:245-51 
51. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of 
poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J 
Med 2009;361:123-34 
52. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. 
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N 
Engl J Med 2012;366:1382-92 
53. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, 
Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a 
germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-50 
54. Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, et al. FDA Approval 
Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-
Mutated Advanced Ovarian Cancer Treated with Three or More Lines of 
Chemotherapy. Clin Cancer Res 2015;21:4257-61 
55. Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and 




56. Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors--three and counting. 
Cancer Discov 2013;3:20-3 
57. Sonnenblick A, de Azambuja E, Azim HA, Piccart M. An update on PARP 
inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41 
58. Westendorf JM, Rao PN, Gerace L. Cloning of cDNAs for M-phase 
phosphoproteins recognized by the MPM2 monoclonal antibody and determination 
of the phosphorylated epitope. Proc Natl Acad Sci U S A 1994;91:714-8 
59. Korver W, Roose J, Clevers H. The winged-helix transcription factor Trident is 
expressed in cycling cells. Nucleic Acids Res 1997;25:1715-9 
60. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. 
Nature reviews Cancer 2007;7:847-59 
61. Wierstra I, Alves J. Despite its strong transactivation domain, transcription factor 
FOXM1c is kept almost inactive by two different inhibitory domains. Biol Chem 
2006;387:963-76 
62. Chen X, Muller GA, Quaas M, Fischer M, Han N, Stutchbury B, et al. The forkhead 
transcription factor FOXM1 controls cell cycle-dependent gene expression through 
an atypical chromatin binding mechanism. Molecular and cellular biology 
2013;33:227-36 
63. Ye H, Kelly TF, Samadani U, Lim L, Rubio S, Overdier DG, et al. Hepatocyte 
nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and 
mesenchymal cells of embryonic and adult tissues. Molecular and cellular biology 
1997;17:1626-41 
64. Yao KM, Sha M, Lu Z, Wong GG. Molecular analysis of a novel winged helix 
protein, WIN. Expression pattern, DNA binding property, and alternative splicing 
within the DNA binding domain. J Biol Chem 1997;272:19827-36 
65. Ma RY, Tong TH, Cheung AM, Tsang AC, Leung WY, Yao KM. Raf/MEK/MAPK 
signaling stimulates the nuclear translocation and transactivating activity of 
FOXM1c. Journal of cell science 2005;118:795-806 
66. Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, et al. Forkhead box 
M1 regulates the transcriptional network of genes essential for mitotic progression 
and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 
2005;25:10875-94 
67. Wonsey DR, Follettie MT. Loss of the forkhead transcription factor FoxM1 causes 
centrosome amplification and mitotic catastrophe. Cancer Res 2005;65:5181-9 
68. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, et al. FoxM1 
is required for execution of the mitotic programme and chromosome stability. Nat 
Cell Biol 2005;7:126-36 
69. Krupczak-Hollis K, Wang X, Kalinichenko VV, Gusarova GA, Wang IC, Dennewitz 
MB, et al. The mouse Forkhead Box m1 transcription factor is essential for 
hepatoblast mitosis and development of intrahepatic bile ducts and vessels during 
liver morphogenesis. Dev Biol 2004;276:74-88 
70. Costa RH. FoxM1 dances with mitosis. Nat Cell Biol 2005;7:108-10 
71. Laoukili J, Alvarez-Fernandez M, Stahl M, Medema RH. FoxM1 is degraded at 
mitotic exit in a Cdh1-dependent manner. Cell Cycle 2008;7:2720-6 
72. Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. 
Biochim Biophys Acta 2007;1775:92-102 
73. Pandit B, Halasi M, Gartel AL. p53 negatively regulates expression of FoxM1. Cell 
cycle 2009;8:3425-7 
74. Barsotti AM, Prives C. Pro-proliferative FoxM1 is a target of p53-mediated 
repression. Oncogene 2009;28:4295-305 




(Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular 
cancer therapeutics 2009;8:582-91 
76. Blanco-Bose WE, Murphy MJ, Ehninger A, Offner S, Dubey C, Huang W, et al. C-
Myc and its target FoxM1 are critical downstream effectors of constitutive 
androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology 
2008;48:1302-11 
77. Mencalha AL, Binato R, Ferreira GM, Du Rocher B, Abdelhay E. Forkhead box M1 
(FoxM1) gene is a new STAT3 transcriptional factor target and is essential for 
proliferation, survival and DNA repair of K562 cell line. PloS one 2012;7:e48160 
78. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG. FOXM1 is a 
downstream target of Gli1 in basal cell carcinomas. Cancer research 
2002;62:4773-80 
79. Kong X, Li L, Li Z, Le X, Huang C, Jia Z, et al. Dysregulated expression of FOXM1 
isoforms drives progression of pancreatic cancer. Cancer research 2013;73:3987-
96 
80. Xia LM, Huang WJ, Wang B, Liu M, Zhang Q, Yan W, et al. Transcriptional up-
regulation of FoxM1 in response to hypoxia is mediated by HIF-1. J Cell Biochem 
2009;106:247-56 
81. Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R, et al. ATM 
and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment 
and resistance. Molecular cancer therapeutics 2011;10:1046-58 
82. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, et al. Array-
based comparative genomic hybridization identifies CDK4 and FOXM1 alterations 
as independent predictors of survival in malignant peripheral nerve sheath tumor. 
Clin Cancer Res 2011;17:1924-34 
83. Korver W, Schilham MW, Moerer P, van den Hoff MJ, Dam K, Lamers WH, et al. 
Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the 
winged-helix transcription factor Trident. Curr Biol 1998;8:1327-30 
84. Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of FoxM1 transcription factor: 
lessons from transgenic mouse models. Cell Cycle 2011;10:396-405 
85. Teh MT, Gemenetzidis E, Chaplin T, Young BD, Philpott MP. Upregulation of 
FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer 
2010;9:45 
86. Liu Y, Gong Z, Sun L, Li X. FOXM1 and androgen receptor co-regulate CDC6 gene 
transcription and DNA replication in prostate cancer cells. Biochim Biophys Acta 
2014;1839:297-305 
87. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, et al. A systematic 
screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence 
suppression in cancer cells. Cancer Cell 2011;20:620-34 
88. Kotsantis P, Petermann E, Boulton SJ. Mechanisms of Oncogene-Induced 
Replication Stress: Jigsaw Falling into Place. Cancer Discov 2018 
89. Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, et al. FOXM1 
upregulation is an early event in human squamous cell carcinoma and it is 
enhanced by nicotine during malignant transformation. PLoS One 2009;4:e4849 
90. Molinuevo R, Freije A, de Pedro I, Stoll SW, Elder JT, Gandarillas A. FOXM1 
allows human keratinocytes to bypass the oncogene-induced differentiation 
checkpoint in response to gain of MYC or loss of p53. Oncogene 2017;36:956-65 
91. Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 
transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 
2007;27:1007-16 




Rev Pathol 2015;10:425-48 
93. Gaillard H, García-Muse T, Aguilera A. Replication stress and cancer. Nat Rev 
Cancer 2015;15:276-89 
94. Dobbelstein M, Sørensen CS. Exploiting replicative stress to treat cancer. Nat Rev 
Drug Discov 2015;14:405-23 
95. Costantino L, Sotiriou SK, Rantala JK, Magin S, Mladenov E, Helleday T, et al. 
Break-induced replication repair of damaged forks induces genomic duplications 
in human cells. Science 2014;343:88-91 
96. Arlt MF, Wilson TE, Glover TW. Replication stress and mechanisms of CNV 
formation. Curr Opin Genet Dev 2012;22:204-10 
97. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage 
model for cancer development. Science 2008;319:1352-5 
98. Abbas T, Keaton MA, Dutta A. Genomic instability in cancer. Cold Spring Harb 
Perspect Biol 2013;5:a012914 
99. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev 
Mol Cell Biol 2008;9:616-27 
100. Cotta-Ramusino C, McDonald ER, 3rd, Hurov K, Sowa ME, Harper JW, Elledge 
SJ. A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 
interacting protein required for ATR signaling. Science 2011;332:1313-7 
101. Kousholt AN, Menzel T, Sorensen CS. Pathways for genome integrity in G2 phase 
of the cell cycle. Biomolecules 2012;2:579-607 
102. Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. International 
journal of cancer Journal international du cancer 2014;134:1013-23 
103. Jackson SP, Helleday T. DNA REPAIR. Drugging DNA repair. Science 
2016;352:1178-9 
104. Buisson R, Boisvert JL, Benes CH, Zou L. Distinct but Concerted Roles of ATR, 
DNA-PK, and Chk1 in Countering Replication Stress during S Phase. Mol Cell 
2015;59:1011-24 
105. Karnitz LM, Zou L. Molecular Pathways: Targeting ATR in Cancer Therapy. Clin 
Cancer Res 2015 
106. O'Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell 
2015;60:547-60 
107. Fang B. Development of synthetic lethality anticancer therapeutics. J Med Chem 
2014;57:7859-73 
108. Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, 
Kaufmann SH, et al. ATR inhibition broadly sensitizes ovarian cancer cells to 
chemotherapy independent of BRCA status. Cancer Res 2013;73:3683-91 
109. Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol 
Ther 2015;149:124-38 
110. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 
inhibitors as cancer therapeutics. Trends Mol Med 2011;17:88-96 
111. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving 
hallmark of cancer. Nat Rev Mol Cell Biol 2010;11:220-8 
112. Adachi N, Lieber MR. Bidirectional gene organization: a common architectural 
feature of the human genome. Cell 2002;109:807-9 
113. Takai D, Jones PA. Origins of bidirectional promoters: computational analyses of 
intergenic distance in the human genome. Mol Biol Evol 2004;21:463-7 
114. Trinklein ND, Aldred SF, Hartman SJ, Schroeder DI, Otillar RP, Myers RM. An 
abundance of bidirectional promoters in the human genome. Genome Res 
2004;14:62-6 




and mouse genomes. BMC Bioinformatics 2014;15 Suppl 17:S1 
116. Yang MQ, Taylor J, Elnitski L. Comparative analyses of bidirectional promoters in 
vertebrates. BMC Bioinformatics 2008;9 Suppl 6:S9 
117. Wakano C, Byun JS, Di LJ, Gardner K. The dual lives of bidirectional promoters. 
Biochim Biophys Acta 2012;1819:688-93 
118. Bornelov S, Komorowski J, Wadelius C. Different distribution of histone 
modifications in genes with unidirectional and bidirectional transcription and a role 
of CTCF and cohesin in directing transcription. BMC Genomics 2015;16:300 
119. Lin JM, Collins PJ, Trinklein ND, Fu Y, Xi H, Myers RM, et al. Transcription factor 
binding and modified histones in human bidirectional promoters. Genome Res 
2007;17:818-27 
120. Yang MQ, Koehly LM, Elnitski LL. Comprehensive annotation of bidirectional 
promoters identifies co-regulation among breast and ovarian cancer genes. PLoS 
Comput Biol 2007;3:e72 
121. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, Luo J, et 
al. ATM and ATR substrate analysis reveals extensive protein networks responsive 
to DNA damage. Science 2007;316:1160-6 
122. Kim JW, Fukukawa C, Ueda K, Nishidate T, Katagiri T, Nakamura Y. Involvement 
of C12orf32 overexpression in breast carcinogenesis. Int J Oncol 2010;37:861-7 
123. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an 
essential kinase that is regulated by Atr and required for the G(2)/M DNA damage 
checkpoint. Genes Dev 2000;14:1448-59 
124. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumours [by] S. F. 
Serov [and] R. E. Scully in collaboration with L. H. Sobin and pathologists in ten 
countries. Geneva,: World Health Organization; 1973. 56 p. p. 
125. Li NF, Broad S, Lu YJ, Yang JS, Watson R, Hagemann T, et al. Human ovarian 
surface epithelial cells immortalized with hTERT maintain functional pRb and p53 
expression. Cell Prolif 2007;40:780-94 
126. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new 
opportunities for translation. Nature reviews Cancer 2009;9:415-28 
127. Gunn A, Bennardo N, Cheng A, Stark JM. Correct end use during end joining of 
multiple chromosomal double strand breaks is influenced by repair protein RAD50, 
DNA-dependent protein kinase DNA-PKcs, and transcription context. J Biol Chem 
2011;286:42470-82 
128. Gunn A, Stark JM. I-SceI-based assays to examine distinct repair outcomes of 
mammalian chromosomal double strand breaks. Methods Mol Biol 2012;920:379-
91 
129. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. 
Gene set enrichment analysis: a knowledge-based approach for interpreting 
genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50 
130. Fang P, Madden JA, Neums L, Moulder KR, Forrest ML, Chien J. Olaparib-induced 
Adaptive Response is Disrupted by FOXM1 Targeting which Enhances Sensitivity 
to PARP Inhibition. Mol Cancer Res 2018 
131. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-
directed repair of DNA damage in mammalian cells. Genes Dev 1999;13:2633-8 
132. Sanders DA, Gormally MV, Marsico G, Beraldi D, Tannahill D, Balasubramanian 
S. FOXM1 binds directly to non-consensus sequences in the human genome. 
Genome Biol 2015;16:130 
133. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of 
carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian 




134. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-
BLAST: a tool to design target-specific primers for polymerase chain reaction. 
BMC Bioinformatics 2012;13:134 
135. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image 
analysis. Nat Methods 2012;9:671-5 
136. Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, et al. A 
Landscape of Pharmacogenomic Interactions in Cancer. Cell 2016;166:740-54 
137. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: a 
web-based suite of genomic and pharmacologic tools to explore transcript and 
drug patterns in the NCI-60 cell line set. Cancer research 2012;72:3499-511 
138. Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, et al. 
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. 
BMC Genomics 2009;10:277 
139. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated 
cytosines. Nucleic acids research 1994;22:2990-7 
140. MethPrimer. 
141. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The 
human genome browser at UCSC. Genome Res 2002;12:996-1006 
142. Jackson DA, Pombo A. Replicon clusters are stable units of chromosome 
structure: evidence that nuclear organization contributes to the efficient activation 
and propagation of S phase in human cells. J Cell Biol 1998;140:1285-95 
143. Ray Chaudhuri A, Hashimoto Y, Herrador R, Neelsen KJ, Fachinetti D, Bermejo 
R, et al. Topoisomerase I poisoning results in PARP-mediated replication fork 
reversal. Nat Struct Mol Biol 2012;19:417-23 
144. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, et al. TCPA: a resource for cancer 
functional proteomics data. Nat Methods 2013;10:1046-7 
145. Li J, Akbani R, Zhao W, Lu Y, Weinstein JN, Mills GB, et al. Explore, Visualize, 
and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. 
Cancer Res 2017;77:e51-e4 
146. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. 
Assessing the significance of chromosomal aberrations in cancer: methodology 
and application to glioma. Proceedings of the National Academy of Sciences of the 
United States of America 2007;104:20007-12 
147. Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, et al. A single-cell 
survey of the small intestinal epithelium. Nature 2017;551:333-9 
148. Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, et al. 
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-
seq. Science 2016;352:189-96 
149. Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, et al. Single cell 
sequencing reveals heterogeneity within ovarian cancer epithelium and cancer 
associated stromal cells. Gynecol Oncol 2017;144:598-606 
150. Li WV, Li JJ. An accurate and robust imputation method scImpute for single-cell 
RNA-seq data. Nat Commun 2018;9:997 
151. Consortium EP. An integrated encyclopedia of DNA elements in the human 
genome. Nature 2012;489:57-74 
152. Miotto B, Ji Z, Struhl K. Selectivity of ORC binding sites and the relation to 
replication timing, fragile sites, and deletions in cancers. Proc Natl Acad Sci U S A 
2016;113:E4810-9 
153. Stavrovskaya ED, Niranjan T, Fertig EJ, Wheelan SJ, Favorov AV, Mironov AA. 
StereoGene: rapid estimation of genome-wide correlation of continuous or interval 




154. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, et al. Analysis of DNA 
copy number alterations in ovarian serous tumors identifies new molecular genetic 
changes in low-grade and high-grade carcinomas. Cancer research 
2009;69:4036-42 
155. Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, et al. Cyclin E1 
deregulation occurs early in secretory cell transformation to promote formation of 
fallopian tube-derived high-grade serous ovarian cancers. Cancer Res 
2014;74:1141-52 
156. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, et al. A pan-
cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 
2014;5:3887 
157. Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, et al. Toil enables 
reproducible, open source, big biomedical data analyses. Nat Biotechnol 
2017;35:314-6 
158. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA 
methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. 
Cancer immunity 2007;7:21 
159. Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat 
G, et al. Coordinated cancer germline antigen promoter and global DNA 
hypomethylation in ovarian cancer: association with the BORIS/CTCF expression 
ratio and advanced stage. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2011;17:2170-80 
160. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as 
tumour models by comparison of genomic profiles. Nature communications 
2013;4:2126 
161. McCloskey CW, Goldberg RL, Carter LE, Gamwell LF, Al-Hujaily EM, Collins O, et 
al. A new spontaneously transformed syngeneic model of high-grade serous 
ovarian cancer with a tumor-initiating cell population. Frontiers in oncology 
2014;4:53 
162. Garson K, Gamwell LF, Pitre EM, Vanderhyden BC. Technical challenges and 
limitations of current mouse models of ovarian cancer. Journal of ovarian research 
2012;5:39 
163. Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC. Conditional 
inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of 
leiomyosarcomas. PloS one 2009;4:e8534 
164. Nicolay BN, Danielian PS, Kottakis F, Lapek JD, Sanidas I, Miles WO, et al. 
Proteomic analysis of pRb loss highlights a signature of decreased mitochondrial 
oxidative phosphorylation. Genes Dev 2015;29:1875-89 
165. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for 
CRISPR screening. Nat Methods 2014;11:783-4 
166. Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY, et al. Over-
expression of FoxM1 stimulates cyclin B1 expression. FEBS letters 2001;507:59-
66 
167. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box 
M1 transcription factor leads to the inhibition of invasion and angiogenesis of 
pancreatic cancer cells. Cancer research 2007;67:8293-300 
168. Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW, Cheung AN, et al. Over-expression 
of FOXM1 transcription factor is associated with cervical cancer progression and 
pathogenesis. The Journal of pathology 2008;215:245-52 





170. Littler DR, Alvarez-Fernández M, Stein A, Hibbert RG, Heidebrecht T, Aloy P, et 
al. Structure of the FoxM1 DNA-recognition domain bound to a promoter 
sequence. Nucleic Acids Res 2010;38:4527-38 
171. Chen YJ, Dominguez-Brauer C, Wang Z, Asara JM, Costa RH, Tyner AL, et al. A 
conserved phosphorylation site within the forkhead domain of FoxM1B is required 
for its activation by cyclin-CDK1. J Biol Chem 2009;284:30695-707 
172. Neelsen KJ, Zanini IM, Herrador R, Lopes M. Oncogenes induce genotoxic stress 
by mitotic processing of unusual replication intermediates. J Cell Biol 
2013;200:699-708 
173. Bianco JN, Poli J, Saksouk J, Bacal J, Silva MJ, Yoshida K, et al. Analysis of DNA 
replication profiles in budding yeast and mammalian cells using DNA combing. 
Methods 2012;57:149-57 
174. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. 
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by 
DNA damage checkpoints. Nature 2006;444:633-7 
175. Jones RM, Mortusewicz O, Afzal I, Lorvellec M, García P, Helleday T, et al. 
Increased replication initiation and conflicts with transcription underlie Cyclin E-
induced replication stress. Oncogene 2013;32:3744-53 
176. Singhal G, Leo E, Setty SK, Pommier Y, Thimmapaya B. Adenovirus E1A 
oncogene induces rereplication of cellular DNA and alters DNA replication 
dynamics. J Virol 2013;87:8767-78 
177. Deutzmann A, Ganz M, Schönenberger F, Vervoorts J, Kappes F, Ferrando-May 
E. The human oncoprotein and chromatin architectural factor DEK counteracts 
DNA replication stress. Oncogene 2015;34:4270-7 
178. Rimmelé P, Komatsu J, Hupé P, Roulin C, Barillot E, Dutreix M, et al. Spi-1/PU.1 
oncogene accelerates DNA replication fork elongation and promotes genetic 
instability in the absence of DNA breakage. Cancer Res 2010;70:6757-66 
179. Sincennes MC, Humbert M, Grondin B, Lisi V, Veiga DF, Haman A, et al. The 
LMO2 oncogene regulates DNA replication in hematopoietic cells. Proc Natl Acad 
Sci U S A 2016;113:1393-8 
180. Hills SA, Diffley JF. DNA replication and oncogene-induced replicative stress. Curr 
Biol 2014;24:R435-44 
181. Dominguez-Sola D, Gautier J. MYC and the control of DNA replication. Cold Spring 
Harb Perspect Med 2014;4 
182. Kurat CF, Yeeles JTP, Patel H, Early A, Diffley JFX. Chromatin Controls DNA 
Replication Origin Selection, Lagging-Strand Synthesis, and Replication Fork 
Rates. Mol Cell 2017;65:117-30 
183. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase 
protein array: validation of a novel proteomic technology and utility for analysis of 
primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 
2006;5:2512-21 
184. Li X, Wang W, Wang J, Malovannaya A, Xi Y, Li W, et al. Proteomic analyses 
reveal distinct chromatin-associated and soluble transcription factor complexes. 
Mol Syst Biol 2015;11:775 
185. Carr JR, Kiefer MM, Park HJ, Li J, Wang Z, Fontanarosa J, et al. FoxM1 regulates 
mammary luminal cell fate. Cell Rep 2012;1:715-29 
186. Wierstra I, Alves J. FOXM1c is activated by cyclin E/Cdk2, cyclin A/Cdk2, and 
cyclin A/Cdk1, but repressed by GSK-3alpha. Biochem Biophys Res Commun 
2006;348:99-108 
187. Wierstra I, Alves J. Transcription factor FOXM1c is repressed by RB and activated 




188. Wierstra I, Alves J. Cyclin E/Cdk2, P/CAF, and E1A regulate the transactivation of 
the c-myc promoter by FOXM1. Biochem Biophys Res Commun 2008;368:107-15 
189. Antequera F. Structure, function and evolution of CpG island promoters. Cell Mol 
Life Sci 2003;60:1647-58 
190. Chen Y, Li Y, Wei J, Li YY. Transcriptional regulation and spatial interactions of 
head-to-head genes. BMC genomics 2014;15:519 
191. Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, et 
al. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer 
and functional contribution to cell cycle progression. Oncotarget 2015 
192. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, et al. Silencing of bidirectional 
promoters by DNA methylation in tumorigenesis. Cancer Res 2006;66:5077-84 
193. Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, 
et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation 
screening. Nat Protoc 2017;12:828-63 
194. Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, et al. 
Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of 
distal regulatory elements. Nat Methods 2015;12:1143-9 
195. Maachani UB, Shankavaram U, Kramp T, Tofilon PJ, Camphausen K, Tandle AT. 
FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells. 
Oncotarget 2016;7:77365-77 
196. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, et al. 
FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. 
Carcinogenesis 2012;33:1843-53 
197. Monteiro LJ, Khongkow P, Kongsema M, Morris JR, Man C, Weekes D, et al. The 
Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in 
epirubicin treatment. Oncogene 2013;32:4634-45 
198. Khongkow P, Karunarathna U, Khongkow M, Gong C, Gomes AR, Yagüe E, et al. 
FOXM1 targets NBS1 to regulate DNA damage-induced senescence and 
epirubicin resistance. Oncogene 2014;33:4144-55 
199. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, et al. 
FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer 
Res 2010;8:24-34 
200. Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, et al. FOXM1 
expression is significantly associated with chemotherapy resistance and adverse 
prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res 
2017;36:63 
201. Nestal de Moraes G, Delbue D, Silva KL, Robaina MC, Khongkow P, Gomes AR, 
et al. FOXM1 targets XIAP and Survivin to modulate breast cancer survival and 
chemoresistance. Cell Signal 2015;27:2496-505 
202. Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, et al. ATR 
inhibition disrupts rewired homologous recombination and fork protection 
pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 
2017;31:318-32 
203. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, et al. 
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 
and cisplatin. Clin Cancer Res 2008;14:3916-25 
204. Zhang X, Cheng L, Minn K, Madan R, Godwin AK, Shridhar V, et al. Targeting of 
mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances 
carboplatin sensitivity in cancer cells. Oncotarget 2014;5:11365-80 
205. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging 




206. Yamamoto Y, Ning G, Howitt BE, Mehra K, Wu L, Wang X, et al. In vitro and in 
vivo correlates of physiological and neoplastic human Fallopian tube stem cells. J 
Pathol 2016;238:519-30 
207. Lam AK, Ngan AW, Leung MH, Kwok DC, Liu VW, Chan DW, et al. FOXM1b, 
which is present at elevated levels in cancer cells, has a greater transforming 
potential than FOXM1c. Frontiers in oncology 2013;3:11 
208. Schimmel J, Eifler K, Sigurðsson JO, Cuijpers SA, Hendriks IA, Verlaan-de Vries 
M, et al. Uncovering SUMOylation dynamics during cell-cycle progression reveals 
FoxM1 as a key mitotic SUMO target protein. Mol Cell 2014;53:1053-66 
209. Laoukili J, Alvarez M, Meijer LA, Stahl M, Mohammed S, Kleij L, et al. Activation 
of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by 
the FoxM1 N-terminal domain. Mol Cell Biol 2008;28:3076-87 
210. Schimmel J, Eifler K, Sigurethsson JO, Cuijpers SA, Hendriks IA, Verlaan-de Vries 
M, et al. Uncovering SUMOylation dynamics during cell-cycle progression reveals 
FoxM1 as a key mitotic SUMO target protein. Mol Cell 2014;53:1053-66 
211. Barrett CL, DeBoever C, Jepsen K, Saenz CC, Carson DA, Frazer KA. Systematic 
transcriptome analysis reveals tumor-specific isoforms for ovarian cancer 
diagnosis and therapy. Proceedings of the National Academy of Sciences of the 
United States of America 2015;112:E3050-7 
212. Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell 
Biochem 2012;113:433-9 
213. Halasi M, Gartel AL. A novel mode of FoxM1 regulation: positive auto-regulatory 
loop. Cell Cycle 2009;8:1966-7 
214. Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ, Liu WC. FoxM1 expression is 
significantly associated with cisplatin-based chemotherapy resistance and poor 
prognosis in advanced non-small cell lung cancer patients. Lung Cancer 
2013;79:173-9 
215. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P. FoxM1 mediates 
resistance to herceptin and paclitaxel. Cancer Res 2010;70:5054-63 
216. Sanjiv K, Hagenkort A, Calderón-Montaño JM, Koolmeister T, Reaper PM, 
Mortusewicz O, et al. Cancer-Specific Synthetic Lethality between ATR and CHK1 
Kinase Activities. Cell Rep 2016;17:3407-16 
217. Wang M, Gartel AL. Micelle-encapsulated thiostrepton as an effective 
nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human 
xenografts. Molecular cancer therapeutics 2011;10:2287-97 
218. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL. 
Identification of a chemical inhibitor of the oncogenic transcription factor forkhead 
box M1. Cancer research 2006;66:9731-5 
219. Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, Matak-Vinkovic D, 
et al. Suppression of the FOXM1 transcriptional programme via novel small 
molecule inhibition. Nature communications 2014;5:5165 
220. Kalinichenko VV, Kalin TV. Is there potential to target FOXM1 for 'undruggable' 
lung cancers? Expert Opin Ther Targets 2015:1-3 
 
